2014 CRS Annual Meeting Program Book

CRS Annual Meeting and Exposition July 13–16, 2014 • Chicago, Illinois, U.S.A.

CRS 2014 Program

©Choose Chicago

©iStockphoto.com/Konstatin Inozemtsev

of Delivery Technology: Innovation to Commercialization

©Jens Goepfert / Shutterstock.com

Download the CRS Annual Meeting App

˝˝2013 2013 ˝˝ 2013 Catalent 2013 Catalent Catalent Catalent Pharma Pharma Pharma Pharma Solutions.

Solutions.

Solutions.

Solutions.

All Allrights All rights All rights rights reserved. reserved. reserved. reserved.

OSDrC OSDrC OSDrC OSDrC isisaais registered registered is a registered a registered trademark trademark trademark trademark ofofSanwa Sanwa of of Sanwa Sanwa Kagaku Kagaku Kagaku Kagaku Kenkyusho Kenkyusho Kenkyusho Kenkyusho Co. Co.Co. Co. ˝˝2013 2013 ˝˝ 2013 ˝˝ Catalent 2013 Catalent 2013 2013 ˝Catalent ˝ 2013 Catalent Catalent 2013 Catalent Pharma Pharma Catalent Catalent Pharma Pharma Pharma Pharma Solutions.

Solutions.

Pharma Solutions.

Pharma Solutions.

Solutions.

Solutions.

Solutions.

All All Solutions. rights All rights All All rights All rights reserved. rights All reserved. rights All reserved. rights reserved. rights reserved. reserved. reserved. reserved.

OSDrC OSDrC OSDrC OSDrC OSDrC OSDrC isisaOSDrC ais registered OSDrC registered is aisis registered aaa registered is registered registered is a registered trademark atrademark registered trademark trademark trademark trademark trademark ofof trademark Sanwa Sanwa of of Sanwa ofof Sanwa Sanwa Kagaku Sanwa of Kagaku of Sanwa Kagaku Sanwa Kagaku Kagaku Kagaku Kenkyusho Kenkyusho Kagaku Kenkyusho Kagaku Kenkyusho Kenkyusho Kenkyusho Kenkyusho Co. Co. Kenkyusho Co. Co. Co. Co.Co. Co.

˝˝2013 2013 ˝˝ 2013 Catalent 2013 Catalent Catalent Catalent Pharma Pharma Pharma Pharma Solutions.

Solutions.

Solutions.

Solutions.

All Allrights All rights All rights rights reserved. reserved. reserved. reserved.

OSDrC OSDrC OSDrC OSDrC isisaais registered registered is a registered a registered trademark trademark trademark trademark ofofSanwa Sanwa of of Sanwa Sanwa Kagaku Kagaku Kagaku Kagaku Kenkyusho Kenkyusho Kenkyusho Kenkyusho Co. Co.Co. Co.

optimized optimized delivery delivery optimized optimized delivery delivery optimized delivery optimized delivery technologies. technologies. technologies. technologies. technologies. technologies. better better outcomes. outcomes. better better outcomes. outcomes. better better outcomes. outcomes.

every molecule has a challenge. We have a solution. From orphan drugs to blockbusters, our development every molecule has a challenge. We have a solution. From orphan drugs to blockbusters, our development every has a We have a From orphan drugs to blockbusters, our development every molecule molecule has a challenge. challenge.

We have supply a solution. solution.

From orphan drugsfor to payers, blockbusters, our development expertise, delivery technologies and reliable deliver better outcomes patients and innovators. expertise, delivery technologies and reliable supply deliver better outcomes for payers, patients and innovators. expertise, delivery technologies and reliable supply deliver better outcomes for payers, patients and expertise, delivery technologies and reliable supply deliver better outcomes for payers, patients and innovators. innovators.

INNOVATIVE INNOVATIVE DELIVERY OPTIONS INNOVATIVE INNOVATIVE DELIVERY OPTIONS DELIVERY OPTIONS Solutions for more molecules DELIVERY OPTIONS

Solutions for more molecules with versatile, proven RP Solutions for molecules Solutions for more more molecules with versatile, proven RP Scherer softgelproven technologies. with versatile, RP with versatile, RP Scherer softgelproven technologies. ™ for complex optishell Scherer softgel technologies. ™ for complex Scherer softgel technologies. optishell fill formulations ™ for complex optishell fill formulations ™ complex optishell ™ for optigel biofor macromolecules fill fill formulations formulations optigel bio™ for macromolecules ™ optigel lock formacromolecules abuse deterrence ™ for optigel bio ™ bio ™for optigel lock formacromolecules abuse deterrence optigel ™ for optigel lock lock™ for abuse abuse deterrence deterrence

enhanCed enhanCed BioavailaBility enhanCed enhanCed BioavailaBility BioavailaBility Improved solubility and BioavailaBility

Improved solubility and permeablity.

Optimized final Improved solubility and Improved solubility and final permeablity.

Optimized dose forms. Integrated services permeablity.

Optimized final permeablity.

Optimizedservices final dose forms. Integrated from forms. development to supply. dose Integrated services dose Integrated services from forms. development to supply. rp scherer softgel technologies from development to supply. supply. from development to rp scherer softgel technologies ™ hme technology optimelt rp softgel technologies ™ hme rp scherer scherer softgel technologies optimelt technology zydis® nano technology ™ hme optimelt technology ™ hme technology optimelt zydis® nano technology ® nano technology zydis ® zydis nano technology

optiMized optiMized ContRolled Release optiMized optiMized ContRolled Release ContRolled Release Better outcomes with improved ContRolled Release

Better outcomes with improved regimens and target release Better with improved Better outcomes outcomes withrelease improved regimens and target profiles.

Aand wide range of regimens target release regimensAand target release profiles. wide range of dosing options: combination, profiles.

A wide range of profiles.options: A wide combination, range of dosing dividable and pulsed release. dosing options: options: combination, dosing combination, dividable and pulsed release. controlled release technologies dividable and pulsed release. dividable and pulsed release. controlled release technologies ™ tablets osdrc® optidose controlled release technologies ™ tablets controlled release technologies rc® optidose osd ® optidose™ tablets r c osd ® ™ osdrc optidose tablets

solutions foR solutions foR taRget populations solutions foR solutions foR taRget populations taRget populations Better adherence and patient taRget populations

Better adherence and patient outcomes.

Ideal for pediatric and Better and patient Better adherence adherence and patient and outcomes.

Ideal for pediatric geriatric populations, specificand outcomes.

Ideal for pediatric outcomes.

Ideal for pediatric geriatric populations, specificand conditions and disease areas. geriatric populations, geriatric populations, specific conditions and diseasespecific areas. ® fast-dissolve zydis conditions and disease disease areas. areas. ® fast-dissolve conditions and zydis tablets & granules ® zydis tablets & granules fast-dissolve zydis® fast-dissolve ™ technology optigel micro tablets micro & granules granules ™ technology tablets & optigel optigel ™ technology optigel micro micro™ technology

Catalent. More products. Better treatments. Reliably supplied.™ Catalent. More products. Better treatments. Reliably supplied.™ ™ @catalent.com Catalent.

More Better treatments.

Reliably + 1 888 SOLUTION solutions www.catalent.com/betteroutcomes Catalent.

More products. products.

Better treatments.

Reliably supplied. supplied.™ @catalent.com + 1 888 SOLUTION solutions www.catalent.com/betteroutcomes + @catalent.com + 11 888 888 SOLUTION SOLUTION solutions solutions@ catalent.com www.catalent.com/betteroutcomes www.catalent.com/betteroutcomes

every every molecule molecule has has a challenge. a challenge.

We We have have a solution. a solution.

From From orphan orphan drugs drugs to to blockbusters, blockbusters, our our development development every every molecule molecule has has a challenge. a challenge.

We We have have a solution. a solution.

From From orphan orphan drugs drugs to to blockbusters, blockbusters, our our development development every every molecule molecule has has a challenge. a challenge.

We We have have a solution. a solution.

From From orphan orphan drugs drugs to to blockbusters, blockbusters, our our development development every molecule has a challenge.

We have a supply solution.

From orphan drugs tofor blockbusters, our development expertise, expertise, delivery delivery technologies technologies and and reliable reliable supply deliver deliver better better outcomes outcomes for payers, payers, patients patients and and innovators. innovators. every molecule has a challenge.

We have a solution.

From orphan drugs to blockbusters, our development expertise, expertise, delivery delivery technologies technologies and and reliable reliable supply supply deliver deliver better better outcomes outcomes forfor payers, payers, patients patients and and innovators. innovators. every molecule has a challenge.

We have a solution.

From orphan drugs to blockbusters, our development expertise, expertise, delivery delivery technologies technologies and and reliable reliable supply supply deliver deliver better better outcomes outcomes for for payers, payers, patients patients and and innovators. innovators. every molecule has a challenge.

We have a solution.

From orphan drugs to blockbusters, our development expertise, expertise, delivery delivery technologies technologies and and reliable reliable supply supply deliver deliver better better outcomes outcomes for for payers, payers, patients patients and and innovators. innovators. every molecule has a challenge. We have a solution. From orphan drugs to blockbusters, our development expertise, delivery technologies and reliable supply deliver better outcomes for payers, patients and innovators. expertise, delivery technologies technologies and reliable reliable supply supply deliver deliver better outcomes outcomes for for payers, payers, patientsfoR and innovators. enhanCed enhanCed optiMized optiMized solutions solutions foRinnovators.

INNOVATIVE INNOVATIVE expertise, delivery and better patients and INNOVATIVE INNOVATIVE DELIVERY DELIVERY OPTIONS OPTIONS INNOVATIVE INNOVATIVE INNOVATIVE INNOVATIVE DELIVERY DELIVERY OPTIONS OPTIONS INNOVATIVE INNOVATIVE DELIVERY DELIVERY OPTIONS OPTIONS Solutions Solutions for for more more molecules molecules DELIVERY DELIVERY OPTIONS OPTIONS DELIVERY OPTIONS Solutions Solutions for for more more molecules molecules INNOVATIVE INNOVATIVE DELIVERY OPTIONS with with versatile, versatile, proven proven RP RP Solutions Solutions for for more more molecules molecules Solutions Solutions for for more more molecules molecules with with versatile, versatile, proven proven RP RP DELIVERY OPTIONS Solutions for more molecules DELIVERY OPTIONS Scherer Scherer softgel softgel technologies. technologies. with with versatile, versatile, proven RP RP Solutions forproven more molecules

with with versatile, versatile, proven proven RP RP Scherer Scherer softgel softgel technologies. technologies. with versatile, proven RP ™ for ™for Solutions more molecules for complex complex optishell optishell Solutions for more molecules Scherer Scherer softgel softgel technologies. technologies. with versatile, proven RP ™ for ™ for Scherer Scherer softgel softgel technologies. technologies. complex complex optishell optishell Scherer softgel technologies. fill fill formulations formulations with versatile, proven RP ™ ™ with versatile, proven RP Scherer softgel technologies. for for complex complex optishell optishell filloptishell fill formulations formulations ™ for ™ for complex optishell ™ for complex optishell ™softgel ™complex optigel optigel biobio for for macromolecules macromolecules Scherer technologies. fill fill formulations formulations ™ for Scherer technologies. complex optishell ™softgel ™ for filloptigel fill formulations formulations optigel biobio for macromolecules macromolecules fill formulations ™ for ™ for ™ optigel optigel lock lock abuse abuse deterrence deterrence complex optishell ™ ™ fill formulations optigel optigel bio bio for for macromolecules macromolecules for complex optishell ™™ ™™ ™ optigel optigel bio bio for for macromolecules macromolecules ™ lock lock for abuse abuse deterrence deterrence optigel bio for for macromolecules fill formulations fill formulations ™™ ™ bio for macromolecules optigel optigel lock lock for for abuse abuse deterrence deterrence ™ for ™ for optigel optigel lock lock abuse abuse deterrence deterrence ™ optigel lock for abuse deterrence optigel bio for macromolecules ™™ optigel lock bio™ for macromolecules for abuse deterrence ™ for abuse deterrence optigel lock optigel lock™ for abuse deterrence

enhanCed enhanCed BioavailaBility BioavailaBility enhanCed enhanCed enhanCed enhanCed BioavailaBility BioavailaBility enhanCed enhanCed BioavailaBility BioavailaBility Improved Improved solubility solubility andand BioavailaBility BioavailaBility BioavailaBility Improved Improved solubility solubility andand enhanCed enhanCed BioavailaBility permeablity. permeablity.

Optimized Optimized final final Improved Improved solubility solubility and Improved Improved solubility solubility andand and permeablity. permeablity.

Optimized Optimized final final BioavailaBility Improved solubility and BioavailaBility dose dose forms. forms.

Integrated Integrated services services permeablity. permeablity.

Optimized Optimized final final Improved solubility and

permeablity. permeablity.

Optimized Optimized final final dose dose forms. forms.

Integrated Integrated services services permeablity.

Optimized final from from development development to supply. to supply.

Improved solubility and Improved solubility and dose dose forms. forms.

Integrated Integrated services services permeablity.

Optimized final dose dose forms. forms.

Integrated Integrated services services from from development development to supply. to supply. dose forms.

Integrated services permeablity.

Optimized final rp scherer rp scherer softgel softgel technologies technologies permeablity.

Optimized final from from development development to supply. to supply. dose forms.

Integrated services from from development development to technologies supply. to rp scherer rp scherer softgel softgel technologies from development to supply. supply. dose forms.

Integrated services ™ hme ™ hme optimelt optimelt technology technology dose forms.

Integrated services from development to supply. rp rp scherer softgel softgel technologies technologies ™ hme ™ hme rp scherer scherer rp scherer softgel softgel technologies technologies optimelt optimelt technology technology rp scherer softgel technologies from development to supply. ® ® zydis zydis nano technology from development to supply. ™nano ™technology rp scherer softgel technologies optimelt optimelt hme hme technology technology ™ hme ® nano ®™nano optimelt optimelt hme technology technology ™ zydis zydis technology technology optimelt hme technology rp softgel technologies ™technology rp®®scherer scherer softgel technologies ® nano optimelt hme technology zydis zydis nano technology ® nano zydis zydis nano technology technology ® zydis nano technology ™ hme optimelt ™ hme technology optimelt technology zydis® nano technology ® zydis zydis® nano nano technology technology

optiMized optiMized ContRolled ContRolled Release Release optiMized optiMized optiMized optiMized ContRolled ContRolled Release Release optiMized optiMized ContRolled ContRolled Release Release Better Better outcomes outcomes with with improved improved ContRolled ContRolled Release Release ContRolled Release Better Better outcomes outcomes with with improved improved optiMized optiMized ContRolled Release regimens regimens andand target target release release Better Better outcomes outcomes with with improved improved Better Better outcomes outcomes with with improved improved regimens regimens andand target target release release ContRolled Release Better outcomes with improved ContRolled Release profiles. profiles. wide Aand wide range range ofrelease of regimens regimens and target target release BetterAoutcomes with improved

regimens regimens target target release profiles. profiles.

Aand wide Aand wide range range ofrelease of regimens and target release dosing dosing options: options: combination, combination, Better outcomes with improved Better with improved profiles. profiles.

A wide A wide range range of of regimens and target profiles. profiles.

Aoutcomes wide A wide range range ofrelease of dosing dosing options: options: combination, combination, profiles.

A wide range of dividable dividable and and pulsed pulsed release. release. regimens and target release regimens and target release dosing dosing options: options: combination, combination, profiles.

Aand wide range of dosing dosing options: options: combination, combination, dividable dividable and pulsed pulsed release. release. dosing options: combination, profiles.

A wide range of controlled controlled release release technologies technologies profiles.

A wide range of dividable dividable and and pulsed pulsed release. release. dosingand options: combination, dividable dividable and pulsed pulsed release. release. controlled controlled release release technologies technologies dividable and pulsed release. dosing options: ™ tablets ™combination, rc® roptidose c® optidose tablets osdcontrolled osd dosing options: combination, dividable and pulsed release. controlled release release technologies technologies ® roptidose ® optidose ™ tablets ™ technologies controlled controlled release release technologies r c c tablets osd osd controlled release technologies dividable and pulsed release. dividable and pulsed release. ® ® ™ ™ controlled release technologies c® rroptidose optidose c®® optidose optidose tablets tablets osdosd osd ™ tablets ™ tablets rrc osd ™ rc c optidose tablets osd controlled release technologies ™ tablets controlled release technologies rc® optidose osd ® ™ osd c® optidose optidose™ tablets tablets osdrrc

solutions solutions foR foR taRget taRget populations populations solutions solutions foR foR solutions solutions foR foR taRget taRget populations populations solutions foR solutions foR taRget taRget populations populations Better Better adherence adherence and and patient patient taRget taRget populations populations taRget populations Better Better adherence adherence and and patient patient solutions foR solutions foR taRget populations outcomes. outcomes.

Ideal Ideal for for pediatric pediatric andand Better Better adherence adherence and and patient patient Better Better adherence adherence and and patient patient outcomes. outcomes.

Ideal Ideal for for pediatric pediatric andand taRget populations Better adherence and patient taRget populations geriatric geriatric populations, specific specific outcomes. outcomes.

Ideal Ideal for for pediatric pediatric andand Betterpopulations, adherence and patient outcomes. outcomes.

Ideal Ideal for for pediatric pediatric andand geriatric geriatric populations, populations, specific specific outcomes.

Ideal for pediatric conditions conditions and and disease disease areas. areas.and Better adherence and patient Betterpopulations, adherence and patient geriatric geriatric populations, specific specific outcomes.

Ideal for pediatric geriatric geriatric populations, populations, specific specific conditions conditions and and disease disease areas. areas.and geriatric populations, specific ® ® outcomes.

Ideal for and fast-dissolve fast-dissolve zydis zydis outcomes.

Ideal for pediatric pediatric and conditions conditions and and disease disease areas. areas. geriatric populations, specific ® fast-dissolve conditions conditions and disease disease areas. areas. zydis zydis conditions and disease areas. tablets tablets &®® fast-dissolve granules &and granules geriatric ® fast-dissolve geriatric populations, specific conditions and diseasespecific areas. zydis zydis tablets tablets &®® fast-dissolve granules & populations, granules ® fast-dissolve fast-dissolve zydis zydis fast-dissolve ™and ™ technology zydis optigel optigel micro micro technology conditions disease tablets tablets & granules & granules conditions disease areas. areas. ™and ™ technology zydis tablets tablets &® fast-dissolve granules & optigel optigel micro micro technology tablets & granules granules ® fast-dissolve ™ technology ™ technology zydis tablets & granules ® fast-dissolve optigel optigel micro micro ™ ™ zydis optigel optigel micro micro technology technology ™ technology optigel micro tablets & ™ technology tablets micro & granules granules optigel optigel ™ technology optigel micro micro™ technology

™ ™ Catalent.

Catalent.

More More products. products.

Better Better treatments. treatments.

Reliably Reliably supplied. supplied. ™ ™ Catalent.

Catalent.

More More products. products.

Better Better treatments. treatments.

Reliably Reliably supplied. supplied. ™ ™ ™ ™ @ @ Catalent.

Catalent.

More More products. products.

Better Better treatments. treatments.

Reliably Reliably supplied. supplied. + 1 + 888 1 888 SOLUTION SOLUTION solutions solutions catalent.com catalent.com www.catalent.com/betteroutcomes www.catalent.com/betteroutcomes ™ Catalent.

Catalent.

More More products. products.

Better Better treatments. treatments.

Reliably Reliably supplied. supplied.

Catalent.

More products.

Better treatments.

Reliably supplied. @catalent.com @catalent.com + 1+ 888 1 888 SOLUTION SOLUTION solutions solutions www.catalent.com/betteroutcomes www.catalent.com/betteroutcomes ™ Catalent.

More products.

Better treatments.

Reliably supplied. @ @ + 1 + 888 1 888 SOLUTION SOLUTION solutions solutions catalent.com catalent.com www.catalent.com/betteroutcomes www.catalent.com/betteroutcomes ™ @catalent.com @catalent.com + 1Catalent. + 888 1 888 SOLUTION SOLUTION solutions solutions www.catalent.com/betteroutcomes www.catalent.com/betteroutcomes ™ @ More products.

Better treatments.

Reliably supplied. + 1 888 SOLUTION (765 8846) solutions catalent.com www.catalent.com/betteroutcomes Catalent.

More products.

Better treatments.

Reliably supplied. + 1 888 SOLUTION solutions@catalent.com www.catalent.com/betteroutcomes @ + 1 888 SOLUTION solutions catalent.com www.catalent.com/betteroutcomes + 1 888 SOLUTION solutions@catalent.com www.catalent.com/betteroutcomes

President’s Welcome to the Annual Meeting translation (n): transference to a different place It isn’t easy to extract ourselves from day-to-day demands and arrive at an annual meeting miles and time zones away. But overcoming jet lag is insignificant when compared to the impact we can make when, together, we overcome the biological and technological barriers confronting us.

For your efforts, passion, and professionalism, I thank you for being present at the 41st Annual Meeting & Exposition of the Controlled Release Society.

Ian Tucker

During the last year as your CRS president, I have led the drive to build an efficient, nimble society that is continually adapting to rapidly changing needs across disciplines and around the globe. I’ve talked about “controlled delivery of relevant information” that keeps our community well-informed of breakthroughs and challenges. To bring knowledge to a broader audience, I am excited to announce that a webinar series beginning in September is well underway. (Please visit CRS Central in the Exhibition Hall for more information about this initiative.)

Our vibrant organization will also need to rely on the enthusiasm of young professionals to carry the torch for the next 41 years and beyond. To be the society of choice, we must continue to provide a clearly articulated sense of purpose—one we can all embrace and support through education, knowledge sharing, and partnership. Young professionals, be sure to take advantage of all the targeted programs here in Chicago, created just for you.

Translation of Delivery Technology: Innovation to Commercialization is our theme this year, and it defines our critical role in transferring science and technology from research to “real world” applications. But translation also means transference to a different place. I hope you will make this year’s annual meeting a personal journey and that you emerge on the other side with new focus, renewed vigor, and the drive to contribute to the long-term success of your society.

Welcome to the 41st Annual Meeting. It has been a privilege to serve as your president this past year.

Ian Tucker University of Otago Dunedin, New Zealand

1

2014 Program Team

Table of Contents

Chair Ick Chan Kwon KIST, Korea

Deputy Chair Justin Hanes Johns Hopkins University, U.S.A.

You Han Bae University of Utah, U.S.A.

Donald Barbieri Patheon, U.S.A.

Ben Boyd Monash University, Australia

Peter Cheifetz Merial Limited, U.S.A.

General Meeting Information .................................... 4 Hilton Chicago Salons A–D Lower Level ................. 6 Schedule-at-a-Glance Saturday – Sunday ................................................. 7 Monday – Tuesday ................................................ 8 Tuesday – Wednesday ........................................... 9 Daily Schedule Saturday .............................................................. 10 Sunday ................................................................ 11 Technology Forums ........................................ 14 Soapbox Sessions ............................................ 16 Monday .............................................................. 17 Tuesday ............................................................... 24 Wednesday .......................................................... 33 Posters ...................................................................... 36 Exposition ................................................................ 45 Sponsors ................................................................... 52 Awards & Recognition ............................................. 55 Acknowledgements .................................................. 61 2014 CRS Presenting Author Index ......................... 63

Advertisers’ Index Catalent Pharma Solutions.............. Inside Front Cover www.catalent.com Patheon Pharmaceuticals Services .............. Back Cover www.patheon.com

Samir Mitragotri University of California, U.S.A.

Ruth Schmid SINTEF, Norway

Hardik Shah Alkermes Pharma Ireland Limited, Ireland

Ronald Smith Merck, U.S.A.

Geert Verreck Janssen Pharmaceutica, Belgium

Fanwen Zeng Dow Chemical Company, U.S.A.

2

Controlled Release Society Publications .............................................................. 19 CRS Headquarters Staff ........................................... 26 Springer .................................................................... 27 Abstracts .............................................................. 33, 56 CRS and AAPS Workshop ...................................... 44 CRS Foundation ...................................................... 60 42nd Annual Meeting & Exposition of the Controlled Release Society .......... Inside Back Cover

Access the Meeting Anytime, Anywhere 2014 CRS Annual Meeting App • • •

• • •

Check the program schedule Read the abstracts Create your personal schedule and to-do lists Receive announcements Connect with fellow attendees See what companies are in the exhibit hall

Download Now. It’s Fast and Easy.

Search “CRS Meeting” in your app store.

Or access the app website: mobileapp.controlledrelease.org When accessing the app for the first time, you will have the option to set a password. If you choose not to set a password, no password will be needed to access your app and CRS Connect profile.

WiFi is available in the Hilton Chicago meeting spaces for all CRS annual meeting attendees, free of charge.

General Meeting Information Registration Desk

WiFi Access

The Registration Desk is located on the lower level in the Exhibit Hall Saturday through Tuesday and on lobby level at the 8th Street Registration desk on Wednesday. The desk will be open as follows:

CRS has contracted with the Hilton Chicago to provide WiFi access during the annual meeting. This access will be available to all attendees for the duration of the meeting. WiFi coverage is available throughout the meeting space at the Hilton. Power up your laptop to connect to meeting abstracts on the CRS website, or use your mobile device to utilize CRS Connect and the mobile app. Select the Hilton Chicago meeting network; after connecting with the Hilton network launch your web browser, which will redirect you to the login page.

Saturday, July 12 Sunday, July 13 Monday, July 14 Tuesday, July 15 Wednesday, July 16

07:00 – 15:00 07:30 – 18:00 07:00 – 17:30 07:00 – 17:30 07:30 – 12:00

Access the Abstracts CRS Annual Meeting abstracts can easily be accessed using the CRS Annual Meeting app, the CRS website, and the abstract printing station. The app provides access via your mobile device or laptop; simply click on the Posters icon to begin viewing poster abstracts, and view podium abstracts directly from the schedule. Sign into the CRS website to view and search the abstracts, available to all registered attendees. The abstract printing station is located in CRS Central and provides the convenience of printing abstracts of interest.

Visit CRS Central CRS tools and resources help you stay on top of the growing global and multidisciplinary field of delivery science. Check out CRS books, journals, webcasts, and other CRS offerings at CRS Central, located in Exhibit Hall Salon D.

CRS Connect As a CRS Annual Meeting attendee, CRS Connect is your foremost opportunity to network with colleagues while in Chicago. After accessing the CRS Annual Meeting app, select the CRS Connect icon and search through the database of meeting attendees. Once you identify an individual you wish to contact, click on their name to either send them a private message or request an appointment. All of this takes place through CRS Connect while maintaining full privacy, as personal contact information is never shared.

CRS Annual Meeting App View the program, read the abstracts, create your personal schedule and to-do lists, receive announcements, connect with fellow attendees using CRS Connect, and see what companies are in the Exhibit Hall—all with your CRS Annual Meeting App. Download the CRS 2014 app by searching for “CRS Meeting” in the iTunes Store or Google Play. Reach the app from your BlackBerry or laptop via the app website: mobileapp.controlledrelease.org

Electronic Devices As a courtesy to other meeting attendees, please turn off or silence all electronic devices during all workshops, sessions, and presentations.

4

Username: CRS2014 Password: CRS

Share Your Annual Meeting Photos on Instagram!

For the first time, CRS will be using Instagram to share images taken during the annual meeting. Upload your CRS Annual Meeting photos using #CRSMeeting.

Share all of your experiences while in Chicago, including the C&DP and Women in Science Luncheons, the boat tour during the Young Scientist Networking Event, Buddy Guy’s Legends during the PSAH Networking Get-Together, and more with your colleagues!

Photography Photography of scientific content is not permitted in the session rooms, exhibit hall, or poster sessions. Contact CRS staff at the Registration Desk for further clarification.

Awards CRS will be honoring several awardees throughout the meeting.

Awards will be given out at the Monday Opening Session and during the three plenary sessions. See daily highlights and the Awards & Recognition section of this program book for more information.

Exposition Hours and Location The Exposition is located in the lower level Salons C & D and has dedicated hours when all exhibitors are present at their booths. The scheduled Exposition activities are as follows: Set-Up Saturday, July 12 08:00 – 17:00

Sunday, July 13 08:00 – 14:00

Exposition Open Sunday, July 13 17:30 – 19:30 Exposition Grand Opening and Welcome Reception Monday, July 14 09:30 – 10:30 Exposition Open – Meet with Exhibitors, Refreshment Break 09:30 – 17:30 Exposition Hall Open 16:30 – 17:30 Poster Viewing and Exposition

Happy Hour – Meet with Exhibitors, Refreshment Break

Tuesday, July 15 09:30 – 10:30 Exposition Open – Meet with Exhibitors, Refreshment Break 09:30 – 16:00 Exposition Hall Open 15:00 – 16:00 Exposition Open – Meet with Exhibitors, Refreshment Break Take-Down Tuesday, July 15 16:00 – 18:00 Exhibit Take-Down

Poster Sessions The posters are located in Exhibit Hall Salons A & D. All posters will be on display Sunday through Tuesday during the designated hours. Poster authors will be present during one of three prespecified time slots. All posters must be removed during Poster Take-Down or they will be removed and discarded. The poster viewing area will be secured overnight.

Photographing of posters is not permitted.

2014 Poster Schedule Sunday, July 13 08:00 – 14:00 Exhibit and Poster Set-Up 17:30 – 19:30 Poster Viewing Hours, Exposition Grand Opening and Welcome Reception Monday, July 14 09:30 – 10:30 Poster Session 1 – Authors Present 09:30 – 17:30 Poster Viewing Hours 16:30 – 17:30 Poster Viewing and Exposition Happy Hour Tuesday, July 15 07:00 – 16:00 Poster Viewing Hours 09:30 – 10:30 Poster Session 2 – Authors Present 15:00 – 16:00 Poster Session 3 – Authors Present 16:00 – 17:00 Poster Take-Down

Poster Snapshots Poster Snapshots are three-minute audio recordings that provide a summary preview of poster content. Attendees can listen to a recording at any time, including prior to attending the poster sessions and even while standing in front of a poster.

Poster Snapshots are submitted by poster presenters and are available through the CRS Annual Meeting App.

Speaker Preparation Room PDR #2 (3rd Level) The Speaker Preparation Room is available for PowerPoint previewing and downloading presentation materials. Speakers are to upload presentations one day prior to their presentation date (e.g., if you speak on Monday, July 14, you will upload your presentation on Sunday, July 13). Presenters are not allowed to use their own laptops to give their presentations. The Speaker Preparation Room will not be open on Wednesday, July 16.

The Speaker Preparation Room will be staffed and open as follows: Saturday, July 12 07:00 – 17:00 Sunday speakers upload presentations Sunday, July 13 07:00 – 17:30 Monday speakers upload presentations Monday, July 14 07:00 – 17:30 Tuesday speakers upload presentations Tuesday, July 15 07:00 – 17:30 Wednesday speakers upload presentations

Committee Meetings CRS committees (and other attendees) are invited to schedule meetings by reserving a meeting room at the Registration Desk.

A limited number of meeting rooms are available for use Sunday through Wednesday.

Meeting Schedule (as of June 12, 2014)

Monday, July 14 Young Scientist Committee 09:30 – 10:30 Tuesday, July 15 DDTR Editorial Board 07:00 – 08:00 International Committee 09:30 – 10:30 JCR Editorial Board 12:00 – 13:00 Satellite Meeting Committee 15:00 – 16:00 Consumer & Diversified Products Division 16:00 – 17:30 Board of Scientific Advisors 16:00 – 17:30 Wednesday, July 16 Finance Committee Volunteer Recruitment Committee 2015 CRS Annual Meeting Program Committee Preclinical Sciences & Animal Health Division

4K – 4th level 4K – 4th level 4L – 4th level 4M – 4th level 4K – 4th level 4L – 4th level 4M – 4th level

07:00 – 08:00

4K – 4th level

07:00 – 08:00

4L – 4th level

11:00 – 12:00

4M – 4th level

11:00 – 12:00

4K – 4th level

Photo Release Many photographs will be taken throughout the CRS Annual Meeting & Exposition and are used in CRS electronic and printed promotional materials during the meeting and after it has concluded. By virtue of your attendance, you agree to the Controlled Release Society’s use of your likeness in said promotional media.

Children and the CRS Annual Meeting & Exposition The CRS Annual Meeting & Exposition is a professional, scientific meeting. CRS does not permit children under the age of 18 to attend the scientific sessions, poster sessions, exposition, and social events. For safety reasons, only registered exhibitors and poster presenters are permitted in the exposition/ poster hall during set-up and take-down hours. Children 18+ must register and buy applicable individual tickets if not attending/registering as a student.

Message Board For your convenience, a message board is located next to the CRS Registration Desk. The board may be used to post job openings/resumes, messages to colleagues, or other relevant information.

Meeting and Future Event Literature Space for the display of promotional materials for future educational meetings is available near the CRS Registration Desk. Organizers of educational meetings and events may display their materials in this reserved location. Any literature that is left in areas other than the designated location or that does not promote educational meetings will be discarded.

5

HILTON CHICAGO SALONS A-D LOWER LEVEL

ELEC. FS

FS

SERVICE CORRIDOR FS

FH FEX

STORAGE

STORAGE

FROM NE FROM NW

CL.

FS

FS EE

FEX

ELEC.

FS

STORAGE

STORAGE

STORAGE ROOM

FS

FS FH

RAMP RAMP

SALON B

FEX

EE

NOT IN USE

FS

EXIT

FS FEX

FEX FS

ELEC. FS

FEX

SALON A

FS

POSTERS

EXIT

HOTEL SIGN 7' x 7" x 6" 8'5" HIGH

HOTEL SIGN 7' x 7" x 6" 8'7" HIGH

DN

FEX

FEX

EXHIBIT REGISTRATION

MOBLEY ROOM

FS FEX

FEX

FEX FH

RAMP

FROM SW

RAMP

FS EE FS

FEX FEX

FE

FEX

LOADING AREA

UP

CAUTION: LOW SPRINKLER HEADS

NW FREIGHT ELEVATOR

STORAGE

FS

FEX

ELEVATOR LOBBY

BEAUTY AND BARBER SHOP

HOTEL SIGN HOTEL SIGN

UP FEX

FS

FS

FS

FS

LIFT

EE

RAMP

ENTRANCE

FE HOTEL SIGN 8'0" HIGH

FROM SW

TO SE

7'x7"x6"

UP

FEX FS FH

FS

8'5" HIGH

FS

FS

7' x 7" SIGN

FH FEX

FE

FS

FS

FS

FS

UP TO RESTROOMS

SW FREIGHT ELEVATOR CAR 27 FS

CL.

EXPOSITION CRS CENTRAL POSTERS

EE

SALON C

MECH.

SALON D

FS

FH FEX FS

UP

OVERHEAD DOOR 8'2"W X 7'H

FS

FEX

FS FH FEX

FS

DN

ENTRANCE

MECH. EE

UP

FEX

MECH. HANDICAP ELEV.

STAIRWELL TO WABASH AVE.

HOTEL SIGN

DN

HOTEL SIGN

FEX STORAGE FDC OFFICE

SE FREIGHT ELEVATOR CAR 25

DN

EXPOSITION REGISTRATION FS FEX

FEX

EE

HILTON STORAGE

FH FEX

UP TO RESTROOMS

FS

FDC OFFICE

FH FEX

FS

FS

PIPES

EE

FS

FS FS

6

FS

MECH.

FS

ELEC.

FEX FS

STORAGE

PLMG. ROOM

KEEP CLEAR HOTEL STORAGE

Schedule-at-a-Glance Saturday, July 12 07:00 – 15:00 07:00 – 17:00 08:00 – 12:00 08:00 – 17:00 08:00 – 17:00

08:00 – 17:00 08:45 – 17:00

12:00 – 14:00 13:00 – 17:00

CRS Registration Open Speaker Preparation Room Open Young Scientist Workshop: The Science of Publishing Exhibit Set-Up Premeeting Workshop: Nanotechnology – Process and Formulation, Characterization and Applications* Premeeting Workshop: Oral Delivery of Peptides and Proteins* Premeeting Workshop: Albumin: The Next Generation Protein Therapeutic* Leadership Forum (by invitation) Young Scientist Workshop: Novel Technologies in Solubility Enhancement

Exhibit Hall Salon C – lower level PDR #2 – 3rd level Marquette – 3rd level Exhibit Hall Salons C & D – lower level Continental C – lobby level Continental A – lobby level Continental B – lobby level Astoria – 3rd level Marquette – 3rd level

Sunday, July 13 07:00 – 17:30 Speaker Preparation Room Open PDR #2 – 3rd level 07:30 – 18:00 CRS Registration Open Exhibit Hall Salon C – lower level 08:00 – 12:00 Premeeting Workshop: Computational Pharmaceutics – Continental B – lobby level

The Application of Computer Modeling in Drug Delivery* 08:00 – 12:00 Premeeting Workshop: Locally Acting Dermal Products – Joliet – 3rd level

Global Challenges for Development and Registration* 08:00 – 12:00 Premeeting Workshop: Nanotechnology – Process and Continental C – lobby level

Formulation, Characterization and Applications* 08:00 – 12:00 Premeeting Workshop: Oral Delivery of Peptides and Proteins* Continental A – lobby level 08:00 – 12:00 Young Scientist Workshop: Communication and Networking: Marquette – 3rd level

How to Develop and Utilize These Skills for a Successful Career 08:00 – 14:00 Exhibit and Poster Set-Up Exhibit Hall Salons A, C & D – lower

level 09:00 – 10:00 Technology Forum: Catalent Pharma Solutions Boulevard B – 2nd level 09:00 – 10:00 Technology Forum: Gattefossé Corporation Buckingham – lobby level 09:00 – 11:00 Technology Forum: Nanomi & Purac Corbion Biomaterials Boulevard C – 2nd level 09:00 – 11:15 Technology Forum: Evonik Corporation Boulevard A – 2nd level 10:15 – 11:15 Technology Forum: Lubrizol LifeScience Polymers Boulevard B – 2nd level 10:15 – 12:15 Technology Forum: Octoplus N.V., Aradigm & Regulus Buckingham – lobby level 11:30 – 12:30 First Timers’ Meeting International Ballroom South – 2nd level 11:30 – 12:30 Technology Forum: Apidel Boulevard A – 2nd level 11:30 – 12:30 Technology Forum: Patheon Pharmaceuticals Services Inc. Boulevard B – 2nd level 11:30 – 12:30 Technology Forum: Shin-Etsu Chemical Group Co. Ltd. Boulevard C – 2nd level 12:30 – 14:00 Young Scientist Roundtable: Imaging in Drug Delivery: Marquette – 3rd level

Current Practice, Regulatory Challenges, and Future Trends 13:00 – 15:00 Soapbox Sessions Continental AB – lobby level 14:00 – 15:30 Mentor/Protégé Meet & Greet Marquette – 3rd level 15:30 – 17:30 Industry Roundtable: Patient Adherence and the Future Continental AB – lobby level

of Innovative Drug Delivery 17:30 – 19:30 Exposition Grand Opening and Welcome Reception Exhibit Hall Salons A, C & D – lower

level 17:30 – 19:30 Poster Viewing Hours Exhibit Hall Salons A & D – lower level

*Additional registration, payment, and ticket required.

7

Schedule-at-a-Glance Monday, July 14 07:00 – 08:00 Get Up! Get Educated! Writing a Successful Grant Application Continental C – lobby level 07:00 – 17:30 Speaker Preparation Room Open PDR #2 – 3rd level 07:00 – 17:30 CRS Registration Open Exhibit Hall Salon C – lower level 08:10 – 09:30 CRS Opening Session Grand Ballroom – 2nd level 09:30 – 10:30 Exposition Open – Meet with Exhibitors, Refreshment Break Exhibit Hall Salons C & D – lower level 09:30 – 10:30 Poster Session 1 – Authors Present Exhibit Hall Salons A & D – lower level 09:30 – 10:30 Young Scientist Committee Meeting 4K – 4th level 09:30 – 17:30 Exposition Hall Open Exhibit Hall Salons C & D – lower level 09:30 – 17:30 Poster Viewing Hours Exhibit Hall Salons A & D – lower level 10:30 – 12:00 Scientific Sessions • Advances in Process Engineering – New Methods Continental A – lobby level

for the Production of Particles, Capsules, and Coatings • Innovations in Oral Drug Delivery Grand Ballroom – 2nd level

• Intracellular Delivery of Nucleic Acids and Proteins Continental B – lobby level

• Mini-Symposium: Interspecies Clinical Pharmacology Boulevard ABC – 2nd level

Dosing Concepts • Overcoming Biological Barriers Continental C – lobby level

Women in Science Luncheon* Marquette – 3rd level 12:00 – 13:30 13:30 – 14:45 Plenary Session: David W. Grainger Grand Ballroom – 2nd level Scientific Sessions 15:00 – 16:30 • Advances in RNA and DNA Delivery Grand Ballroom – 2nd level • Evaluation and Characterization of Controlled Continental A – lobby level Release Products and Production Processes • Mini-Symposium: Advancements to Develop and Delivery Continental C – lobby level Biologics • Nanoparticle-Based Delivery to the Brain Continental B – lobby level • Transdermal Delivery Boulevard ABC – 2nd level Poster Viewing and Exposition Happy Hour – Meet with Exhibit Hall Salons 16:30 – 17:30

Exhibitors, Refreshment Break A, C & D – lower level PSAH Networking Get-Together* Buddy Guy’s Legends 17:30 – 18:30 21:00 – 22:30 Young Scientist Networking Event* Mystic Blue Boat Ride – Navy Pier

Tuesday, July 15 07:00 – 08:00

07:00 – 08:00

07:00 – 16:00 07:00 – 17:30 07:00 – 17:30 08:00 – 09:30 09:30 – 10:30

09:30 – 10:30 09:30 – 10:30 09:30 – 16:00 10:30 – 12:00

Drug Delivery and Translational Research Editorial 4K – 4th level Board Meeting Get Up! Get Educated! Evolution of Controlled Release Continental C – lobby level R&D: From Pharmaceutics to Biopharmaceutics Poster Viewing Hours Exhibit Hall Salons A & D CRS Registration Open Exhibit Hall Salon C – lower level Speaker Preparation Room Open PDR #2 – 3rd level Plenary Session: Kristi Anseth Grand Ballroom – 2nd level Exposition Open – Meet with Exhibitors, Exhibit Hall Salons Refreshment Break C & D – lower level International Committee Meeting 4L – 4th level Poster Session 2 – Authors Present Exhibit Hall Salons A & D – lower level Exposition Hall Open Exhibit Hall Salons C & D – lower level Scientific Sessions • Advances in Drug Delivery to the Eye Continental B – lobby level • Mini-Symposium: Micro- and Nano-Encapsulation: Continental A – lobby level From Innovation to Commercialization • Nanoparticles in Tumor Treatment Grand Ballroom – 2nd level • Overcoming Barriers in the GI Tract Continental C – lobby level • Predictive Animal Models for Assessing Long-Acting Boulevard ABC – 2nd level Formulations for Human and Animal Health and Their

Challenges 8

Schedule-at-a-Glance Tuesday, July 15 (continued) 12:00 – 13:00 12:00 – 13:30 13:30 – 15:00

Journal of Controlled Release Editorial Board Meeting 4M – 4th level Consumer & Diversified Products Division Luncheon* Marquette – 3rd level Scientific Sessions: • Advances in Drug Delivery to the Lung Boulevard ABC – 2nd level • Controlled Release Applications in Food, Feed, and Beverages Continental A – lobby level • Innovations in Micro- and Nano-Based Delivery Continental B – lobby level • Mini-Symposium: Cancer Epigenetics, Epigenetic Continental C – lobby level Drugs, and Delivery • Proteins, Peptides, and Vaccines Grand Ballroom – 2nd level Exposition Open – Meet with Exhibitors, Exhibit Hall Salons C & D – lower level 15:00 – 16:00

Refreshment Break 15:00 – 16:00 Poster Session 3 – Authors Present Exhibit Hall Salons A & D – lower

level Satellite Meeting Committee Meeting 4K – 4th level 15:00 – 16:00 16:00 – 17:00 Poster Take-Down Exhibit Hall Salons A & D – lower

level Board of Scientific Advisors Meeting 4M – 4th level 16:00 – 17:30 College of Fellows Panel Discussion: Innovation to Continental C – lobby level 16:00 – 17:30 Commercialization 16:00 – 17:30 Consumer & Diversified Products Division Meeting 4L – 4th level Roundtables 16:00 – 17:30

• Ocular Drug Delivery Continental A – lobby level

• Oral Drug Delivery Continental B – lobby level Exhibit Take-Down Exhibit Hall Salons C & D – lower 16:00 – 18:00

level CRS President’s Banquet* Boulevard ABC – 2nd level 18:30 – 22:00

Wednesday, July 16 07:00 – 08:00 07:00 – 08:00 07:30 – 12:00 08:00 – 09:30

Finance Committee Meeting Volunteer Recruitment Committee Meeting CRS Registration Open Scientific Sessions • Breakthrough Technologies • Cells as Delivery Vehicles • Controlled Release of Actives in Consumer Products • Mini-Symposium: Individualized Medicine and Theranostics • Novel Development in Formulation, Analytical Chemistry, and Processing in Animal Health and Preclinical Sciences 09:45 – 11:00 Plenary Session: David Edwards 11:00 – 12:00 2015 CRS Annual Meeting Program Committee Meeting 11:00 – 12:00 Preclinical Sciences & Animal Health Division Meeting

4K – 4th level 4L – 4th level 8th Street Registration Desk – lobby level Grand Ballroom – 2nd level Continental B – lobby level Continental A – lobby level Continental C – lobby level Boulevard ABC – 2nd level Grand Ballroom – 2nd level 4M – 4th level 4K – 4th level

*Additional registration, payment, and ticket required.

9

Daily Schedule Saturday, July 12

Saturday

07:00 – 15:00 07:00 – 17:00 08:00 – 12:00 08:00 – 17:00 08:00 – 17:00

08:00 – 17:00 08:45 – 17:00

12:00 – 14:00 13:00 – 17:00

CRS Registration Open Speaker Preparation Room Open Young Scientist Workshop: The Science of Publishing Exhibit Set-Up Premeeting Workshop: Nanotechnology – Process and Formulation, Characterization and Applications* Premeeting Workshop: Oral Delivery of Peptides and Proteins* Premeeting Workshop: Albumin: The Next Generation Protein Therapeutic* Leadership Forum (by invitation) Young Scientist Workshop: Novel Technologies in Solubility Enhancement

Exhibit Hall Salon C – lower level PDR #2 – 3rd level Marquette – 3rd level Exhibit Hall Salons C & D – lower level Continental C – lobby level Continental A – lobby level Continental B – lobby level Astoria – 3rd level Marquette – 3rd level

Saturday Program Highlights Premeeting Workshops Oral Delivery of Peptides and Proteins* Cosponsored by Catalent Pharma Solutions 08:00 – 17:00 • Continental A – lobby level Organizers: David Brayden, University College Dublin, Ireland; and Randall Mrsny, University of Bath, United Kingdom

Controlled Release), Korea Institute of Science and Technology, Korea; Anne Marie Pordon (Publisher, Pharmacology & Pharmaceutical Sciences), Elsevier, The Netherlands; and Thomas Rades (Editor, Journal of Pharmaceutical Sciences and European Journal of Pharmaceutics and Biopharmaceutics), University of Copenhagen, Denmark;

08:00 – 17:00 • Continental C – lobby level Organizers: Teresa Virgallito, Microtek Laboratories, Inc., U.S.A.; and Nicole Papen-Botterhuis, TNO, The Netherlands

Publishing is the cornerstone of scientific research and of great importance in the career of every academic. This workshop aims to educate young scientists in the different aspects of publishing and peer review in scientific journals as well as to highlight and discuss current controversies such as open access journals, scientific integrity, impact factors, and more. The workshop will be presented by prominent editors and publishers of wellestablished pharmaceutical journals. The workshop is open to all conference attendees.

Albumin: The Next Generation Protein Therapeutic*

Novel Technologies in Solubility Enhancement

Cosponsored by Novozymes 08:45 – 17:00 • Continental B – lobby level Organizers: Kenneth Howard, Aarhus University, Denmark; and Daniel Shelly, Novozymes Biopharma US, Inc., U.S.A.

13:00 – 17:00 • Marquette – 3rd level

Nanotechnology – Process and Formulation, Characterization and Applications*

Young Scientist Workshops The Science of Publishing 08:00 – 12:00 • Marquette – 3rd level Chairs: Adam Bohr, Institute Galien Paris-Sud, France; and Jorrit Water, University of Copenhagen, Denmark Moderator: Thomas Rades, University of Copenhagen, Denmark Speakers: Ronald T. Borchardt (Editor-in-Chief, Journal of Pharmaceutical Sciences), University of Kansas, U.S.A.; Achim Göpferich (Editor-in-Chief, European Journal of Pharmaceutics and Biopharmaceutics), University of Regensburg, Germany; Ick Chan Kwon (Editor, Journal of

*Additional registration, payment, and ticket required.

10

Chairs: Marcus Brewster, Johnson & Johnson, Belgium; and Joke Meeus, KU Leuven, Belgium Speakers: Marcus Brewster, Johnson & Johnson, Belgium; Joe Lubach, Genentech, U.S.A.; Clive Roberts, The University of Nottingham, United Kingdom; Ben Boyd, Monash University, Australia; and Geert Verreck, Johnson & Johnson, Belgium Contemporary drug pipelines contain an increasing number of poorly water-soluble candidates. To overcome this problem, solubility-enhancing technologies often focus on impacting aspects of the Noyes–Whitney relationship by increasing dissolution rate or drug solubility. In view of this, the workshop aims to provide a context for deciding whether formulation enablement is necessary and which technique is most appropriate for which problem. Moreover, novel screening, analytical, and manufacturing approaches are within the scope of this training forum.

Daily Schedule 07:00 – 17:30 Speaker Preparation Room Open PDR #2 – 3rd level CRS Registration Open Exhibit Hall Salon C – lower level 07:30 – 18:00 Premeeting Workshop: Computational Pharmaceutics – Continental B – lobby level 08:00 – 12:00

The Application of Computer Modeling in Drug Delivery* 08:00 – 12:00 Premeeting Workshop: Locally Acting Dermal Products – Joliet – 3rd level

Global Challenges for Development and Registration* Premeeting Workshop: Nanotechnology – Process and Continental C – lobby level 08:00 – 12:00

Formulation, Characterization and Applications* 08:00 – 12:00 Premeeting Workshop: Oral Delivery of Peptides and Proteins* Continental A – lobby level 08:00 – 12:00 Young Scientist Workshop: Communication and Networking: Marquette – 3rd level

How to Develop and Utilize These Skills for a Successful Career 08:00 – 14:00 Exhibit and Poster Set-Up Exhibit Hall Salons A, C & D – lower

level 09:00 – 10:00 Technology Forum: Catalent Pharma Solutions Boulevard B – 2nd level 09:00 – 10:00 Technology Forum: Gattefossé Corporation Buckingham – lobby level 09:00 – 11:00 Technology Forum: Nanomi & Purac Corbion Biomaterials Boulevard C – 2nd level Technology Forum: Evonik Corporation Boulevard A – 2nd level 09:00 – 11:15 Technology Forum: Lubrizol LifeScience Polymers Boulevard B – 2nd level 10:15 – 11:15 Technology Forum: Octoplus N.V., Aradigm & Regulus Buckingham – lobby level 10:15 – 12:15 First Timers’ Meeting International Ballroom South – 11:30 – 12:30

2nd level Technology Forum: Apidel Boulevard A – 2nd level 11:30 – 12:30 11:30 – 12:30 Technology Forum: Patheon Pharmaceuticals Services Inc. Boulevard B – 2nd level Technology Forum: Shin-Etsu Chemical Group Co. Ltd. Boulevard C – 2nd level 11:30 – 12:30 Young Scientist Roundtable: Imaging in Drug Delivery: Marquette – 3rd level 12:30 – 14:00

Current Practice, Regulatory Challenges, and Future Trends 13:00 – 15:00 Soapbox Sessions Continental AB – lobby level Mentor/Protégé Meet & Greet Marquette – 3rd level 14:00 – 15:30 Industry Roundtable: Patient Adherence and the Future Continental AB – lobby level 15:30 – 17:30

of Innovative Drug Delivery 17:30 – 19:30 Exposition Grand Opening and Welcome Reception Exhibit Hall Salons A, C & D – lower level

17:30 – 19:30 Poster Viewing Hours Exhibit Hall Salons A & D – lower level *Additional registration, payment, and ticket required.

11

Sunday

Sunday, July13

Sunday Program Highlights CRS Innovation Sunday

Soapbox Sessions

Cosponsored by Pfizer

Cosponsored by Catalent Pharma Solutions

Sunday

Delivery Science Meets Business Opportunities

13:00 – 15:00 • Continental AB – lobby level

CRS Innovation Sunday is all about the business of delivery science, taking innovative ideas and technologies into the commercial sector. All of these sessions give you important new information on companies and technologies as well as great opportunities for networking face-to-face. This is the start of the CRS Annual Meeting program—don’t miss it!

Cochairs: Joe Fix, Pharma-Fix Consulting, U.S.A.; and Michael J. Valazza, Catalent Pharma Solutions, U.S.A. Moderated by: Michael J. Valazza, Catalent Pharma Solutions

Technology Forums These workshop forums are open to all registered attendees on a complimentary basis, offering in-depth coverage of controlled release technologies and services, hosted by the following companies: 09:00 – 10:00 Catalent Pharma Solutions Gattefossé Corporation 09:00 – 11:00 Nanomi & Purac Corbion Biomaterials

09:00 – 11:15 Evonik Corporation 10:15 – 11:15 Lubrizol LifeScience Polymers

Boulevard B – 2nd level Buckingham – lobby level Boulevard C – 2nd level

Boulevard A – 2nd level Boulevard B – 2nd level

10:15 – 12:15 Octoplus N.V., Aradigm & Regulus Buckingham – lobby level 11:30 – 12:30 Apidel Patheon Pharmaceuticals Services Inc. Shin-Etsu Chemical Group Co. Ltd.

Boulevard A – 2nd level Boulevard B – 2nd level Boulevard C – 2nd level

What’s new in delivery science? Come to the program where presenters “get up on their soapbox” to give you a quick glimpse of some of the most innovative technologies and products in development today. Session breaks allow time to network with presenters at their designated tables during beverage breaks, hosted by our sponsor.

Adhesives Research Apidel Avanti Polar Lipids Inc. Catalent Pharma Solutions Ceramisphere Diurnal Dow Corning Corporation Institute of Chemical & Engineering Sciences

Intec Pharma Nanocopoeia Inc. PharmaSol GmbH ProMed Pharma Southwest Research Institute SynVivo TNO University of Queensland

Industry Roundtable Cosponsored by Pfizer

15:30 – 17:30 • Continental AB – lobby level

Patient Adherence and the Future of Innovative Drug Delivery Patient non-adherence to medication takes a huge toll on healthcare budgets and on human health. Estimates indicate that in the United States alone, non-adherence to prescription regimens wastes roughly $300 billion in healthcare system costs and results in approximately 125,000 preventable deaths each year. Solving the adherence challenge is now as critical as finding the next new drug and will profoundly impact the future direction of drug delivery. This Industry Roundtable will discuss perspectives and provide insight on the latest innovative delivery technologies, devices, packaging, patient interactive feedback systems, and other future strategies to increase patient adherence and treatment outcomes.

Moderator: Ronald Smith, Merck & Company, U.S.A. Panelists: Gary Cleary, Corium International, U.S.A. Tom Tice, Evonik Corp., U.S.A. Julia Rashba-Step, Pfizer, U.S.A. Ronald Smith, Merck & Company, U.S.A. Cornell Stamoran, Catalent Pharma Solutions, U.S.A.

12

Sunday Program Highlights Premeeting Workshops

Young Scientist Roundtable

Computational Pharmaceutics – The Application of Computer Modeling in Drug Delivery*

Imaging in Drug Delivery: Current Practice, Regulatory Challenges, and Future Trends

08:00 – 12:00 • Continental B – lobby level

Cosponsored by Aspect Imaging

Locally Acting Dermal Drug Products – Global Challenges for Development and Registration* 08:00 – 12:00 • Joliet – 3rd level

Organizers: Howard Maibach, University of California, San Francisco, U.S.A.; and Tapash Ghosh, ONDQA/CDER/ FDA, U.S.A.

12:30 – 14:00 • Marquette – 3rd level Chairs: Patrick Lim Soo, Blend Therapeutics, U.S.A.; and Jinzi Zheng, Princess Margaret Cancer Centre, Canada Speakers: Christine Allen, University of Toronto, Canada; Neesha Dhani, Princess Margaret Cancer Centre, Canada; Keyvan Farahani, Cancer Imaging Program, NCI, NIH, U.S.A.; Twan Lammers, RWTH Aachen University, Germany; and Helen Lee, Merrimack Pharmaceuticals, U.S.A.

Oral Delivery of Peptides and Proteins*

Imaging has been increasingly exploited for assessment of the in vivo performance of drug delivery systems. These include nanosystems suitable for imaging and therapy, as well as functional and molecular imaging techniques capable of assessing the effectiveness of drug targeting and delivery. However, major barriers exist for successful translation and clinical adoption of new image-guided drug delivery techniques. This roundtable brings together academic and industrial scientists, a clinician, and a funding agency representative to illustrate current advances and discuss opportunities and strategies to achieve future successes in image-guided drug delivery.

Cosponsored by Catalent Pharma Solutions

Young Scientist Mentor/Protégé Meet and Greet

Organizers: David Brayden, University College Dublin, Ireland; and Randall Mrsny, University of Bath, United Kingdom

Organized by the Young Scientist Committee

Nanotechnology – Process and Formulation, Characterization and Applications* (continued from Saturday)

08:00 – 12:00 • Continental C – lobby level

Organizers: Teresa Virgallito, Microtek Laboratories, Inc., U.S.A.; and Nicole Papen-Botterhuis, TNO, The Netherlands (continued from Saturday)

08:00 – 12:00 • Continental A – lobby level

Young Scientist Workshop Communication and Networking: How to Develop and Utilize These Skills for a Successful Career 08:00 – 12:00 • Marquette – 3rd level Chairs: Shahriar Absar, FDA, U.S.A.; and Kaushal Dave, South Dakota State University, U.S.A. Speakers: Marilyn Martinez, FDA Center for Vet Medicine, U.S.A.; Mark Prausnitz, Georgia Institute of Technology, U.S.A.; and Mark Tracy, Tracy BioConsulting LLC, U.S.A. Networking and communication have become necessary tools for a successful career. It is important to gain knowledge and be able to disseminate it among others, which requires effective communication and networking skills. This interactive workshop will discuss the tools that are necessary to sharpen one’s written and verbal communication attributes and will outline important networking strategies. Speakers will share their experience on how to reach out to a target audience and build an effective professional network. Thus, participants in this workshop will learn the most effective ways to develop and utilize networking and communication tools.

*Additional registration, payment, and ticket required.

14:00 – 15:30 • Marquette – 3rd level

This is a must-attend session for those who preregistered and were accepted into the 2014–2015 CRS Young Scientist Mentor-Protégé Program. Mentors and protégés will be introduced during this event and will be given the opportunity to discuss the protégé’s goals, exchange expectations for what is hoped to be gained from the mentoring relationship, and develop a plan of interaction for the yearlong program. Do not miss this exciting occasion to meet face-to-face with your mentor or protégé.

Please note, only those who received notification of acceptance into the program may attend this event.

First Timers’ Meeting 11:30 – 12:30 • International Ballroom South – 2nd level If this is your first CRS Annual Meeting & Exposition, or even if you have attended for many years, learn how to get the most from the annual meeting program by attending this welcome and question-and-answer session presented by the CRS Board of Directors.

Grand Opening and Welcome Reception 17:30 – 19:30 • Exhibit Hall Salon A, C & D – lower level Innovation Sunday concludes in the Exposition Hall, where you’ll find more new and emerging products and services, along with the opportunity to connect with some of delivery science’s leading suppliers. Enjoy an array of foods and beverages as you meet with exhibitors, view posters, and visit with colleagues.

13

Sunday

Organizers: Defang Ouyang, Aston University, United Kingdom; and Alex Bunker, University of Helsinki, Finland

Technology Forums These forums are open to all registered attendees on a complimentary basis, offering in-depth coverage of controlled release technologies and services, hosted by the following companies:

09:00 – 10:00 Forums

Sterile by Design Boulevard B – 2nd level Presenter: Bill Hartzel, Director of Strategy Presentation Areas: Formulation, Processing, Quality & Analytical This presentation will focus on the use of advanced aseptic filling techniques utilized in blow/fill/seal technology. It will provide details on how the principles of QbD are leveraged in the equipment and process design to dramatically reduce the risk profile and particulate contamination in parenteral filling through control and automation.

Company website: www.catalent.com

From Bench to Shelf: A Case Study Describing the Development, Manufacturing and Commercialization of PLG Microparticle Technology to Meet an Unmet Clinical Need Boulevard A – 2nd level Presenter: Dr. Thomas R. Tice, Sr. Director, Global Technical Marketing, Pharma Polymer & Services, Health Care Presentation Areas: Formulation, Processing Progress in delivery science and manufacturing technologies is playing a critical role in advancing the development of complex parenteral formulations. Using practical examples, this presentation will provide insight on the delivery and manufacturing of extended release formulations for peptides, proteins, and small molecules. Bioabsorbable microparticles and implant dosage forms are included.

Company website: www.evonik.com/pharma

14

Biorelevant Models for Assessing Lipid Formulation Performance Buckingham – lobby level Chair: Delphine Marchaud, Marketing & Innovation Director, Gattefossé SAS Presenters: Prof. Anette Müllertz, University of Copenhagen, Denmark; and Dr. Yvonne Rosiaux, Manager Solid Oral Dosage Forms, Gattefossé SAS Presentation Areas: Formulation, Quality & Analytical Appropriate use of biorelevant media in (pre)formulation can translate into improved rate of success and significant savings for the drug development process. This workshop concerns biorelevant systems for assessing the performance of novel lipid-based formulations and dosage forms in both controlled release and bioavailability-enhancing systems.

Company website: www.gattefosse.com

09:00 – 11:00 Forum

Life Cycle Management Strategies for Complex PLGA Injectable Particle Drug Delivery Systems Boulevard C – 2nd level Presenters: Okke Franssen, Director of Pharmaceutical Development, Nanomi; and Michiel van Alst, Director NBD & Marketing Biomaterials, Corbion Purac Biomaterials Presentation Area: Formulation Nanomi is a Dutch drug delivery company (subsidiary of Lupin) that develops pharmaceutical sustained release products based on very uniform particles. Nanomi’s complex injectables have improved injectability and offer the possibility of extending the lifetime of existing products and treating unmet medical needs/indications where current therapies fail to succeed. Corbion Purac Biomaterials develops, manufactures, and markets resorbable polymers worldwide under the PURASORB® brand name. Michiel van Alst covers the use of PURASORB polymers in controlled release formulation enabling the delivery of therapeutic API levels to patients over days, weeks, or months, with a single injection.

Company websites: www.nanomi.com; www.puracbiomaterials.com

10:15 – 11:15 Forums

Advanced Functional Polymers for Targeted Oral Delivery: From Functional Coating to Bioavailability Enhancement Boulevard A – 2nd level Presenter: Dr. Min Yang, Principal Scientist, Pharma Polymers & Services, NA Region, Health Care Presentation Areas: Formulation, Processing New oral delivery technologies for BCS II/III/IV compounds are advancing patient-friendly formulations for extended, sustained, and timed release delivery. This presentation will provide insights on the current delivery science of precise targeted drug delivery systems, pulse delivery systems, and easy-to-use dispersions for enteric release and taste masking.

Company website: www.evonik.com/pharma

Pathway™ Excipients – New GMP Thermoplastic Polyurethane for Implantable Drug Delivery Boulevard B – 2nd level Presenter: Pallavi Kulkarni, Ph.D., Research Chemist Presentation Area: Formulation Lubrizol LifeScience Polymers would like to introduce Pathway™ excipients, customizable GMP-grade thermoplastic polyurethane excipients that are ideal for implantable drug delivery systems. Pathway™ excipients may be formulated for zero-order release kinetics for a wide variety of hydrophilic or hydrophobic actives over short to long time periods.

Company website: www.Lubrizol.com

10:15 – 12:15 Forum

Liposomes: The Process from Innovation to Market Buckingham – lobby level Presenters: Ethlinn van Gaal, Scientist, Octoplus; Dr. Priya Karmali, Senior Manager, Formulation Development, Regulus Therapeutics; and David Cipolla, Sr. Director Pharmaceutical Sciences, Aradigm Presentation Areas: Formulation, Quality & Analytical, Processing Ethlinn van Gaal will talk on the “Liposomes from Concept to Large Scale Manufacturing.” Dr. Priya Karmali will discuss “Creating New Class of Innovative Medicines Using MicroRNA Therapeutics,” and David Cipolla will address “Development of Inhaled Liposomal Ciprofloxacin to Treat Lung Infections.”

Company websites: www.octoplus.nl; www.regulusrx.com; www.aradigm.com

11:30 – 12:30 Forums

Apidel Drug Delivery Company Boulevard A – 2nd level Presenters: Vincent Lenaerts, CEO; and Doris Gabriel, R&D Manager Presentation Area: Formulation Apidel is a Swiss company with two technologies: Apid-COR is a six-month release single-dose liquid formulation in prefilled syringes applicable from small molecules to proteins; Apid-SOL is a nanocarrier with unique drug transportation capabilities to the dermal and corneal tissues following topical administration. Apidel has deals with seven pharma/biotech partners.

Company website: www.Apidel.com

Stepwise Approach to Preformulation and Formulation Development to Maximize Clinical Success Boulevard B – 2nd level Presenter: Paul Sabo, Sr. Scientific Leader Presentation Area: Formulation The presentation will cover suggested rapid early development strategies focusing on understanding the target product profile, importance of physicochemical properties, formulation approaches for phase 1 studies, and dealing with solubility challenges/limitations.

Company website: www.patheon.com

QbD (Quality by Design) Approach to Formulations of Hydrophilic Matrix Tablets Using Sample Kit of Hypromellose (METOLOSE® SR) Boulevard C – 2nd level Presenter: Sakae Obara, Technical Director Presentation Areas: Formulation, Processing, Quality & Analytical For QbD purposes, a sample kit of hypromellose consisting of high and low extreme levels of hydroxylpropoxy content, viscosity, and particle size has been developed. The presentation will show some case studies on robustness and impact of these polymeric factors to drug release from hydrophilic matrix tablets using this sample kit.

Company website: www.shinetsupharmausa.com

15

Soapbox Sessions Cosponsored by Catalent Pharma Solutions 13:00 – 15:00 • Continental AB – lobby level What’s new in delivery science? Come to the program where presenters “get up on their soapbox” to give you a quick glimpse of some of the most innovative technologies and products in development today. Session breaks allow time to network with presenters at their designated tables during beverage breaks, hosted by our sponsor.

13:00 – 13:10 Introduction and Welcome Moderator: Michael J. Valazza, Catalent Pharma Solutions, U.S.A.

14:00 – 14:05

Session I 13:10 – 13:15

13:15 – 13:20

13:20 – 13:25

13:25 – 13:30

13:30 – 13:35

13:35 – 13:40

13:40 – 13:50

SynVivo: A Microfluidic Platform for Screening Drug Particles B. Prabhakar Pandian, SynVivo, U.S.A. CapsMorph –Amorphous Oral Formulation Technology Based on Encapsulation in Mesoporous Materials Rainer Müller, PharmaSol GmbH, Germany Biodegradable Silica Particles for Oral and Mucosal Delivery of Vaccines Chris Barbé, Ceramisphere Pty. Ltd., Australia A Novel and Effective Drug Formulation and Delivery Platform Reginald Tan, Institute of Chemical & Engineering Sciences, Singapore The Apidel Technologies: ApidSOL Nanocarriers and ApidCOR Sustained Release Injectable Vincent Lenaerts, Apidel SA, Switzerland Overcoming the Therapeutic Challenge: Formulation Technology to Improve Acceptance and Adherence in Animal Health Dan Peizer, Catalent Pharma Solutions, U.S.A. Networking Break

Session II 13:50 – 13:55

13:55 – 14:00

16

The Accordion Pill™ – A New Solution for Key Unmet Needs Nadav Navon, Intec Pharma Ltd., Israel Molded Silicone Dosage Forms – Applications and Challenges Jim Arps, ProMed Pharma, U.S.A.

14:05 – 14:10

14:10 – 14:15

14:15 – 14:25

Elongate Microparticles Enhance Topical Drug Delivery in Volunteers Tarl Prow, University of Queensland, Australia Weight-Bearing Skin Adhesives for Body- Worn Devices Gozde Karabiyik, Adhesives Research, U.S.A. Efficient Topical Drug Delivery Enabled by a Novel Silicone Technology Hyder Aliyar, Dow Corning Corporation, U.S.A. Networking Break

Session III 14:25 – 14:30

14:30 – 14:35

14:35 – 14:40

14:40 – 14:45

14:45 – 14:50

14:50 – 15:00

Aurora™-Nanoparticles: Enhancing Liposomal Research Walter Shaw, Avanti Polar Lipids Inc., U.S.A. ElectroNanospray™: Particle Engineering and Rapid Nanoformulation Prototyping Jane Nichols, Nanocopoeia Inc., U.S.A. Next Generation Spray-Drying by Uniform Inkjet Printing-Drying Joris Salari, TNO, The Netherlands Chronocort® – An Innovative Modified Release Therapy for Diseases of Cortisol Deficiency Martin Whitaker, Diurnal Limited, United Kingdom Contract R&D Services at Southwest Research Institute James Oxley, Southwest Research Institute, U.S.A. Networking Break

Daily Schedule 07:00 – 08:00 Get Up! Get Educated! Writing a Successful Grant Application Continental C – lobby level Speaker Preparation Room Open PDR #2 – 3rd level 07:00 – 17:30 CRS Registration Open Exhibit Hall Salon C – lower level 07:00 – 17:30 CRS Opening Session Grand Ballroom – 2nd level 08:10 – 09:30 Exposition Open – Meet with Exhibitors, Refreshment Break Exhibit Hall Salons C & D – lower level 09:30 – 10:30 09:30 – 10:30 Poster Session 1 – Authors Present Exhibit Hall Salons A & D – lower level Young Scientist Committee Meeting 4K – 4th level 09:30 – 10:30 Exposition Hall Open Exhibit Hall Salons C & D – lower level 09:30 – 17:30 Poster Viewing Hours Exhibit Hall Salons A & D – lower level 09:30 – 17:30 10:30 – 12:00 Scientific Sessions • Advances in Process Engineering – New Methods Continental A – lobby level

for the Production of Particles, Capsules, and Coatings • Innovations in Oral Drug Delivery Grand Ballroom – 2nd level

• Intracellular Delivery of Nucleic Acids and Proteins Continental B – lobby level

• Mini-Symposium: Interspecies Clinical Pharmacology Boulevard ABC – 2nd level

Dosing Concepts • Overcoming Biological Barriers Continental C – lobby level

12:00 – 13:30 Women in Science Luncheon* Marquette – 3rd level Plenary Session: David W. Grainger Grand Ballroom – 2nd level 13:30 – 14:45 Scientific Sessions 15:00 – 16:30 • Advances in RNA and DNA Delivery Grand Ballroom – 2nd level • Evaluation and Characterization of Controlled Continental A – lobby level Release Products and Production Processes • Mini-Symposium: Advancements to Develop and Delivery Continental C – lobby level Biologics • Nanoparticle-Based Delivery to the Brain Continental B – lobby level • Transdermal Delivery Boulevard ABC – 2nd level 16:30 – 17:30 Poster Viewing and Exposition Happy Hour – Meet with Exhibit Hall Salons

Exhibitors, Refreshment Break A, C & D – lower level 17:30 – 18:30 PSAH Networking Get-Together* Buddy Guy’s Legends 21:00 – 22:30 Young Scientist Networking Event* Mystic Blue Boat Ride – Navy Pier *Additional registration, payment, and ticket required.

Monday Program Highlights Get Up! Get Educated!

Opening Session

Writing a Successful Grant Application

08:10 – 09:30 • Grand Ballroom – 2nd level

07:00 – 08:00 • Continental C – lobby level

Chairs: Joke Meeus, University of Leuven, Belgium; and Yewande Oni, The University of Nottingham, United Kingdom

Speakers: Keyvan Farahani, National Institutes of Health, U.S.A.; and Clive Roberts, The University of Nottingham, United Kingdom

It is currently essential for the majority of academic and industrial scientists to apply for funding. With many funding bodies available and increasing competition, how do we begin writing an application? This session will consult an experienced academic as well as a funding body representative. They will share their experiences and invaluable tips from their perspective. This session aims to teach you how to set your application apart from others and increase your chances of securing funding.

The Opening Session will feature a welcome by President Ian Tucker, who will provide a brief update on what your association is doing to further delivery science and technology during the annual business meeting portion of the meeting.

This session will also be a time to honor the 2014 CRS Distinguished Service awardee and Fellows awardees, along with talks from our Founders Award winner, Paolo Colombo; CRS T. Nagai Postdoctoral Research Achievement Award winner, Lin Zhu; and Young Investigator Award winner, Suzie Pun. Five new members of the College of Fellows will also be inducted.

continued 17

Monday

Monday, July 14

Monday Program Highlights (continued) Poster Session All scientific posters will be on display throughout the meeting.

Poster authors have been designated into one of three sessions.

On Monday, authors will be present at posters during the time specified below. To determine which poster authors will be present during Monday’s session, please use the poster information found in the CRS program book, meeting app, CRS website, and abstract printing station.

Poster Session 1: 09:30 – 10:30

Women in Science Luncheon*

Monday

Cosponsored by Ashland Inc.

data quality with more accurate, tissue-specific information to significantly improve the technical output, predictive value, and translation between in vitro, animal, and clinical human studies.

Further developments using 3D models that yield native extracellular matrix, relevant tissue architectures, and restoration of both chemical and mechanical tissue-like stimulation using bioreactors are critical for advancing in vitro experimental capabilities to obtain clinically relevant in vitro behaviors in drug screening.

Prior to the plenary, the CRS Foundation’s 2014 Alexander “Sandy” Florence Postdoctoral Fellowship will be given to Christopher Nelson, Vanderbilt University, U.S.A.

12:00 – 13:30 • Marquette – 3rd level

Poster Viewing and Exposition Happy Hour

In the Middle of Difficulty Lies Opportunity

Enjoy a variety of refreshments while viewing over 500 posters on a variety of topics.

Moderator: Debra Bingham, Valeo Partners, U.S.A. Speaker: Danchen Gao, AbbVie, U.S.A. Come ready to network at this popular event and participate in a fireside chat with Danchen Gao, Director, Intellectual Property Strategy, AbbVie.

16:30 – 17:30 • Exhibit Hall Salons A & D

PSAH Networking Get-Together* Cosponsored by Merial Ltd. 17:30 – 18:30 • Buddy Guy’s Legends

Plenary Taking Shape: Transitioning 3D Assays to Improve Drug Screening and Toxicity Predictions 13:30 – 14:45 • Grand Ballroom – 2nd level Moderator: Ick Chan Kwon, KIST, Korea

David Grainger, university distinguished professor and chair of the Department of Pharmaceutics and Pharmaceutical Chemistry and a professor of bioengineering at the University of Utah, U.S.A. Many new 3D cell culture models seek to preserve in vivo-like organization within tissue-like or organoid constructs to elicit more relevant pharmacological toxicity and toxicity marker upregulation. Validation of 3D tissue culture models against 2D “gold standard cultures” for in vitro toxicological evaluation in drug testing should compare clinical toxicity biomarkers. In vitro 3D organoid models developed to date often confirm that systems with native cellular interactions better ensure biological requirements for sustaining tissue-relevant responses to drugs. These 3D cell culture models can yield better

*Additional registration, payment, and ticket required.

18

Join members of the CRS Preclinical Sciences & Animal Health (PSAH) Division and fellow meeting attendees at Chicago’s premier blues club, Buddy Guy’s Legends. The event is directly across the street from the Hilton and will begin with a brief presentation about the division and its involvement within CRS. Afterward, attendees can enjoy networking in this unique venue owned by six-time Grammy Award–winning artist Buddy Guy. You do not need to be a member of the PSAH Division to attend. Included in the ticket price are hors d’oeuvres, one drink ticket, and a wristband for admittance into the nighttime live show at the venue.

Young Scientist Networking Event* Cosponsored by Upsher-Smith Labs and Diurnal Limited 21:00 – 22:30 • Mystic Blue Boat Ride – Navy Pier Join your colleagues for an enjoyable evening of networking aboard the Mystic Blue yacht when you attend the popular Young Scientist Networking Event. Reunite with familiar faces and make new connections as you enjoy a boat cruise on Lake Michigan. The yacht will depart from and return to Navy Pier, offering spectacular panoramic views of Chicago’s world-famous skyline. Hors d’oeuvres will be served, and attendees will receive a complimentary beverage.

CRS Advances in Delivery Science and Technology Book Series

←

NEW TITLE

←

Focal Controlled Drug Delivery

Edited by A.J. Domb, School of Pharmacy-Faculty of Medicine, Jerusalem, Israel; W. Khan, School of Pharmacy-Faculty of Medicine, Jerusalem, Israel • Includes fundamental introductory chapters for focal drug delivery • Describes drug delivery to body sites/system

• Provides an authoritative account of the essential pharmaceutical, technological, physiological, and biological sciences The concept of focal drug delivery has been applied for treating illnesses that are localized to a certain tissue or organ. These delivery systems are applied directly to the diseased site and deliver a desired dose for an extended time period while minimizing systemic distribution of toxic drug. Despite the upsurge of interest in focal targeted drug delivery, there is currently no single reference text on this subject. Thus, the aim of Focal Controlled Drug Delivery is to bring together leading experts and researchers in this field to provide an authoritative account of the essential pharmaceutical, technological, physiological, and biological sciences underpinning the topic. This book contains two sections. The first includes fundamental introductory chapters for focal drug delivery, whereas the second section includes chapters describing drug delivery to body sites/ system. The book allows clinical, pharmaceutical, and biological scientists to offer their own perspectives on the subject, making it of potential interest to a wider audience than just drug delivery scientists.

2014, XVII, hardcover, 700 pages.

Stop by Springer Booth 218 to order.

controlledreleasesociety.org

#8754-6/2014

CRS members qualify for a 25% discount on all books in the Advances in Delivery Science and Technology series from CRS, along with all Springer book titles if you purchase through Springer’s online site and use the exclusive CRS member discount token when ordering. CRS members must sign in to the CRS site to gain access to the discount token before ordering at the Springer site.

19

Podium • Monday Morning Monday Morning Continental A

Grand Ballroom

Advances in Process Engineering New Methods for the Production of Particles, Capsules, and Coatings

Innovations in Oral Drug Delivery

E Mathiowitz, S Lee

J Oxley, N Papen-Botterhuis

Continental B

Intracellular Delivery of Nucleic Acids and Proteins S Pun, Y Katayama

1

Production of Nano/Micro Drug Particles by Supercritical Fluid Technology S Sathigari Patheon Pharmaceuticals, U.S.A.

6

Invited Speaker: Oral delivery of heparin conjugate Y Byun Seoul National University, Korea

11 Invited Speaker: Intracellular Delivery of BIologic Drugs P Stayton University of Washington, U.S.A.

11:00

2

The NanoAssemblr Platform: Scalable, Microfluidics-based Manufacture of siRNA Lipid Nanoparticles C L Walsh, K Ou, A Ansari, T J Leaver, A W Wild, R J Taylor, E Ramsay, P R Cullis Precision NanoSystems Inc., U.S.A.

7

Synergistic Effect of M Cell Targeting Peptide and Mucoadhesive Vehicle on Induction of Immune Responses in Oral Vaccine Delivery C Cho Seoul National University, South Korea

13 Nucleodendrimers for endosomal escape S Muro University of Maryland, U.S.A.

11:15

3

Accepting the challenge of scale-up - A 8 new approach for the treatment of colon cancer based on nanoparticles overcomes the limitations of batch size S Beyer Goethe University, Germany

Can ion pairing mediate drug uptake via active carriers?

A ElShaer, A S Rahman, P Hanson, A R Mohammed Kingston University, United Kingdom

11:30

4

Dissolution of Poorly Soluble Drug Nanoparticles from Edible Polymer Stripfilms J Zhang, Z Ma, E Bilgili, R N Davé Chemical Biological and Pharmaceutical Engineering, New Jersey Institute of Technology, U.S.A.

9

High-throughput, slit-surface, coresheath electrospinning: Improving the formulation and dissolution of poorly soluble drugs Q Pham, E Fan, L Ruiz, J Podyma, R Mulligan, T Freyman Arsenal Medical, U.S.A.

12 The Multifaceted Role of Glycosaminoglycans in the Cellular Uptake of Cell-Penetrating Peptides R Wallbrecher, S Schmidt, W P Verdurmen, P H Bovee-Geurts, F Bröcker, A Reinhardt, T H van Kuppevelt, J Eilander, S Fanghänel, J Bürck, P Wadhwani, P H Seeberger, A S Ulrich, R Brock Radboud University Medical Centre, Netherlands 14 Wrapping Polyplex with a Monolayer of Rationally Designed Block Copolymer for Inter- and Intra-cellular Delivery of siRNA X Ge, T Jin Shanghai Jiao Tong University, China

11:45

5

Designing Sustained Release Encapsulates loaded with Water Soluble Oxidant: Carbamide Peroxide F L Tchuenbou-Magaia, J Gwyer, N Young, Z Zhang University of Birmingham, United Kingdom

10 Mucus Penetrating Nanoparticles Improve Drug and Gene Delivery to the Gastrointestinal Tract K Maisel, L Ensign, M Reddy, R Cone, J Hanes Johns Hopkins University, U.S.A.

15 Attenuation of High Mobility Group Box 1 Release into Extracellular Milieu

by TAT-High Mobility Group Box 1 A Fusion Protein Binding in islet cells Y Hwang, M Lee, D Lee Hanyang University, Korea

End of Session

End of Session

10:30

Monday

10:45

12:00

End of Session

Cosponsored by Patheon Pharmaceutical Services Inc.

20

Podium Continental C

Overcoming Biological Barriers

H Chen, A Kim 16 Invited Speaker: Overcoming Macrophage Barriers: 驶Self始 peptides on Nanoparticles, Viruses, and Molecular Therapy D Discher University of Pennsylvania, U.S.A.

D Brayden, M Kastellorizios 21 Invited Speaker: The Biopharmaceutics of Veterinary Drug Delivery S C Sutton University of New England, U.S.A.

Monday

10:30

Boulevard ABC

Mini Symposia: Interspecies Clinical Pharmacology Dosing Concepts

10:45

11:00

18 Exploring the Potential of the Tat Cell 22 Invited Speaker: Interspecies Clinical Penetrating Peptide in Drug Delivery Pharmacology Dosing Concepts Mini Using Both Drug Conjugation and SelfSymposia Assembly Strategies M G Papich P Zhang, A Cheetham, L Lock, Y Lin, H North Carolina State University, U.S.A. Cui The Johns Hopkins University, U.S.A.

11:15

19 Design of hypoxically activated prodrug to overcome hypoxic barrier Y Ikeda, H Hisano, Y Nagasaki University of Tsukuba, Japan

11:30

20 Physiology of intrathecal bolus as revealed by quantitative PET studies M I Papisov, V Belov, A J Fischman, J Titus, M Gagne, C Gillooly, A Bonab, D Levine Massachusetts General Hospital, Harvard Medical School, and Shriners Hospitals for Children, U.S.A.

11:45

17 Bypassing Endocytosis SizeRestrictions M Ansar, D Serrano, I Papademetriou, T Bhowmick, S Muro University of Maryland, U.S.A.

12:00

End of Session

23 Invited Speaker: Zoological Pharmacology: Of Mice and Elephants R P Hunter Parnell, U.S.A.

End of Session

21

Podium • Monday Afternoon Monday Afternoon Grand Ballroom

Advances in RNA and DNA Delivery

T Lammers, J Steinbach

Continental A

Evaluation and Characterization of Controlled Release Products and Production J Meiners, C McDaniel

Continental B

Nanoparticle Based Delivery to the Brain

B Boyd, S Svenson

24 Invited Speaker: Intracellular SignalResponsive Carriers as New Strategy to Secure Cell Specificity in Tumor Gene Delivery Y Katayama, C Kim, K Li, G Zhao, Y Nakamura, A Kishimura Kyushu University, Japan

29 Invited Speaker: An Introduction to Dynamic Imaging Particle Analysis for Use in Controlled Release R&D and Production Environments L Brown Fluid Imaging Technologies, U.S.A.

15:30

25 Suppression of Notch Signaling for Rheumatoid Arthritis Therapy Using Polymerized siRNA/ Thiolated Glycol Chitosan Nanoparticles M Kim, J Park, S Lee, D Jo, S Kim, I Kim, I Kwon, K Kim Korea Institute of Science and Technology, Korea

30 Real time Raman imaging to 35 Highly compacted pH-responsive DNA understand dissolution performance of nanoparticles mediate efficient amorphous solid dispersions transgene silencing in experimental F Tres, S A Wren, J W Aylott, J C Burley glioma University of Nottingham, United Kingdom A J Kim, N J Boylan, J Suk, J Hanes, G F Woodworth University of Maryland, U.S.A.

15:45

26 A cationic nanoemulsion for the delivery of next generation RNA vaccines L A Brito Novartis Vaccines and Diagnostics, U.S.A.

31 The influence of spray drying parameters on particle composition, structure and in vitro release of injectable microspheres for controlled release J Meeus, M Lenaerts, D J Scurr, K Amssoms, M C Davies, C J Roberts, G Van den Mooter University of Leuven, Belgium

16:00

27 Versatile Platform for Sustained Gene Silencing Improves Excisional Wound Healing in Diabetic Rats C E Nelson, J R Martin, M K Gupta, E J Adolph, F Yu, J M Davidson, S A Guelcher, C L Duvall Vanderbilt University, U.S.A.

32 Mass Spectrometry for Comprehensive 517 Squalenoyl Adenosine Nanoparticles Characterization of Controlled Release and Cerebral Ischemia Systems A Gaudin, S Lepetre, M Yemisci, O Tagit, S F Borgos, A Brunsvik, P Kristiansen, F N Hildebrandt, K Andrieux, T Dalkara, P Männle, Ý Mørch, R Schmid-Baumberger, Couvreur K Vernstad, K Zahlsen Institut Galien, France SINTEF Materials and Chemistry, Norway

16:15

28 Lipid nanoparticles for organ-specific delivery of RNA H Haas, D Fritz, M Meng, L M Kranz, K C Reuter, M Diken, S Kreiter, S Funari, D Pawlowska, G Brezesinski, U Sahin Ribological GmbH, Germany

33 Non-Disruptive Measurement of Encapsulation Efficiency For Hydrophobic Actives F Zeng The Dow Chemical Company, U.S.A.

16:30

End of Session

15:00

34 Invited Speaker: Dendrimer-based targeted systemic therapies for neuroinflammation in CNS disorders R Kannan Johns Hopkins Hospital, U.S.A.

Monday

15:15

22

End of Session

506 Amino-Functionalized Multi-Walled Carbon Nanotubes: Uptake and Transcytosis across the Blood-Brain Barrier in vitro H Kafa, N Rubio, J Tzu-Wen Wang, K Venner, E Pach, B Ballesteros, N Abbott, K T Al-Jamal King's College London, United Kingdom

38 Mechanism of Nanocarrier Release from the Abluminal Endothelium R L Manthe, S Muro Foster Corporation, U.S.A.

End of Session

Podium Boulevard ABC

Transdermal Delivery

T Durig, S Mitragotri

Continental C

Mini Symposia: Advancements to Develop and Deliver Biologics T Robinson, I Rupenthal 44 Invited Speaker: Examining the challenges underlying the delivery of therapeutic proteins S T Buckley Novo Nordisk A/S, Denmark

15:30

40 Novel coating mechanism for silicon microneedle arrays based upon pHsensitive electrostatic interactions K Van der Maaden, H Yu, K Sliedregt, R Leboux, A Kros, W Jiskoot, J Bouwstra Leiden Academic Centre for Drug Research, Netherlands

45 Invited Speaker: Recent Innovations in Oral Vaccine Delivery R T McLaughlin Catalent Pharma Solutions, United Kingdom

15:45

41 Tyrosine-derived Nanospheres (TyroSphereTM): A New Carrier System for Topical Delivery of Adapalene T Ramezanli, Z Zhang, J Kohn, B B Michniak-Kohn Rutgers The State University of New Jersey, U.S.A.

16:00

42 Transdermal Nanographene Oxide Hyaluronic Acid Conjugate for Photothermal Ablation Therapy of Skin Cancer S Hahn, H Jung, W Kong, K Kim, S Yun POSTECH, South Korea

16:15

43 Delivery of recombinant human epidermal growth factor via hair follicles with a nano liposome system J Seo, S Jeon, S Lee Keimyung University, Korea

16:30

End of Session

Monday

39 Invited Speaker: Improving The Reach Of Vaccines To The Developing World With Nanopatches M Kendall University of Queensland, Australia

15:00

15:15

46 Invited Speaker: Smart PEGylation: Enabling Extended Half-life without Loss of Bioactivity K Lee SungKyunKwan University, Korea

End of Session Cosponsored by Catalent Pharma Solutions

23

Daily Schedule Tuesday, July 15

Tuesday

07:00 – 08:00

07:00 – 08:00

07:00 – 16:00 07:00 – 17:30 07:00 – 17:30 08:00 – 09:30 09:30 – 10:30

09:30 – 10:30 09:30 – 10:30 09:30 – 16:00 10:30 – 12:00

Drug Delivery and Translational Research Editorial 4K – 4th level Board Meeting Get Up! Get Educated! Evolution of Controlled Release Continental C – lobby level R&D: From Pharmaceutics to Biopharmaceutics Poster Viewing Hours Exhibit Hall Salons A & D CRS Registration Open Exhibit Hall Salon C – lower level Speaker Preparation Room Open PDR #2 – 3rd level Plenary Session: Kristi Anseth Grand Ballroom – 2nd level Exposition Open – Meet with Exhibitors, Exhibit Hall Salons Refreshment Break C & D – lower level International Committee Meeting 4L – 4th level Poster Session 2 – Authors Present Exhibit Hall Salons A & D – lower level Exposition Hall Open Exhibit Hall Salons C & D – lower level Scientific Sessions • Advances in Drug Delivery to the Eye Continental B – lobby level • Mini-Symposium: Micro- and Nano-Encapsulation: Continental A – lobby level From Innovation to Commercialization • Nanoparticles in Tumor Treatment Grand Ballroom – 2nd level • Overcoming Barriers in the GI Tract Continental C – lobby level • Predictive Animal Models for Assessing Long-Acting Boulevard ABC – 2nd level Formulations for Human and Animal Health and Their

Challenges 12:00 – 13:00 Journal of Controlled Release Editorial Board Meeting 4M – 4th level 12:00 – 13:30 Consumer & Diversified Products Division Luncheon* Marquette – 3rd level 13:30 – 15:00 Scientific Sessions: • Advances in Drug Delivery to the Lung Boulevard ABC – 2nd level • Controlled Release Applications in Food, Feed, and Beverages Continental A – lobby level • Innovations in Micro- and Nano-Based Delivery Continental B – lobby level • Mini-Symposium: Cancer Epigenetics, Epigenetic Continental C – lobby level Drugs, and Delivery • Proteins, Peptides, and Vaccines Grand Ballroom – 2nd level 15:00 – 16:00 Exposition Open – Meet with Exhibitors, Exhibit Hall Salons

Refreshment Break C & D – lower level 15:00 – 16:00 Poster Session 3 – Authors Present Exhibit Hall Salons A & D – lower level 15:00 – 16:00 Satellite Meeting Committee Meeting 4K – 4th level 16:00 – 17:00 Poster Take-Down Exhibit Hall Salons A & D – lower level 16:00 – 17:30 Board of Scientific Advisors Meeting 4M – 4th level 16:00 – 17:30 College of Fellows Panel Discussion: Innovation to Continental C – lobby level Commercialization 16:00 – 17:30 Consumer & Diversified Products Division Committee Meeting 4L – 4th level 16:00 – 17:30 Roundtables

• Ocular Drug Delivery Continental A – lobby level

• Oral Drug Delivery Continental B – lobby level 16:00 – 18:00 Exhibit Take-Down Exhibit Hall Salons C & D – lower level 18:30 – 22:00 CRS President’s Banquet* Boulevard ABC – 2nd level *Additional registration, payment, and ticket required.

24

Tuesday Program Highlights Get Up! Get Educated!

Poster Sessions

Evolution of Controlled Release R&D: From Pharmaceutics to Biopharmaceutics

All scientific posters will be on display throughout the meeting.

Poster authors have been designated into one of three sessions.

On Tuesday, authors will be present at posters during one of the two times specified below. To determine which poster authors will be present during which session, please use the poster information found in the CRS program book, meeting app, CRS website, and abstract printing station.

Chair: Yewande Oni, University of Nottingham, United Kingdom Speakers: Ali Rajabi-Siahboomi Colorcon, U.S.A.; and Irwin C. Jacobs, Jacobs Controlled Release Consulting LLC, U.S.A. From the late 1900s the interest of pharmaceutical controlled release predominantly laid with compressed hydrophilic matrices. With current technological advancements, has this trend of interest ceased over the past six decades? This session will review the advances of controlled release technology from hydrophilic matrices to nanoparticle drug carriers and genetic engineering. How have these changes come about, and what are the future prospects of controlled release?

Plenary Speaker Drug Delivery to Promote Tissue Regeneration: How Simple Is Complex Enough?

08:00 – 09:30 • Grand Ballroom – 2nd level Moderator: Justin Hanes

Kristi Anseth, Howard Hughes Medical Institute investigator and distinguished professor of chemical and biological engineering at the University of Colorado at Boulder, U.S.A. A better understanding of the dynamic physical and biomolecular cues present in tissue microenvironments has led to a growing interest in the development of biomaterial systems for improved 3D culture environments, as well as delivery vehicles for cell-based therapies. As discovery of new biological signals and targets has evolved, so has the need for improved delivery systems to facilitate improvements in wound healing, stem cell engraftment, and reversal of fibrotic diseases. As a result, biomaterial scaffolds based on both protein components and highly tunable synthetic chemistries have evolved to address many of these needs. This talk will highlight several examples in which advances in four-dimensional control of scaffold properties can be used to better understand how to present and manipulate the presentation of biochemical signals, as well as to promote tissue regeneration.

Awards presented prior to the plenary will include the CRS Jorge Heller Journal of Controlled Release Outstanding Paper Award to Frits Thorsen, University of Bergen, Norway, and the Drug Delivery and Translational Research Outstanding Paper Award to Prabodh Sadana, Northeast Ohio Medical University, U.S.A.

Poster Session 2: 09:30 – 10:30 Poster Session 3: 15:00 – 16:00

C&DP Division Luncheon*

Cosponsored by Coating Place Inc., The Dow Chemical Company, Microtek Labs Inc., Ronald T. Dodge Co., and Vision Processing Technologies Inc. 12:00 – 13:30 • Marquette – 3rd level Join your fellow Consumer & Diversified Products Division members for this networking buffet luncheon at the Hilton Chicago. All attendees interested in C&DP, which includes encapsulation and controlled release research for food, nutraceuticals, personal care, cosmetics, home care, agriculture, textiles, and coatings, are welcome to attend.

Roundtables and Focus Groups Join your colleagues for these in-depth interactive sessions where a panel of experts will share their findings and opinions, creating an extended discussion on focused topics. This is a great opportunity to connect with colleagues with similar interests.

Ocular Drug Delivery Roundtable and Focus Group Polymers in Ocular Drug Delivery – More Than Meets the Eye? 16:00 – 17:30 • Continental A – lobby level Chairs: Ilva Rupenthal, University of Auckland, New Zealand; and Andrew Urquhart, Technical University of Denmark, Denmark Topical application of eye drops is still the most common method for treating anterior segment diseases. However, the protective ocular barriers prevent achieving an effective drug concentration at the target site. Many polymers have been investigated over the years to overcome the poor drug bioavailability associated with conventional eye drops and to develop sustained release systems for intravitreal or periocular application. This session will focus on recent advances in polymeric formulations used for ocular drug delivery and will feature invited presentations followed by a panel discussion.

Speakers: Maria José Alonso, University of Santiago de Compostela, Spain David Grainger, University of Utah, U.S.A. Michael O’Rourke, GrayBug LLC, U.S.A.

25

Tuesday

07:00 – 08:00 • Continental C – lobby level

Tuesday Program Highlights (continued) Oral Drug Delivery Roundtable and Focus Group Continuous Processing of Oral Modified Release Products 16:00 – 17:30 • Continental B – lobby level Chair: Ali Rajabi-Siahboomi, Colorcon, Inc., U.S.A.

Tuesday

It has taken the pharmaceutical industry many years to acknowledge, understand, and accept the principles of quality by design (QbD). Now that the concept is in place in the minds of most formulators and manufacturers, the evolution o f QbD is to use continuous processing for manufacturing of pharmaceutical products. This comes with many challenges from the design and technology to the regulatory hurdles.

There are efforts among leading scientists and machine manufacturers in this area to evolve the historical mindset of batch manufacture to continuous processing. Key advantages from quality, economy, and speed to market can be gained through this evolution. This roundtable session will provide an overview of current activities with the background of the principles, followed by case studies to show the challenges and opportunities. Please join us to hear from industry leaders on this hot topic and share your experiences and concerns during the discussion.

Speakers: Ali Rajabi-Siahboomi, Colorcon, Inc., U.S.A. Salvatore Mascia, MIT, U.S.A.

College of Fellows Panel Discussion Innovation to Commercialization 16:00 – 17:30 • Continental C – lobby level

This special panel discussion on innovation to commercialization is presented by the CRS College of Fellows.

The panel this year features College of Fellows members who have direct and successful experience in bringing pharma and non-pharma (consumer and diversified) products to market where controlled release is essential.

Panel Moderator: Susan Cady, Merial Ltd., U.S.A. Panelists: Terry Allen, University of Alberta, Canada Gary Cleary, Corium International Inc., U.S.A. Joseph (Yosi) Kost, Ben-Gurion University, Israel Art Tipton, Southern Research Institute, U.S.A. Ron Versic, Ronald T. Dodge Company, U.S.A.

CRS President’s Banquet*

18:30 – 22:00 • Boulevard ABC – 2nd level CRS President Ian Tucker invites you to join your colleagues for an enjoyable evening that will showcase the science and history of the Controlled Release Society through a popular pub quiz style event. One drink ticket is included with your dinner. Cash bar available. Be entertained and educated while dining with your colleagues. *Additional registration, payment, and ticket required.

CRS Headquarters & Staff 3340 Pilot Knob Road, St. Paul, MN 55121 U.S.A. Telephone +1.651.454.7250 • Facsimile +1.651.454.0766 • controlledreleasesociety.org Amy Hope Executive Vice President +1.651.994.3827 ahope@scisoc.org Susan Kohn Executive Director +1.651.994.3812 skohn@scisoc.org Megan Pagel Membership Manager • News Capsules • Chapter Coordinator +1.651.994.3854 mpagel@scisoc.org

26

Sue Stein Meeting Manager +1.651.994.3813 sstein@scisoc.org Linda Schmitt Program Manager • Annual Meeting Program • Awards +1.651.994.3828 lschmitt@scisoc.org Sue Casey Registration and Abstracts Meeting Coordinator +1.651.994.3846 scasey@scisoc.org

Cindy Anderson Director of Sales • Exhibits, Sponsorship • Advertising Sales +1.651.994.3848 canderson@scisoc.org Cheryl Kruchten Member Relations Specialist +1.651.994.3801 ckruchten@scisoc.org Lyssa Campbell Marketing Manager +1.651.994.3817 lcampbell@scisoc.org

Brian Simdars Webmaster +1.651.994.3849 bsimdars@scisoc.org Greg Grahek Publications Director +1.651.994.3841 ggrahek@scisoc.org Carol Duling CRS Newsletter Technical Editor +1.651.994.3869 cduling@scisoc.org Lisa Johnson Webcast Manager +1.651.994.3824 ljohnson@scisoc.org

27

Podium • Tuesday Morning Tuesday Morning Continental B

Advances in Drug Delivery to the Eye

M Alonso, A Urquhart

Grand Ballroom

Nanoparticles in Tumor Treatment

R Gemeinhart, S Lee

Continental C

Overcoming Barriers in the GI Tract

Y Byun, E Mathiowitz

47 Invited Speaker: Facilitated Drug Delivery to the Retina by Controlled Modulation of Permeability at the Inner Blood-retina Barrier M Campbell, P Humphries University of Dublin, Ireland

52 Invited Speaker: Nanocarrierʼs Function Integration and Synchronization for Cancer Drug Delivery Cascade Y Shen, X Sun Zhejiang University, China

57 Invited Speaker: Overcoming gastrointestinal barriers to nanoparticle delivery K Maisel, M Reddy, R Cone, J Hanes, L Ensign Johns Hopkins Hospital, U.S.A.

11:00

48 Ocular delivery of a model biopharmaceutical, lacritin, using protein polymers J A MacKay, W Wang, P Hsueh, M Edman-Woolcott, S F Hamm-Alvarez University of Southern California, U.S.A.

53 Nanoparticles Targeting Pancreatic Tumor S Mura, S Valetti, F Maione, B Stella, D Desmaële, M Noiray, J Vergnaud, C Vauthier, L Cattel, E Giraudo, P Couvreur Institut Galien Paris-Sud, France

58 A biomimetic strategy for gastric targeting based on Helicobacter pylori N A Hage, S Winkler, P Gellert, S Stolnik, F H Falcone University of Nottingham, United Kingdom

11:15

49 In vivo enhancement of transscleral 54 Folate-conjugated PEG-derivatized 59 Nanostructured lipid-based penetration of macromolecules by lowEmbelin as A Versatile Nanocarrier for mucoadhesive particles formed from intensity and low-frequency ultrasound the Targeted Delivery of Doxorubicin pH responsive vesicles W L Suen, H Wong, Y Yu, C L Lau, C A with Reversal of Multidrug Resistance J Du, T Nguyen, Q Liu, B J Boyd Lo, Y Chau J Lu, Y Huang, W Zhao, H Liu, R B Gibbs, Monash Institute of Pharmaceutical Hong Kong University of Science and J Li, S Li Sciences, Australia Technology, Hong Kong University of Pittsburgh, U.S.A.

11:30

50 Injectable, Degradable and Biocompatible Poly(oligoethylene glycol methacrylate) Hydrogels E Bakaic, N M Smeets, T Hoare McMaster University, Canada

612 Targeted Cellular Interactions of Dendron Micelles using PEG linkers R M Pearson, M Pasko, M Gaske, H Hsu, P Kral, S Hong University of Illinois, U.S.A.

60 Intestinal mucosa permeability following oral delivery of wheat germ agglutinin non-sheddable nanocage stabilized nanocrystals D Xia, J Tao, Y He, F Cui, Y Gan Shanghai Institute of Materia Medica, China

11:45

51 In vivo evaluation of intravitreally 56 Anticancer polymeric nanomedicine injected connexin43 mimetic peptide in bearing synergistic drug combination reducing retinal ganglion cell loss and E Markovsky, H Baabur-Cohen, R Satchivessel leak after retinal ischemia Fainaro Y Chen, C R Green, R Teague, J Perrett, Tel Aviv University, Israel H V Danesh-Meyer, I Toth, I D Rupenthal University of Auckland, New Zealand

61 Magnetic Beads to Enhance Drug Penetration Across Intestinal Membrane A Seth, D Lafargue, C Poirier, J Péan University Pierre et Marie Curie, France

10:30

Tuesday

10:45

12:00

28

End of Session

End of Session

End of Session

Podium Boulevard ABC

Predictive Animal Models for Assessing Long-Acting Formulations for Human and Animal Health and Their Challenges T Bowersock, M Martinez

Continental A

Mini Symposia: Micro- and NanoEncapsulation: From Innovation to Commercialization K Carson, F Zeng

62 Invited Speaker: Models for Predicting Functional Response to Drug and Vaccine Delivery To and Through Skin J C Birchal Cardiff University, Wales

67 Invited Speaker: Progress in Complex Parenteral Formulations for the Delivery of Biopharmaceuticals and Samll Molecules - Microencapsulation Scale Up and Product Enhancements T Tice Evonik, U.S.A.

11:00

63 Composite Coatings to Suppress the Foreign Body Response in a Large Animal Model M Kastellorizios, F Papadimitrakopoulos, D J Burgess University of Connecticut, U.S.A.

68 Invited Speaker: Taste-masked Powders for Pediatric-centric Dispersed Dosage Formats N Dormer, D W Dumbauld, T Zhang, C Berkland Orbis Biosciences, Inc., U.S.A.

11:15

64 Multimodal Imaging-Based Characterization of HER2+ and Triple Negative Metastatic Breast Cancer Xenograft Models in Mice R De Souza, J Zheng, S Serra, G Francia, R Kerbel, C Allen, D Jaffray University Health Network, Canada

11:30

65 A Canine Biorelevant Dissolution Method for Predicting in vivo Performance of Sustained Release Solid Oral Dosage Forms P L Walsh, S Bhardwaj, M Hu, R Nofsinger, J Mann, A Djemai Merck & Co., U.S.A.

11:45

66 Critical attributes for a generic nanosuspension development: physical properties along with in vitro release.

R P K, P K Kondamudi, B S Yeola, H P Bhagwatwar, D Aggarwal Centre of Excellence, India

10:30

12:00

Tuesday

10:45

End of Session

69 Invited Speaker: The Determination of Cost and the Economics for Controlled Release Processes R J Versic Ronald T Dodge Co, U.S.A.

End of Session

29

Podium • Tuesday Afternoon Tuesday Afternoon Boulevard ABC

Advances in Drug Delivery to the Lung E Fattal, O Merkel 13:30

70 Invited Speaker: Advances in Drug Delivery to the Lung: A Controlled Release Perspective P M Young, D Traini The Woolcock Institute of Medical Research, Australia

Continental A

Controlled Release Applications in Food, Feed, and Beverages I Bodnar, J McKinney 75 Invited Speaker: Tailoring gastric food structure disintegration and function release kinetics by gastrointestinal structure engineering (GINSENG) E J Windhab ETH-Zurich, Switzerland

Continental B

Innovations in Micro- and NanoBased Delivery C Boyum, J Moon 80 Invited Speaker: Oxidation- and pHActivated MRI agents based on Triggered Degradation of Polymeric Nanoparticles M L Viger, J Sankaranarayanan, C de Gracia Lux, M Chan, J Lux, A Almutairi University of California, U.S.A.

Tuesday

13:45

14:00

71 Highly Sensitive and Selective Anti76 Elaboration and Characterization of cancer Effect by Conjugated HABarley Protein Nanoparticles as an Cisplatin in CD44 Overexpression NonOral Delivery System for Lipophilic small Cell Lung Cancer Bioactive Compounds Y Quan, H Kim, B Kim, J Park, Y Choi, Y J Yang, Y Zhou, L Chen Choi University of Alberta, Canada Korea University College of Medicine, Korea

81 Programmable Release of a WaterSoluble Drug from Electrospun Nanofibers for HIV Inhibition D S Carson, K A Woodrow University of Washington, U.S.A.

14:15

72 Pulmonary co-delivery system for lung tumor treatment H Tian, C Xu, P Wang, X Chen Chinese Academy of Sciences, China

77 Doubled-layered emulsions as delivery systems to reduce the degradation of Coenzyme Q10 and control its release at the absorption site Y Guan, Q Zhong University of Tennessee, U.S.A.

82 Recognizable polyacrylamide in microbubbles for in situ detection of colon malignancy A Rubinstein, M Bloch, E Yavin, L Jablonowski, M Wheatley, A Nyska The Hebrew University of Jerusalem, Israel

14:30

73 Lung toxicity of biodegradable nanoparticles evaluated in vitro on cocultures and in vivo in mice E Fattal, N Grabowski, L Santiago Aragao, H Hillaireau University of Paris Sud, France

78 Effect of Physical Properties of Enzymatically-Modified Starch Gels on Salt Release of the Gel-Containing Water-in-Oil-in-Water Emulsions Y Kim, S Mun, S Rho, Y Kim Seoul National University, Korea

83 PLGA-LL37 NP promote wound healing K Chereddy, C Her, C Moia, J Vanacker, A des Rieux, H Zhu, G Vandermeulen, V Préat Université catholique de Louvain, Belgium

14:45

74 A New Strategy to Enhance Antibiotic Load for Pulmonary Treatment of Cystic Fibrosis Infections: Ciprofloxacin Lipid Complex Loaded PLGA Nanoparticles N Günday Türeli, J Juntke, A Torge, E A Türeli, E Prinz, C de Souza Carvalho, N Daum, C Lehr, M Schneider MJR PharmJet GmbH & Philipps University Marburg, Germany

79 In vitro and in vivo release of carvacrol encapsulated in Ca-alginate microspheres Q Guo, Y Yang, Y Zhang, H Yu, J Gong, Q Wang Agriculture and Agri-Food Canada, Canada

84 Inactivated Polio Vaccination Using a Microneedle Patch J Joyce, C Edens, H Eichenbaum, N Dybdahl-Sissoko, J Norman, W Weldon, S Oberste, M Prausnitz Georgia Institute of Technology, U.S.A.

15:00

30

End of Session

End of Session

End of Session

Podium Grand Ballroom

Proteins, Peptides, and Vaccines L Ensign, W Pitt

Continental C

Mini Symposia: Cancer Epigenetics, Epigenetic Drugs and Delivery Y Bae, D Oupicky

85 Invited Speaker: Nanobiopharmaceuticals: the Delivery Key for Peptides, Proteins and Vaccines M J Alonso University of Santiago de Compostela, Spain

90 Invited Speaker; Spatiotemporal delivery of epigenetic and chemotherapeutic nucleoside analogs to pancreatic cancer R Govindarajan University of Georgia, U.S.A.

14:00

86 Bone-Targeting Parathyroid Hormone Analogues Outperform Unmodified PTH in the Anabolic Treatment of Osteoporosis in Rats Y Yang, A Panahifar, Y Wu, K Tang, K H Bhandari, M R Doschak University of Alberta, Canada

91 Invited Speaker: Epigenetic Nanotherapy V Labhasetwar Cleveland Clinic Foundation, U.S.A.

14:15

87 Dual labeled polymeric nanoparticles loaded with ovalbumin as model cancer vaccine formulation: In vivo tracking and evaluation of T cell response S Rahimian, J Kleinovink, M F Fransen, M Amidi, L Mezzanotte, W E Hennink, F Ossendorp Utrecht University, Netherlands

14:30

88 RNAdjuvantďƒ’, a novel RNA-based immunomodulator, combines strong immunostimulatory capacities with a favourable safety profile P Baumhof, R Heidenreich, B Scheel, S Voss, K Kallen, M Fotin-Mleczek CureVac GmbH, Germany

14:45

89 Enhanced DNA vaccination using microsphere/polyplex-releasing multilayered microneedles N Kim, M Lee, J Lee, Y Cho, j Jeong Sungkyunkwan University, South Korea

15:00

End of Session

13:30

Tuesday

13:45

92 Invited Speaker: Targeting DNA hypermethylation by nanomedicine for acute myeloid leukemia therapy S Liu, F Yan, N Shen, J Pang Univ of Minnesota, U.S.A.

End of Session

31

Your Membership: Your Access to the Future of Delivery Science and Technology Your membership is your all-access pass to leading research and the delivery science community.

Innovative Research From the research presented in the journals Drug Delivery and Translational Research and the Journal of Controlled Release, to the science presented at the CRS Annual Meeting & Exposition, to books and online webcasts, CRS is your source for the best delivery science and technology research.

Targeted Networking The CRS Annual Meeting & Exposition is just the beginning of the great opportunities to connect with delivery scientists. Utilize the online community through the website, join a committee, connect on LinkedIn, or join your local chapter, and access one of the most valuable resources – each other.

Test tubes and shampoo images courtesy of istock.com. Eye drops courtesy of Comstock.

Career Advancement Advance your professional skills through volunteering, participating in the mentoring program, and more. CRS offers fellowship programs and recognition through awards. The online career center is one more chance to develop your career in delivery science.

Take advantage of everything your membership has to offer now. Access it all online. controlledreleasesociety.org

Daily Schedule Wednesday, July 16 07:00 – 08:00 07:00 – 08:00 07:30 – 12:00 08:00 – 09:30

09:45 – 11:00 11:00 – 12:00 11:00 – 12:00

Finance Committee Meeting Volunteer Recruitment Committee Meeting CRS Registration Open Scientific Sessions • Breakthrough Technologies • Cells as Delivery Vehicles • Controlled Release of Actives in Consumer Products • Mini-Symposium: Individualized Medicine and Theranostics • Novel Development in Formulation, Analytical Chemistry, and Processing in Animal Health and Preclinical Sciences Plenary Session: David Edwards 2015 CRS Annual Meeting Program Committee Meeting Preclinical Sciences & Animal Health Division Meeting

4K – 4th level 4L – 4th level 8th Street Registration Desk – lobby level Grand Ballroom – 2nd level Continental B – lobby level Continental A – lobby level Continental C – lobby level Boulevard ABC – 2nd level Grand Ballroom – 2nd level 4M – 4th level 4K – 4th level

Wednesday

*Additional registration, payment, and ticket required.

Wednesday Program Highlights Plenary Redesigning Nutrition Delivery 09:45 – 11:00 • Grand Ballroom – 2nd level Moderator: Ruth Schmid

David Edwards, Professor of the Practice of Idea Translation at Harvard University and founding faculty member of the Wyss Institute, U.S.A.

The features of man-made delivery systems underlying the trillion-dollar food and beverage industry often contrast poorly with those of natural systems. Natural foods involve little or no environmental waste, encourage portion control, and efficiently deliver functional nutrition in mobile circumstances. These and other qualities, having ensured the sustainable nourishment of animals and humans for many thousands of years, can be critically absent in today’s food industry. This talk highlights the current revolution in the redesign of nutrition delivery aimed at meeting the health and environmental challenges of the 21st century. It especially highlights recent breakthroughs from our labs in the fields of aerosol foods and edible and biodegradable food packaging.

Awards presented prior to the plenary will include the Outstanding Annual Meeting Abstract Paper Awards to Jessica Joyce of Georgia Institute of Technology, U.S.A.; Seung-Young Lee of Purdue University, U.S.A.; Christopher Nelson of Vanderbilt University, U.S.A.; and Hongbo Zhang of University of Helsinki, Finland. Outgoing CRS Board members will also be recognized.

Looking for the Abstracts?

Three easy ways to access the abstracts: 1. USE YOUR MOBILE DEVICE Access the abstracts from your mobile device

using the 2014 CRS Meeting App. Search for “CRS Meeting” in the iTunes store or Google Play to download the app, or use the desktop app website: mobileapp.controlledrelease.org

2. USE THE ABSTRACT PRINTING STATION

Search and print abstracts for both podium and poster presentations at the Abstract Printing Station located within CRS Central in Exhibit Hall Salon D.

3. VISIT THE CRS WEBSITE The abstracts are also available on the CRS

website and can be accessed using your CRS username and password.

33

Podium • Wednesday Morning Wednesday Morning Grand Ballroom

Breakthrough Technologies

D Barbieri, R Smith

Continental B

Cells as Delivery Vehicles

C Allen, H Stamato

Continental A

Controlled Release of Actives in Consumer Products D Dale, C Ortiz

93 Invited Speaker: Edible Electronics: Next generation medical devices for oral delivery C J Bettinger Carnegie-Mellon USA, U.S.A.

98 Invited Speaker: Cells as Delivery Vehicles M S Lesniak University of Chicago, U.S.A.

103 Invited Speaker: Physico-chemical Challenges of Designing Delivery Systems for Consumer and Industrial Applications N Shah The Dow Chemical Company, U.S.A.

08:30

94 From Laboratory to Pilot Scale: Advanced Dosage Forms of Protein/Peptide Medicines T Jin, Z Hu, S Yang, X Hong, W Yuan, F Wu, H Zhu, Z Yin Shanghai Jiao Tong University, China

385 Multifunctional delivery systems for encapsulated islet cell therapy D M Lavin, S Jhunjhunwala, S ArestaDaSilva, R Langer, D G Anderson MIT, U.S.A.

104 Development and Evaluation of Resveratrol and Vitamin E Acetateloaded Solid Lipid Nanoparticles for Skin Care Applications J Chen, N Wei, M Lopez-Garcia, C Annelin, D Ambrose, D Devine, T Peterson Kimberly-Clark Corporation, U.S.A.

08:45

95 Platform-Technology Based on 100 Potential use of engineered B. Prodrug/Enzyme Systems for Rapid choshinensis in in situ TNF-a Absorption of Hydrophobic Drugs: production machine in the tumor of Toward Intranasal Treatment of Seizure xenograft mice and its antitumor Emergencies effects M Kapoor, R A Siegel I H Mukai, M Takahashi, Y Watanabe University of Minnesota, U.S.A. RIKEN Center for Life Science Technologies, Japan

09:00

96 High Surface Area Porous Polypyrrole Structures for Glutamate Delivery D M Svirskis University of Auckland, New Zealand

09:15

97 Rational design of wet spun 239 Local delivery of stem cells on BMP-7 monofilaments and multifilament yarns nanoparticle-loaded fibrous scaffold as controlled-release drug delivery for enhanced articular cartilage repair systems for biomedical applications H Kim, S Do, S Lee D M Lavin, L Zhang, R A Hopkins, E Ewha Womans University, Korea Mathiowitz Brown University, U.S.A.

08:00

08:15

Wednesday

09:30

34

End of Session

723 Efficient Ibuprofen Delivery by a Novel Semi-Solid Silicone Formulation: Invitro and In-vivo Study H A Aliyar, R O Huber, G L Loubert, G K Schalau II Dow Corning Corporation, U.S.A.

99 Development of nanotechnology based 718 Biocompatible Dendritic Nanogels for imaging technique for tracking stem Thermally Triggered Skin Penetration cells within the brain: Cell therapy M Asadian-Birjand, F Rancan, J C application for depression disorders Cuggino, K Achazi, R C Mutihac, J O Betzer, A Shwartz, G Yadid, C Brodie, Dernedde, A Vogt, M Calderón R Popovtzer Freie Universität Berlin, Germany Bar Ilan University, Israel

End of Session

107 Influence of the vehicle type on the invitro skin permeation of acetyl hexapeptide-8 M Hoppel, D Mahrhauser, G Reznicek, C Valenta University of Vienna, Austria

End of Session

Podium Boulevard ABC

Novel Development in Formulation, Analytical Chemistry, and Processing in Animal Health and Preclinical Sciences P Cheifetz, T Vandamme

Continental C

Mini Symposia: Individualized Medicine and Theranostics

A Almutairi, E Fattal

108 Invited Speaker: Advances in Veterinary Extended Release Injectables Formed in situ and a Case Study S M Cady Merial Ltd, U.S.A.

113 Invited Speaker: Nanomedicines and Theranostics: Image-guided and Targeted Treatments for Individualized and Improved Interventions T Lammers RWTH Aachen, Germany

08:30

109 Biodistribution of nanosized liposomes loaded with immunostimulants in zebrafish and rainbow trout, and vaccination efficacy in zebrafish A Ruyra, M Cano-Sarabia, P GarciaValtanen, D Yero, I Gibert, S Mackenzie, A Estepa, N Roher, D Maspoch Universitat Autònoma de Barcelona, Spain

114 Invited Speaker: Nanomedical Technology in Personalized Cancer Medicine Y Huh Yonsei University, Korea

08:45

635 Investigation into the Topical Delivery of Diclofenac into Equine Skin S del RĂ­o-Sancho, D Concas, P Oreste, G Zoppetti, P H Briggs, Y N Kalia University of Geneva, Switzerland

09:00

111 Examination of Polymer Swelling and API Release of Controlled Release Formulations at the Solid-Liquid Interface by UV Surface Imaging C A Zordan, X Lu Bristol-Myers Squibb, U.S.A.

09:15

112 Nano-Emulsions for Biomedical Imaging N Anton, M Attia, X Li, T Vandamme University of Strasbourg, France

08:00

09:30

End of Session

Wednesday

08:15

115 Invited Speaker: A Versatile Nanoplatform for Systemic Delivery of RNAis K Choi, O F Silvestre, X Chen NIH, U.S.A.

End of Session

35

2014 CRS Posters Scientific posters are an essential element of the CRS Annual Meeting & Exposition. The display of posters allows annual meeting attendees an excellent opportunity to share with one another important scientific achievements and learn the newest technologies in delivery science on a personal basis. Each submitted poster abstract is peer reviewed and chosen based upon predetermined selection criteria.

All scientific posters will be on display throughout the meeting during exhibit hours. Poster authors will be present during one of three pre-specified time slots. Photography of posters is not permitted.

Poster Sessions (authors present) Poster Session 1 Monday, July 14 09:30 – 10:30 Poster Session 2 Tuesday, July 15 09:30 – 10:30 Poster Session 3 Tuesday, July 15 15:00 – 16:00 Advances in Drug Delivery to the Eye

116

117

Biomechanical effect of low-intensity and low-frequency ultrasound on cellular transport of retinal pigment epithelium cells; W Suen. Session 1 Bovine Serum Albumin-Meloxicam Nanoaggregates Laden Contact Lenses for Ophthalmic Drug

Delivery in Treatment of Postcataract Endophthalmitis; W Zhang.

Session 2 118 Development of Gatifloxacin loaded Eudragit nanoparticles for ocular drug delivery; R Al Kassas. Session 3 119 Eudragit coated Genistein-loaded NLC for pre-corneal drug delivery; W Pan. Session 1 120 Extended Release of DMPC from Silicone Hydrogel Contact Lenses; W Pitt. Session 2 121 Extended Release of Ovalbumin as a Model for Ranibizumab in an Ocular Drug Delivery

System; C Osswald. Session 3 122 Folate-decorated nanoparticles exhibit size-dependent internalization and prolonged anti angiogenic activity in retinal pigment epithelium cells ; W Suen.

Session 1 123 Formulation and Development of Cyclosporine loaded Lectin Anchored Chitosan Nanoparticles

for Ocular Drug Delivery; K Singh. Session 2 124 In situ-gelling hydrogels for ophthalmic drug delivery using a microinjection device; S Campbell.

Session 3 125 In vitro Transscleral Iontophoresis of Moxifloxacin Hydrochloride;

S Gungor. Session 1 126 Lipid and polymeric nanoparticles designed for the treatment of corneal vascularization; E Lima.

Session 2 127 Modulation of scleral structure by low intensity and low frequency ultrasound; W Suen. Session 3 128 Nanotheranostic liposomes for ocular delivery; H Salem. Session 1 129 Ocular tolerability of chitosan nanoparticles loaded with the antioxidant prodrug 2 oxothiazolidine-4-carboxylic acid ; A Al-kinani. Session 2 130 Particle-Stabilized Emulsion Droplets for Gravity-Mediated Targeting in the Posterior Segment

of the Eye; Y Kim. Session 3 133 Sulprostone-loaded Polylactic Acid Microspheres for Treatment of Glaucoma; K Nieto. Session 3 136 SynBiosys microspheres as a platform for local delivery of Sunitinib: Formulation and

characterization; F Ramazani. Session 3 137 Synthesis and Properties of Novel Hydrogel Containing Organic Nanotubes as a Contact Lens; Y Yamazaki. Session 1

Advances in Drug Delivery to the Lung 138

140

36

A nicotinic acetylcholine receptor α1-specific aptide for potential use in pulmonary drug delivery; S Park. Session 2 Ceramic Nano-assembly for Pulmonary Delivery of Protein and Peptides; D Lowry. Session 1

141 143 144 145 146

147 148

Curcumin nanoparticles attenuates inflammation caused by macrophages: effects of nanoparticles’ surface charges; W Lee. Session 2 In Vivo Delivery, Pharmacokinetic Analysis and Stability Study Of A DPI Formulation of Nanocrystalline Camptothecin for the Treatment of Lung Cancer; D DuBose. Session 1 Local Lung Co-Delivery of siRNA and Drug; V Ivanova. Session 2 NanoXCT: A New Technique to Probe the Interior of Pharmaceutical Particles for Inhalation; J Wong. Session 3 Non-cytotoxic silver nanoparticles-polyvinyl alcohol hydrogels with anti-biofilm activity as coatings for endotracheal tube materials; C Loo. Session 1 Novel PEG-PLA/PLGA microparticles having porous surfaces for pulmonary drug delivery; T Takami. Session 2 Spray-dried Mannitol-Chitosan as Blend Carrier for Dry Powder Inhalation; C Wu. Session 3

Advances in Process Engineering - New Methods for the Production of Particles, Capsules, and Coatings 151 152 156 158 159

160 161

162 164

165

166

Application of Hydroxypropyl Cellulose to Solubility Enhancement of Poorly Soluble Drugs; K Sugisawa. Session 3 Breakthrough and Advances in High-Throughput Core-Sheath Electrospinning Technology; T Freyman. Session 1 Evaluation of Hydroxypropyl Cellulose for Orally Disintegrating Film Drug Application; K Sugisawa. Session 2 Grafting a pH-sensitive Stealth Layer on Polymeric Nanoparticles using the Bioinspired Dopamine Polymerization Method; S Ahmed.

Session 1 Homogeneous and Reproducible Preparation of Chitosan/Nucleic Acid (NA) Nanoparticles Using an Automated Inline Mixing System; A Tavakoli Naeini. Session 2 In Situ Forming Growth Factor-loaded Microparticle-embedded Hydrogels for Directing Stem Cell Fate; O Jeon. Session 3 Microfluidic Templated Multistage Porous Silicon Based Platform for Enhanced Enteric Cancer Drug Delivery ; H Zhang. Session 1 Modeling of drug released from Acyclovir Nanoparticles based on artificial neural networks; F Dorkoosh. Session 2 Physicochemical Characterization and Dissolution Study of Cilostazol Solid Dispersions Prepared by the Supercritical Antisolvent Process; S Hwang. Session 1 Statistical Modeling – A Tool for Interpreting the Correlation between Critical Process Parameters and Responses for Wurster Processing; D Sahoo. Session 2 Thermo-responsive Nanogel Synthesis by Strain Promoted Azide Alkyne Cycloaddition; M Giulbudagian. Session 3

Advances in RNA and DNA Delivery 167

170 171 172

A nano-liposomal formulation of DOTAP/DOPE/cholesterol for transfecting murine osteosarcoma cells in vitro; j ambrose.

Session 1 Biodegradable intravaginal film for the targeted delivery of siRNAloaded nanoparticles to immune cells; J Gu. Session 1 Biodegradable starch derivatives for gene delivery; H Yamada.

Session 2 Bio-responsibility and stability balance for designing polycationic carriers of nucleic acids; S Chen. Session 3

173 174 175

176

177 178

179 180 181 182 183 185

186 187 188 189

190

191 193 194 195 196 198 199

201

202 203

204 205 207 208 210

211

Brain Penetrating Nanoparticles for Brain Gene Therapy; P Mastorakos. Session 1 Cationic phosphorous dendrimers as complexing agents for siRNA delivery; A Bohr. Session 2 Chitosan/siRNA nanoparticles demonstrate in vitro superior silencing efficiency with minimal toxicity compared to lipid standard.; M Alameh. Session 3 CTGF siRNA-Nanomedicine; A Potential Treatment for Renal Fibrosis; F Khaja. Session 1 Delivery of GLP-1 gene and DPP-4 siRNA using chitosan-based nanoparticles for Type-2 Diabetes treatment; M Jean. Session 2 Development of Modified Pectic Galactan Nano-System for Targeted Gene Therapy; N Buaron. Session 3 Dual drug-loaded solid lipid nanoparticles for enhanced cancer stem cell therapy; X Sun. Session 1 Efficient Delivery of siRNA by Hyaluronic Acid-modified Lipoplexes Targeting CD44 Receptors; T Nascimento. Session 2 Enhanced transfection of human stem cells using hyaluronic acid/ calcium phosphate hybrid gene delivery system; J Lee. Session 3 Experimental and Computational Approaches to Probe the Mechanism of Shape Control in PEG-Polycation/DNA Micelle Assembly; J Williford. Session 1 Exploring Redox Responsive Polymeric Drug Delivery System for Codelivery of Hydrophobic Drug and Silencing RNAs; Y Zhang.

Session 2 Human Relaxin Gene Therapy using Dendrimer Bioreducible Polymer of Myocardial Infarction in Rats; Y Lee. Session 1 Intravaginal Gel for the Targeted Delivery of siRNA to T-cells as a Potential Strategy for HIV-1 Prevention; S Yang. Session 2 Knockdown of Apolipoprotein B by Chitosan/ApoB-siRNA Nanoparticles Lowers Plasma Cholesterol in Atherosclerosis Mouse Model; M Jean. Session 3 Knockdown of P-glycoprotein by Chitosan/MDR1-siRNA Nanoparticles Increases Sensitivity to Chemotherapeutics; M Jean.

Session 1 Light-responsive Complex for shRNA Delivery in Cancer Therapy; K Na. Session 2 Lyophilisation and concentration of chitosan polyelectrolyte complexes for delivery of DNA and siRNA; D Veilleux. Session 3 Micelle-like nanoparticles as “two-in-one” platform for targeted delivery of siRNA/drug combinations in cancer therapy; G Navarro.

Session 1 Nanocarrier for Sustained siRNA Delivery; X Zhu. Session 3 Nanohydroxyapatite-based microRNA delivery on Collagennanohydroxyapatite Scaffolds for Bone Tissue Engineering; I Mencia Castaño. Session 1 Nanoparticle delivery of siRNA targeting the oncogenic histone modifying enzyme GASC1 in breast cancer; S Movassaghian.

Session 2 Novel nanostructured lipid carriers dedicated to nucleic acid delivery for RNAi purposes; F Navarro. Session 3 Oligopeptide-Modified Glycol chitosan for Gene Delivery; E Jeong.

Session 2 Overcoming transport barriers using modified starch based nanoparticles and ultrasound application for gene silencing ; E Amar-Lewis. Session 3 Phospholipid-modified PEI-based nanocarriers for in vivo siRNA therapeutics against multi-drug resistant tumors; G Navarro.

Session 2 Polyamines and nucleic acid interaction: a structure property relationship study; V Kolhatkar. Session 3 Preparation of intranasal chitosan/siRNA nanoparticles for inhibition of Influenza A virus in infected cells; F Dorkoosh. Session 1 Preparation of PEGylated oligonucleotides by T4 ligase enzymatic mediated coupling; G Pasut. Session 2 Promotion of Bone Regeneration Using Gene Activated Collagen Matrices; S D’mello. Session 3 RNA interference-mediated reversal of metallothionein-dependent cisplatin resistance using reducible poly(oligo-D-arginine); H Kim. Session 2 siRNA Targeted Delivery to Ovarian Cancer Cells via Folate Conjugated Triblock Co-polymer; S Jones. Session 3 Span nanoparticles as more efficient vectors for in vivo transfection of photoreceptors and RPE cells than adeno-associated viral vectors; A Pensado. Session 2 Spectroscopic characterization of the formation and binding affinities of the PLL- and PEI- polymer-DNA polyplexes; M Yliperttula.

Session 3

212 214 215

216 217

Survivin-targeted siRNA loaded polysaccharide nanoparticles for anti-tumor therapy in mice; Z Gao. Session 1 Targeted deliver therapeutic siRNA into activated T cell by Tf-ss-PEI conjugate for therapy of asthma; y xie. Session 3 The Absence of CpG sequences in Plasmid DNA-Chitosan Polyplexes Increases Transfection Efficiencies and Reduces Inflammatory Responses in Murine Lungs; A Wongrakpanich.

Session 1 The Effect of Serum in Culture on RNAi Efficacy through Modulation of Polyplexes Size; J Liu. Session 2 Using a High Content Screening System to Investigate the Relationship between Transfection Efficiency and Polyethylenimine/ pDNA complex localization; A Wongrakpanich. Session 3

Breakthrough Technologies 220 221

222 223 224 225 226

745

227 228

229 230 231

233

234 236 237

Customized Biomaterials to Enhance Gene Therapy by Augmenting Retention of Target Proteins; I Aguilar. Session 3 Cytotoxic Synthetic Chemical Polymers as a New Class of Anticancer Agents; C Wang. Session 1 Developing a High-Throughput Drug Screening Platform Using Droplet Microfluidics; S Mirza. Session 2 Diffusion of fluorescent insulin from an acrylic derivatised dextranconcanavalin A gel in an implantable closed loop insulin delivery device; D Jacob. Session 3 Drug Releasing Antibacterial Scaffold for Tissue Engineering and Drug Delivery Application; U Nayanabhirama. Session 1 Foaming via melt extrusion for improving the grindability of extrudates and dissolution rate of oral dosages; N Ioannidis. Session 2 Inkjet Printing Guided Micro-patterned Neovessel Formation; M Rich. Session 3 Liposomes for triggered drug delivery: effect of lipid composition on the sensitivity of liposomes to 1.1 MHz ultrasound; H Mujoo.

Session 2 Lubricin-Mimetics to Prevent Progression of Osteoarthritis; M Tan. Session 1 Mesoporous silica-based materials as delivery system for doxorubicin hydrochloride and metronidazole; W Sawicki. Session 2 Nerve-repair conduit formed of beaded PLLA fibers sustainedreleasing nerve growth factor of native form; F Wu. Session 3 Novel diagnostic device with enzyme-responsive beads for detection of wound infection; N Papen-Botterhuis. Session 1 pH-Responsive Fluorescence Polymer Probe for Tumor pH Targeting; Y Hiruta. Session 2 Self-assembling low molecular weight N-acyl nuceloside gelators; K Skilling. Session 1 Spatial Control of Multimodal Microchannels in a Hydrogel ; M Lee. Session 2 Validation of Multifunctional Surfaces for Tumor Cell Capture from Human Blood; J Myung. Session 1 Visualization of Therapeutic Effect for Angiogenesis with a PolymerBased Magnetic Resonance Imaging Probe; Y Tabata. Session 2

Cells as Delivery Vehicles 102 238

Assembly and Characterization of a Cell-particle Hybrid System as a Potential Cancer Vacc; K Ahmed. Session 1 Hydrogel for Protein Repellency; J Zheng. Session 3

Controlled Release Applications in Food, Feed, and Beverages 240 241 242

Antimicrobial Brominated Polystyrene Beads for Water Decontamination ; O AVIV. Session 2 IPP: Permeability, Stability & Toxicity; J Gleeson. Session 3 Starch-Pectin Based Delivery System for Ascorbic Acid; Y Liu. Session 1

Controlled Release of Actives in Consumer Products 244

245 246 248

Controlled Release of Opiate Drugs Using Ion Exchange Resins; A Gehris. Session 3 Evaluation of adsorptive property of anti-microbial agent on artificial tooth and bacteriocidal effect of DA-5502; D Kim. Session 1 Formulation and Characterization of niosomal carriers for topical application of (+)-catechin; D Li. Session 2 Injectable long-term control-released in situ gels of hydrochloric thiothixene for the treatment of schizophrenia; C Xin. Session 1 continued

37

Controlled Release of Actives in Consumer Products continued 249 106

Moisture and Fragrance Release from Hydrogel Air Fresheners; R van Sleeuwen. Session 2 PHBV Nanoparticles of FTY720 (Fingolimod) : Drug Loading and Release Studies of a Water In-Soluble Drug; F Dorkoosh. Session 1

Evaluation and Characterization of Controlled Release Products and Production Processes 251

252 253

254 255

256 257

258

259 260 261 262 263 265

266 267 268 269 270

271 272 273 274 275

276 277 278 280 282 283 285

38

A new injectable liquid crystal-forming system for on month delivery of Leuprolide; M Ki. Session 1 A novel intravaginal ring to deliver a unique combination microbicide, and a contraceptive for 90 days; S Ugaonkar. Session 2 A Robustness Study of an Extended-Release Tablet Formulation Using a Sample Kit of Hypromellose for Quality-by-Design Concept; A Quadir. Session 3 A Synthetic P-IHDD - Based Compact Matrix System for Extended Drug Release: In vitro Characterization and In silico Release Prediction; O Adeleke. Session 1 A Thermosensitive Glycol Chitin Gel For The Vaginal Delivery of Progesterone: In vitro and In vivo Evaluation; A Almomen.

Session 2 Applying statistical process control in process development Liposome manufacturing by sonication, high shear mixing and microfluidics; E Kastner. Session 3 Assessing the Impact of HPMC Physical Properties and Powder Flow on Process Control During Direct Compression of Matrix Tablets; K Hewlett. Session 1 Characteristics of Felodipine:HPMCAS Solid Dispersions: Dissolution Performance and Particle Size Effects ; J Mole.

Session 2 Characterization of HPMC and Polyox: TA; M Brewster. Session 3 Characterization of HPMC and Polyox:MRI; M Brewster. Session 1 Comparative Dissolution Study of Telmisartan Tablets; S Hwang.

Session 2 Comparison of Enteric Polymer Coated to Commercially Available Acid Resistant Capsules for Delayed Release Delivery; A Lambert.

Session 3 Design And In Vitro Evaluation Of Indomethacin Buccal Tablets; O Esim. Session 1 Design of Extended Release Formulation of DRL-119 by QbD Based Approach; S R Gella. Session 3 Designing Modified Release Tablet Formulation of Quetiapine Fumarate by Using Artificial Neural Network Programs; Y Erginer.

Session 1 Determining Loading of Ibuprofen on Mesoporous Silica Nanoparticles; D Burnett. Session 2 Determining Solubility Parameters of Poloxamers by Experimental and Computational Methods; D Burnett. Session 3 Determining Surface Amorphous Content by Surface Energy Distribution Analysis; D Burnett. Session 1 Development and assessment of captopril loaded matrix-type pellets; R Walker. Session 2 Development and assessment of gastroretentive sustained release captopril tablets; R Walker. Session 3 Development of Tissue Equivalent Phantoms for Improved In Vitro Characterization of In Situ Forming Drug Delivery Implants; M Goss.

Session 1 Dissolution Performance of Inhaled Product APIs in Simulated Lung Fluid Using Novel Low Volume Assays; J Mole. Session 2 Effect of component of gel on E2 release; Y Yang. Session 3 Effect of Polymer (Ethylcellulose), Plasticizer (Dibutyl Sebacate) and Curing Time on the Dissolution Rate of Multi-Layer Sustained Release Pellets; C Hollis. Session 1 Engineering in vitro three-dimensional tumor models by surface fabrication; C Shin. Session 2 Evaluation of a New Co-Processed Excipient for Orally-Disintegrating Tablets; S Obara. Session 3 Formulation and characterization of antimicrobial chewing gum delivery of some herbal extracts for the treatment of periodontal diseases; R yadav. Session 1 Formulation optimization of chitosan nanoparticles using experimental design ; A Al-kinani. Session 3 Identification of predictive in vitro fed relevant dissolution condition for DRL-118 modified release drug delivery system; S R Gella. Session 2 In vitro release and theoretical modeling of a selection of formulations in modified mini-IDR™ holders; E Ahnfelt. Session 3 In vivo evaluation of various formulation strategies for controlled

286 287 288 289 290 293 294

295 296 297 298 299

300 303 305

307 308

release injectables of poorly soluble drugs; J Meeus. Session 2 Injectable doxorubicin thermosensitive hydrogels for localized cancer therapy; H Jhan. Session 3 Investigation of the Effect of Ethylcellulose Viscosity Variation Using QbD Sample, on the Acetaminophen Drug Release from Extended Release Multiparticulate; A Rajabi-Siahboomi. Session 1 In-Vivo Pharmacokinetic Study on Microemulsions by Phase Transition into Liquid Crystal and Coarse Emulsion in-situ; K Singh.

Session 2 Noninvasive Evaluation of the Role of Polymer Molecular Weight on Erosion and Degradation of In Situ Forming Implants; H Zhou.

Session 3 Novel Crush Resistant Microspheres: Applications for Enhanced Safety and Abuse Deterrence; A Fleming. Session 1 Physico-mechanical Characterization and Evaluation of Directly Compressible Grades of Hypromellose; D Tewari. Session 1 Pilot Scale Evaluation of METHOCEL™ DC2 for Robust Matrix Tablet Manufacture by Direct Compression; G LaBella. Session 2 Predictive Modeling and Validation of Tamoxifen Release from EVA Copolymers; B Zhang. Session 3 Preparation and characterization of alginate-based ferrogels; H Kim. Session 1 Preparation of Orally Disintegrating Tablets Containing Taste-Masked Coated Pellets; M Fukasawa. Session 2 QbD Small Scale Process Development and Prediction of an MatrixType Extended Release Tablet; X Guo. Session 3 Quantification of PEG surface coverage-density on polymeric nanoparticle and its effect on physico-chemical properties; J Rabanel. Session 1 Rapid formulation development and clinical testing strategies in the development of controlled release products; M Paterson. Session 2 Sustained Delivery of Hydroxychloroquine from a Polyether Urethane Intravaginal Ring; Y Chen. Session 2 Synthesis, Characterization and Cytotoxicity Study of Poly(ethylene glycol)-Hexamethylene Sebacamide Biopolymer; H Al-Lami.

Session 1 The Effect of Polymeric Micelles Concentrations on Two Fluorphores

by Fluorescence Resonance Energy Transfer; J Liaw. Session 3 The Influence of Manufacturing Method on Physical Properties and Drug Release from Push Pull Osmotic Pump (PPOP) Products; G LaBella. Session 1

Innovations in Micro- and Nano-Based Delivery 309 310

311 312 313 316 317 318 319 320

321 322

323

324

325 327

A new Poly (ethylene oxide)/ACV nanofibrous matrix as a potential vaginal drug delivery system; F Dorkoosh. Session 2 A Novel Approach to Detection of Low-Concentration Biomarkers ; L Khoury. Session 3 A PEGylated liposome formulation of Tofacitinib targets a site of inflammation and enhances therapeutic efficacy in a mouse calvarial osteolysis model; x wei. Session 1 A Pure Titanium/Titania Implant for Tunable Zero-Order Drug Delivery; K Fischer. Session 2 A Sheet-Shaped Poly (ethylene glycol)-Modified Chitosan HydrogelContaining Crosslinkable Polymeric Micelles for Wound Dressing and Drug Release; C Yoshida. Session 3 Amylose Based Glyco Star Copolymers: A Platform for New Glycobiomaterials; T Nishimura. Session 3 Amylose complexes intended to design of controlled drug delivery systems; B Cury. Session 1 Antibacterial property of novel coating; J Wu. Session 2 Anti-Oxidative Bilirubin Nanovesicles Show Potential for Use in AntiInflammation Therapy; Y Lee. Session 3 Aspartic Acid Based Peptides Modify on PLGA-PEG Nanoparticles for Bone Targeting; C Lin. Session 1 Beads of gellan gum and gellan gum/pectin: comparative study of mucoadhesion and dissolution properties; B Cury. Session 2 Biodegradable particles for co-delivery of doxorubicin and CpG ODN oligonucleotides as an improved therapy for tumors; V Joshi. Session 3 Branched Glycerol-Modified Liposomes as a New Candidate of Drug Carriers; Y Kawashima. Session 1 Catechol-Containing Antioxidant Micelles for Anti-Angiogenic Therapy; M Moriyama. Session 2 Cellular Interactions of Dendron Micelles Controlled by the Length of Hydrophilic Chains; H Hsu. Session 3 Characterization and Pharmaceutical Evaluation of Antifungal Textiles; M Hossain. Session 2

328 329 332 334 335 336 337 338 339 340 341

342 343 344 345

346 347

348 350 351 352

353 354 355 357 359

360 362 363 364 365 366 367

Characterization of Functional Liposome with Tunable Surface Property and Cellular Uptake by Temperature Control; J Wang.

Session 3 Chitosan-coated nanofibrous sheet including human growth factor for treating oral mucositis; H Yoo. Session 1 Controlled release by hydrogel dissipative properties; M Nassajian Moghadam. Session 1 Core-shell anticancer drug LbL nanoformulation with protein resistant properties; T Levchenko. Session 3 Core-Shell Fibers for Zero-Order Intravaginal Drug Delivery of Hydrophilic Antiretrovirals; C Ball. Session 1 Design and optimization of Teriparatide loaded PHBV/PLGA blend nanoparticles; F Dorkoosh. Session 2 Design and Preparation of a Polymeric H2S Donor; A van der Vlies.

Session 3 Design and use of silica-containing redox nanoparticles, siRNP, for protection of encapsulating peritoneal sclerosis; Y Nagasaki. Session 1 Development and characterization of dexamethasone-loaded microsphere formulations for long-term continuous release; B Gu. Session 2 Development and Optimization of PLGA Nanoparticles as a Carrier System for Oral Delivery of Gemcitabine; G Chen. Session 3 Development of Liquid Crystal Systems from Meglumine-Based Supra-Amphiphile for Topical Delivery of Drugs; M Fonseca.

Session 1 Development of Novel Biodegradable and Biocompatible Poly(diaminosulfide) Microparticles as a Chemotherapeutic Drug Delivery System; S D’mello. Session 2 Development of Photothermally-Active Gold Shell-Coated Lipid Nanoparticles; J Nam. Session 3 Development of Temperature-Sensitive Hydrogel Nanoparticles for Targeted Chemotherapy; T Shirakura. Session 1 Dithiolethione-Bearing Polymeric Micelles for Hydrogen SulfideBased Therapy; U Hasegawa. Session 2 Drug-Induced Nanocarrier Assembly for the Delivery of Nucleotides and Nucleotide Analogues; H Hillaireau. Session 3 Dual stimuli-responsive antioxidant polymer nanoparticles as therapeutics for oxidative stress-associated diseases; D Lee. Session 1 Effect of Formulation Process Parameters on the Development of Nalbuphine HCl-Loaded Poly D,L-lactide-co-glycolide (PLGA) Microparticles; S D’mello. Session 2 Encapsulation of insulin peptides in liposomes for preventing type 1 diabetes; M Cano-Sarabia. Session 1 Enhanced Apoptosis Induction by Bortezomib loaded in Liposomal Nanocarriers: A Comparison between Cationic and Ceramide Liposomes; M Joshi. Session 2 Enhancement of Cytotoxic and Antineoplastic Activities of Doxorubicin via Vitamin C Co-delivered by Multi-layered Microparticles; C Wang. Session 3 Evaluation of mucoadhesiveness of micro/nano particles containing zidovudine; B Cury. Session 1 Extended circulation and accumulation of p(HPMA-co-AzMA) in arthritic joints; K Howard. Session 2 Fabrication of Nanogel-Crosslinked Porous Gels for Tissue Engineering Applications; Y Hashimoto. Session 3 Formulation and Characterization of Niacin Loaded PLGA-Based Nanoparticles; D Cooper. Session 1 Formulation development and evaluation of nanoparticles for sustained delivery of levodopa- dendrimer conjugate for treatment of Parkinson’s disease; N Mulla. Session 1 Freeze-Dried Nanocrystalline Cellulose Derived from Water SugarCane Bagasse as a Novel Tablet Excipient; A El-Ashmawy. Session 2 Growth Factor-Carrying Hybrid Hydrogel/Nanogel Composite for the Treatment of Urethral Incontinence; K Park. Session 1 Hepatocyte Targetted Delivery of Primaquine Phosphate Nanocarboplex Using a Carbohydrate Ligand; H Maithania. Session 2 Hsp16.5 Protein Nano-Cages Conjugated Magnetic Resonance Contrast Agents with High Efficient Relaxivity Properties; T Kawano.

Session 3 Hyaluronate - Gold Nanoparticle / Tocilizumab Complex for Combination Therapy of Rheumatoid Arthritis; H Lee. Session 1 Hyaluronic Acid Nanoparticles for Delivery of γ-Secretase inhibitor; R Heo. Session 2 Hydrogel nanoparticles for delivery of short cationic antimicrobial peptides; J Water. Session 3

368 369 370 371 372 373 374 375 376 377 378 379 380 382 383 384

387

388 389 390 391 392 393 394 395 396 397

398

399 400 401

402 403 404

Hydrophobic Pheophorbide A Physically Loaded Bioreducible Poly(ethyleneimine)s : Preparation, Characterization, and Lightinduced Cytotoxicity; H Cho. Session 1 Imaging of Vascular-Injured Tissue by Liposomal Quantum-Dots; G Aizik. Session 2 Impact of ions on double emulsions systems (W/O/W) stabilized by amphiphilic block copolymer; Y Zhang. Session 3 Implantable Pump Actuated by Static Magnetic Field for On-demand Drug Delivery; S Lee. Session 1 Increased in-vitro release time of poorly soluble drugs loaded into injectable crosslinked hyaluronic acid hydrogel formulations; O Dall.

Session 2 Inhibition of bovine lactoferrin proteolysis in luminal contents and mucosal homogenates from rat intestine; J Wen. Session 3 Insulin nanoparticles-containing emulsion for Oral Delivery of Insulin; A Ribeiro. Session 1 Insulin-loaded gellan microcapsules coated with resistant starch/ pectin films: Morphology and mucoadhesive properties; A Meneguin.

Session 2 Intratympanic Injection Drug Delivery System for Extended Steroid Delivery to the Inner Ear; N Dormer. Session 3 Large Scale Production of Cosmetic Hesperidin Nanocrystals by smartCrystal® Technology; S Staufenbiel. Session 1 Liposomal system designed for the sustained release of ropivacaine; C Silva. Session 2 Magnetically Decorated Multi-Walled Carbon Nanotubes as Dual MRI and SPECT Contrast Agents; K Al-Jamal. Session 3 Mechanical and Bioadhesive Behavior of Hexagonal Liquid Crystals From Meglumine-Based Supra-Amphiphile For Topical Drug Delivery Systems; A Souza. Session 1 Metformin hydrochloride-loaded liposomes: a formulation study; J Eloy. Session 3 Microwave-assisted Synthesis of Functionalized SiO2 Nanoparticles; J Cornejo-Bravo. Session 1 Molecular Size and Binding Affinity Influence Effectiveness of Ultrasound-Microbubble Mediated Drug Delivery; J Roberts.

Session 2 Multi-Responsive Nanogels Based on Hyperbranched Polyglycerol; A Sousa-Herves. Session 2 Nanocrystal Formulation of Lercanidipine by Simple Evaporative Antisolvent Technique; N Udupa. Session 3 Nanoparticles as a Promising Delivery System to Improve Hepatitis C Treatment; Y Abo-zeid. Session 1 Novel Encapsulation of Arsenic Trioxide into Polymeric Micelles; Q Zhang. Session 2 Novel sheet-shaped materials in which polymeric micelles are dispersed for the sustained controlled release of proteins; R Anzai.

Session 3 Optimization and Characterization of PACA Nanoparticles for Drug Delivery and Imaging; R Schmid. Session 1 Pectinate Micro-/Nano-particles for Stabilization of Retinyl Palmitate; H Kim. Session 2 Phase-guided microencapsulation, a method to prepare sustainedrelease microspheres for structurally delicate protein drugs ; Z Hu. Session 3 Photothermally controlled drug delivery using a funtionalized graphene oxide; W Kim. Session 1 pH-Sensitive Crosslinked Biodegradable Micelles for Intracellular Doxorubicin Delivery; J Chen. Session 2 Poly(lactide-co-glycolide) Microspheres for MRI-Monitored Delivery of Sorafenib Locally to Liver Tumors; J Chen. Session 3 Polycation-Shielded Calcium/Fludarabin Phosphate Nanocomplexes: Preparation, Characterization, and In Vitro Anti-Tumor Effects; D Cho. Session 1 Polycation-Shielded Calcium/Nucleotide Nanocomplexes: Preparation, Characterization, and Enhanced Cell Survival; Y Choi.

Session 2 Polysaccharide Nanogel-Hybrid Nanofibers by Electrospinning; A Shimoda. Session 3 Preparation and characteristic of nanogel-cross-linked microsphere; Y Tahara. Session 1 Preparation and Characterization of Magnolol Loaded Nano-MicroParticle Complexes; M Shen. Session 2 Preparation and evaluation of Pingyangmycin-loaded chitosan thermogels for vascular malformations therapy; F Chen. Session 3 Preparation and Pharmacological Evaluation of Uniform-sized Drug-loaded PLGA Microspheres by SPG Membrane Emulsification; J Wu. Session 1 continued

39

Innovations in Micro- and Nano-Based Delivery 405 406

407 408

410 412

413

414 416 417

419

420

421

422 424 425

426

Preparation of a Vitamin E-based Polymeric Micelle for Cancer Therapy; T Yamazaki. Session 2 Preservation of Oral Nanosuspensions with Food Preservatives; S Staufenbiel. Session 3 Production of highly loaded Vitamin K1 nanostructures lipid carriers (NLC) against couperosis; R Müller. Session 1 Proliposome technology: A novel large scale method for manufacturing of liposomes.; R Gala. Session 2 SCIO-469 loaded Microparticles for Osteoarthritis treatment: fluorescence imaging and drug delivery; P Maudens. Session 1 Self-assembling hyaluronate-based polyelectrolyte nanocomplexes for oral insulin delivery; S Sladek. Session 3 Silicone embedded nanogels for prolonged resistance against biofilm formation; S Steffensen. Session 1 Size-Tuneable Biodegradable Polymeric Nanoparticles for Controlled Drug Delivery ; A Basra. Session 2 Sugar-based Amphiphiles for Drug Delivery: Library Synthesis and Phase Characterization; G Feast. Session 1 Surface design of thermoresponsive core-corona type nanospheres with well-defined corona layer for regulation of protein adsorption; T Matsuyama. Session 2 Sustained Release of TGF-β from Biodegradable 3-Dimentional fibrous Poly(L-lactic acid) Scaffold for Cartilage Regeneration; H Kyung. Session 1 Synthesis of Biocompatible Nanogels of N-isopropylacrylamide and Carboxyalkyl Methacrylates by Soapless Emulsion Polymerization; D Castro-Vidal. Session 2 The Application of a Fluorescent Pre-Labelling Method for Evaluation of Exosome Biodistribution; K Howard. Session 3 Thermosensitive Liposomes Encapsulated in a Thermoresponsive Hydrogel for On-Demand Release: The Lipogel System; G Duffy.

Session 1 Topical Drug Delivery of Nanoencapsulated Triclosan; P Kakadia.

Session 3 Triggered release of doxorubicin from temperature sensitive poly(N-(2-hydroxypropyl)-methacrylamide mono/dilactate) grafted liposomes; M van Elk. Session 1 Tuning semipermeability of polyion complex vesicles “PICsomes” by varying polycation side chains and crosslinking degree of polyion complex membrane; O Mutaf. Session 2

Innovations in Oral Drug Delivery 427

A Thorough Characterization of the Food Effect in Oral Drug Dissolution in the Stomach; O Rezhdo. Session 3 429 Characterization of PVA and DMAB based Celecoxib Loaded Polymeric Nanoparticles; D Cooper. Session 2 430 Comparing the Blood Glucose Profiles between Rectal and Oral Delivery of Insulin with Our Permeability Promoter A2032; J Lee. Session 3 431 Controlling the Release of Olanzapine by Preparation of selective Molecularly Imprinted Nano-particles as Drug Delivery System; N Jafary Omid. Session 1 432 Development and Evaluation of novel floating-osmotic capsule for

zero order delivery of extract of Andrographis paniculata Nees; P KILAMBI. Session 2 433 Development and Operation of a New IntelliCap Fast Release

System; J Shimizu. Session 3 434 Development of a Bilayer Zydis® Freeze Dried Orally Disintegrating Tablet; L Grother. Session 1 435 Development of a Bioequivalent Taste Masked Cetirizine HCl 10mg Zydis® Dosage Form using Cyclodextrin; L Grother. Session 2 436 Development of a Sachet Formulation of DRL282 Containing

Delayed Release Pellets with Inactive Granules for NG Tube compliance and Bioequivalence; D Sahoo. Session 3 437 Development of Redox Therapy for Periodontitis using Redox Injectable Gel; M Saita. Session 1 438 Direct Visualization Shows that Conventional in vitro Capsule Dissolution Methods do not Reflect the in vivo Situation;

D Bar-Shalom. Session 2 439 Dissolution Behavior of Cyclodextrin Molecular Inclusion Complexes

of Artemether; k Ofokansi. Session 3 441 Drug layering with the aqueous polymer dispersion Kollicoat®

SR 30 D for controlled release pellets; R Bodmeier. Session 2 443 Enhancement of solubility and Bioavailability of a poorly water-soluble drug by Solid dispersion technique; S Patil. Session 1

40

445

Estimating in vivo drug release from a new theophylline Compritol® 888 ATO matrix formulation using appropriate biorelevant test methods; Y Cuppock-Rosiaux. Session 3 Evaluation of Melt Techniques for the Manufacturing of Immediate Release (IR) Solid Dosage Forms; G Loreti. Session 1 Formulation and in vitro release of Telmisartan melt dispersion and tablets; C Kapadia. Session 3 Formulation of Controlled Release Orally Disintegrating Tablets of a Water Soluble Compound; A Kondappan. Session 1 Formulation of Double-Layered Orally Disintegrating Microparticles Containing Desmopressin; K Hwang. Session 2 Formulation Approaches; M Brewster. Session 3 Gabapentin And Flurbiprofen Combination Product: In Vitro Drug Release Comparison of Dome Matrix® Assembled System versus Three-layer Tablet; A Rossi. Session 2 Gellan Gum Fluid Gels as Modified Release Oral Liquids; M Mahdi.

Session 3 Glucose-responsive double-layered nanogel for an oral delivery system; D Lee. Session 1 HPMC Matrix Behaviour in Challenging Ionic Environments as a Function of Polymer Level; L Mason. Session 2 Identification of Critical Material Attribute of an API, affecting granulation end point in a high dose tablet dosage form; S R Gella.

Session 1 In vitro characterization of microcontainers as an oral drug delivery system ; L Hagner Nielsen. Session 3 In vitro enzymatic degradation of lipidified apomorphine; N Borkar.

Session 1 Investigating the In Vivo-In Vitro Correlation for the Effect of Kolliphor® EL, ELP and RH40 on the Bioavailability of Fenofibrate in Rats; A Mullertz. Session 3 Lyophilized Insulin Nanoparticles prepared from Quaternized N-aryl Derivatives of Chitosan: Ex vivo and In vivo Characterizations; M Rafiee-Tehrani. Session 1 Medicated Chewing Gums Loaded With Mucoadhesive Microparticles For Oral Candidiasis Treatment In Children; B Conti. Session 2 Nanoporous magnesium carbonate as phase stabilizer of amorphous Ibuprofen; P Zhang. Session 3 New Drug Delivery Technology Partnership Opportunity; S Rockett.

Session 1 Novel Core-Shell Protein Nanoparticles for Oral Drug Delivery; M Alqahtani. Session 1 Novel Highly Effective Formulation for the Oral Treatment of Hyperphosphatemia: Nanocrystalline Maghemite; R Müller. Session 2 Novel in situ preparation of sustained release oral delivery liquid crystalline nanoparticles; B Boyd. Session 3 Optimization of Hot Melt Extrusion Parameters for Sphericity and Hardness on Polymeric Face-Cut Pellets; J Park. Session 1 Oral nanomedicines for the treatment of parasitic diseases; A Lalatsa. Session 2 PAMAM Dendrimer Based Oral Formulation Development For Colon Specific Delivery; A Asthana. Session 3 Peroral Delivery of Mast Cell Stabilizer Using PLGA Nanoparticles for the Treatment of Allergic Rhinitis: Formulation, Optimization & Characterization; R Patel. Session 1 Physicochemical evaluation of tadalafil solid dispersions obtained by antisolvent precipitation; W Sawicki. Session 2 Poly(carboxyalkyl methacrylamides) as Carriers for Controlled Drug Release; H Magaña-Badilla. Session 3 Preliminary In Vivo Evaluation of an Oral Multiple-Unit Formulation for Colonic Delivery of Insulin; G Loreti. Session 2 Preparation of Proniosomes Containing Candesartan Cilexetil and Assessment of Their In Vivo Bioavailabilties; N Yuksel. Session 3 QbD-based Systematic Development of Self-Nanoemulsifying Systems for Improved Oral Bioavailability of Olmesartan; S Beg. Session 1 Release adjustment of a drug combination formulated in erodible hydrophilic matrix tablets; R Bodmeier. Session 2 Solid Crystalline Dispersions of Sildenafil Citrate in Ethyl Cellulose Produced by Hot-Melt Extrusion; H Patil. Session 3 Solid Dispersions Obtained Using Fusion Method Increases Solubility of Praziquantel; P Dametto. Session 1 Streamlining the Design of Sustained Release Matrix Tablets Using Mathematical Modeling For Drug Release Optimization; Y Rosiaux.

Session 2 Synthesis and Characterization of Vitamin B12 conjugates of Carboxymethyl CHT and TMC to make Nanoparticles for Oral Insulin Delivery; N Jafary Omid. Session 3 Tailoring Drug Release and Utilization of Process Analytical Techniques by FT-IR Imaging employing HME Systems; J Park.

Session 1

446 448 449 450 451 453 454 455 456 458 460 461 463

464 465 466 467 470 471 472 473 474

475

476

477 478 480

481 482

483 484 485 486 487 488

489 490

491

492

The Accordion Pill™, a gastro-retentive controlled release system–a new solution for key unmet needs; N Navon. Session 2 The Effect of the Process on Drug Release of Compritol®888 Sustained Release Tablets: Direct Compression, Wet Granulation and Hot Melt Extrusion; Y Rosiaux. Session 3 Trilaurin Diminishes Food Effect on the Release of Desmopressin from Solid Lipid Microparticles; H Mu. Session 1 Using novel nano-lipospheres to target M-cells for oral vaccine delivery; L Wang. Session 2

Intracellular Delivery of Nucleic Acids and Proteins 493 494

495 496

497 498 499 500 501 502

503 504 505

Amphiphilic polysaccharide nanoballs with chaperon-like function for protein delivery; S Takeda. Session 3 Delivery of Antioxidant Tat-Metallothionein Fusion Protein for Protection of Xenotransplanted Pancreatic Islets from Radical species; M Kim. Session 1 Efficient Cytosolic Release of Encapsulated Molecules in Exosomes Using pH-sensitive Fusogenic Peptide; I Nakase. Session 2 Intracellular delivery and activation of the genetically encoded photosensitizer Killer Red by quantum dots encapsulated in polymeric micelles; I Park. Session 3 Intracellular Delivery of Monoclonal Antibodies into the Living Cells by Charge-Conversional Polyion Complex Micelles; A Kim. Session 1 Lipid-nanoparticles for intracellular delivery of anti-microRNA oligonucleotides into non-small cell lung cancer cells; M ISLAM. Session 2 Mitochondria-targeted PLGA particles that protect against myocardial cell death; A Wongrakpanich. Session 3 Non-Toxic Endogenous nucleotides for Endosomal Disruption and Enhanced Gene Transfection; H Cho. Session 1 Non-Viral Delivery of Gene HPV-16 E7 into Mammalian Cells; F Dorkoosh. Session 2 Novel pH responsive polymeric vesicles for siRNA delivery to the tumor; S Salmaso. Session 3 Polymer-mediated gene transfection efficiency is positively correlated with polyplex-induced autophagy in fibroblasts; X Zhong. Session 1 Polymersomes formed by phase-guided assembly as carriers for intracellular delivery of anti-tumor therapeutic proteins; W Yuan.

Session 2 The Influence of Dendritic Cell Type and Maturation State on Transfection Efficiency of Synthetic Polymer-based DNA Vaccine Carriers; C Wang. Session 3

Nanoparticle-Based Delivery to The Brain 744

507

508 509

510 511 514

515 516 518

519

Anti-Parkinson Drug Delivery to Brain by Targeting Blood-Brain Barrier; D Keskin. Session 3 Blood Brain Barrier Permeable Polymanntiol Gene Transporter Modified with Rabies Virus Glycoprotein with Selective Caveolar Transcytosis Pathway; C Cho. Session 2 Development and assesment of efavirenz-loaded SLN® for potential delivery to the CNS; R Walker. Session 3 Development of cRGDfV-loaded chitosan nanoparticles using factorial design and evaluation of their in vitro cytotoxicity on glioblastoma cell line; C Kiill. Session 1 Intranasally Administered Lectin Functionalized PEG-PLGA Nanoparticles: A Novel Drug Delivery System for the Treatment of Schizophrenia; T Hoare. Session 2 Molecular design and biological evaluation of brain-targeting protein cage; N Hamano. Session 3 Polymersomes Conjugated with Des-octanoyl ghrelin for the Delivery of Therapeutic Agents into Brain Tissues; Y Chen. Session 3 Protein Adsorption Patterns from Differently Coated Azithromycin i.v.

Nanocrystals; S Staufenbiel. Session 1 Self-assembling nanoparticles containing zoledronic acid: A new scenario for the treatment of glioblastoma; G Salzano. Session 2 Target Delivery of Proteins into Central Nervous System with Specific Peptide Identified by Phage Displayed Library In-vivo Panning; y Qiu. Session 1 Transferrin-bearing Polypropylenimine Dendrimer for Targeted Gene Delivery to the Brain; S Somani. Session 2

Nanoparticles in Tumor Treatment 520

3D Cancer Cell Spheroids as a Model For Investigating Co-Delivery of Paclitaxel and Curcumin by Targeted Mixed Micelles; C Sarisozen.

Session 3

522 523

524

525 526

529 531

532 533

534

535

536

537

538 539 540 542 543 544

545 546

547

548

549 551

553 554 555

556 557

558 559

560

561 564

565

A molecular pulling/pushing nanovehicle ; J LEE. Session 2 A Multi-Scale Hybrid Nanoparticle for Controlled Release Kinetics and Efficient Intratumoral Penetration; J Bugno. Session 3 A novel Nanostructure Lipid Carriers with Charge-reversal and pHSensitive Membranolytic Capability for Lysosomolytic Anti-cancer Drug Delivery; M Sun. Session 1 A Pharmacokinetic Modeling Approach for Personalization of Nanomedicine; A Kirtane. Session 2 A Synergistic Theranostic Approach Using a Targeted siRNA Drug Delivery Platform and a Phthalocyanine-Loaded Dendrimer for Ovarian Cancer Treatment; O Taratula. Session 3 acid-activatable fullerene nanogel; S Kim. Session 3 Angiopep-2-conjugated Liposomes Encapsulating Dibenzazepine for Glioblastoma Multiforme; S Xuan. Session 2 Anti-angiogenic effect of heparin-taurocholate conjugate on mouse glioblastoma animal model; J Seol. Session 3 Anti-Tumor Effect of Heparin-Taurocholate Conjugate to Various Kinds of Orthotopic Pancreatic Cancer Animal Model; H Jeong.

Session 1 Bacterially Derived Outer Membrane Vesicles as Cancer Cell-Specific Drug Delivery Vehicles; V Gujrati. Session 2 Biofunctionalized Magnetic Nanoparticle for Targeted Drug Delivery and Thermal Therapy; j gupta. Session 3 Bioreducible poly(ethylene glycol)-pheophorbide a conjugate for the preparation of self-quenchable nanoparticles with controllable photoactivity; H Cho. Session 1 Cathepsin B degradable peptidic macromolecules as delivery vehicle for Geldanamycin; J Suárez del Pino. Session 2 Characterization of optimally designed liposomal formulation of Oxaliplatin; Y Doi. Session 3 Chitosan-g-polycaprolactone Graft Copolymer Nanoparticles for Paclitaxel and p53 Plasmid DNA Delivery; P Davoodi. Session 1 Cholesterol Esterification-Blocking Nanoparticles for Targeted Aggressive Cancer Therapy; S Lee. Session 2 Delivery of siRNA for breast cancer; M Gujrati. Session 1 Densely PEG Coated Cisplatin Nanoparticles for Treatment of Malignant Glioma; C Zhang. Session 2 Developement of a therapeutic cancer vaccine based on polymeric nanoparticles containing HPV synthetic long peptide and poly IC; S Rahimian. Session 2 Development of a specific targeting system for pancreatic tumors utilizing antibody conjugated Pt-loaded micelles; J Ahn. Session 1 Development of an Externally Activated Drug Delivery Vehicle; L Moir. Session 2 Development of glutathione-sensitive polymeric micelles for the delivery of camptothecin to solid tumors; H Yen. Session 3 Development of Localized Cisplatin Chemotherapy: From Benchside to Investigational New Drug Application; S Cai. Session 1 Development of Nanobody Targeted Liposomes Directed Against Tumors for Image-Guided Drug Delivery. ; M Bolkestein. Session 2 Development of stomach cancer-targeted and cytotoxic hybrid peptides; B Lee. Session 1 Disulfide nanosponges as innovative glutathione-responsive nanocarrier for doxorubicin delivery; R Cavalli. Session 3 Encapsulation in nanoparticles improves anti-cancer efficacy of carboplatin; T Sadhukha. Session 1 Enhanced Anticancer Efficacy of Folate Anchored Stealth Polyaspartic Acid Doxorubicin Nanocomplexes; A Chaturvedi.

Session 2 Enhanced Cancer Cell Cytotoxicity of Dual Ligand-Targeted Doxorubicin-Loaded Liposomes; S Sriraman. Session 3 Enhanced Paclitaxel Loading Capacity of Micelles by Introducing Fmoc as a Drug-Interactive Motif; Y Zhang. Session 1 Enhancement of anti-tumor activity of hybrid peptide by conjugation with thiolated carboxymethyl dextran via disulfide linkers; A Gaowa.

Session 2 Facile preparation of paclitaxel-loaded self-assembled polyethyleneglycol-albumin conjugate nanoparticles for effective cancer therapy; M Kim. Session 3 Formulation of Stabilized Ultrasound Visible Nanoparticles for Thermal Sensitizer Delivery ; P Perera. Session 1 Gold Nanorods and Paclitaxel Loaded Solid Lipid Nanoparticles and Their Therapeutic Potential for Near-Infrared PhotothermalChemotherapy of Cancer; J Kim. Session 2 Hyaluronic Acid Derived Fluorescent Nanoparticles for I mage-Guided Tumor Surgery; A Mohs. Session 2 Hydrophobically-modified hyaluronic acid nanocapsules for targeted docetaxel delivery; A Cadete Pires. Session 3 continued

41

Nanoparticles in Tumor Treatment continued 566 568 569 571 573

574

575

576

578 579 580

582 583 584 585

586

587

588

589

590 591 592 594

596 597 598 600 602 603

604

605 606

42

Improved Safety and Efficacy of Surface Engineered Docetaxel Nanoparticles for Targeting in Prostate Cancer; K Singh. Session 1 In Vivo Anti-Tumor Efficacy Study of a Novel Wnt pathway Inhibitor Packed in RH40 Micelles; C Li. Session 3 Investigating the relationship between interstitial fluid pressure, perfusion, and liposome accumulation in solid tumors.; S Stapleton.

Session 1 Magnetic and radiolabeled biodegradable nanoparticles for dual medical imaging; I Rosenberger. Session 3 Monitoring Nanoemulsion-Based Oxygen Delivery using Non-Invasive Tumor Hypoxia Imaging; D Song. Session 2 MUC 1 aptamer conjugated to chitosan nanoparticles, an efficient targeted carrier designed for SN38 delivery toward colon cancer; S Hadipour Moghaddam. Session 3 Multiscale Drug Delivery System: Micelles Encapsulated in Hydrogels; M Tang. Session 1 Nanobioconjugates for Triple-Negative Breast Cancer Treatment; J PORTILLA-ARIAS. Session 2 Nanoparticle Depot for Intraperitoneal Chemotherapy of Ovarian Cancer ; B SUN. Session 1 Nanostructured Lipid Carrier Co-loaded with Doxorubicin and Docosahexaenoic Acid: a Novel Strategy to Improve Activity and Overcome Tumor Resistance; S Mussi. Session 2 Novel Mg-Al Layered Double Hydroxide-Fe3O4 Magnetic Nanohybrids for Efficient Thermo-Chemo Therapy of Cervical Cancer; E Prasadarao K. Session 3 Novel Self-Associating Poly(ethylene oxide)-b-poly(ε-caprolactone) based Drug Conjugate for Delivery of STAT3 Inhibitor JSI-124 to Murine B16 Melanoma; S Garg. Session 2 Optimization of thermosensitive liposome formulations for intravascular drug release; W Lokerse. Session 3 Oxidative stress amplifying polymeric micelles as novel anticancer therapeutics; D Lee. Session 1 PEG-Farnesylthiosalicylate Conjugate with a Drug Interactive Motif as an Improved Micellar System for Delivery of Anticancer Agents; X Zhang. Session 2 PEG-Peptide Conjugate Equipped with Drug-Interactive Motifs as a Safe and Effective Delivery System for Paclitaxel; P Zhang.

Session 3 pH responsive liposomes for gemcitabine enhanced delivery to cancer cells; S Salmaso. Session 1 Phage display based competitive cell panning identifies candidate scFv with selective affinity to pre-metastatic, EMT transitioned breast cancer cells; S Kalscheuer. Session 2 Polyethylene Glycol Conjugated Polymeric Nanocapsules for Targeted Delivery of Quercetin to Folate-Expressing Cancer Cells In Vitro and In Vivo; K Al-Jamal. Session 3 Polymer-bound NIRF Probe to Improve Colorectal Cancer Detection; A David. Session 1 Polymeric micelles based on vitamin E-contained comb-type polymer for application in cancer therapy; K Lee. Session 2 Polymeric micelles containing anti-survivin siRNA and Paclitaxel in combination: A promising strategy to reverse the drug resistance in ovarian cancer; G Salzano. Session 3 Preparation of PLGA nanoparticles to enhance intracellular uptake in dendritic cell ; Y BYOEN. Session 2 Preparation, Characterization and Evaluation of a Liposomal Formulation for Co-Delivery of Paclitaxel and Lapatinib; F Dorkoosh.

Session 1 Radiosensitization Effect of Gossypol-loaded Pluronic Micelles; K Tomoda. Session 2 Redox-Responsive Core Cross-linked Hyaluronic Acid Nanoparticles for Intracellular Delivery of Doxorubicin; H Ko. Session 3 Remote Loading of a Novel Acidic Hypoxia-Activated Prodrug into Liposomes with High Entrapment Efficiency and Drug Loading; M Yang. Session 2 Reversal of Chemoresistance in Ovarian Cancer Cells By Liposomal Co-delivery of Tariquidar and Paclitaxel; S Sriraman. Session 1 siRNA Nanoparticles Targeted to the Extra Cellular Matrix for Cancer Therapy; M Naim. Session 2 Smart ZnO-embedded pH-responsive Liposomes for Cancer Therapy: Triggering Mechanism and Drug Release Behavior; N Tripathy. Session 3 SPIO-Doxorubicin Conjugates as a Tumor Theranostic Agent Enhanced by Applying Magnetic Fields; Y chen. Session 1 Star Polymers with Tailored Transition Temperature for Optimal 5-Fluoruracil Drug Delivery; E Sanchez-Bustos. Session 2

607

608

Surface Chemistry Modification of Paclitaxel Nanocrystals and In Vitro Evaluation; Y Chen. Session 3 Synergistic Delivery of Curcumin to Tumors via PEG-derivatized FTS-based Micellar System; Y Chen. Session 1

609

Synthesis, Evaluation and Optimization of Novel Polymeric Micelle Based on Hyaluronic Acid and Phospholipids for Targeted Delivery of Paclitaxel; F Dorkoosh. Session 2 Synthetic high density lipoproteins for targeted delivery of withalongolides to adrenocortical carcinomas ; R Kuai. Session 3 Targeted Heat-Triggered Doxorubicin Delivery to Tumors by Cationic Thermosensitive Liposomes; G Koning. Session 3 Targeting Multifunctional Nanomedicine Delivery System for Pancreatic Cancer; J Sun. Session 1 The Preparation of High-content Gemcitabine pH Sensitive Liposomes and Evaluation of their Cytotoxicity to Drug Resistant Pancreatic Cancer Cells; H Xu. Session 2 Titanium oxide-based nanoparticles for sonodynamic threapy of cancer; D You. Session 1 Trilayer Micelles for Combination Delivery of Rapamycin and siRNA ; S Zeng. Session 2 Tumor Accumulation and Penetration of Mesoporous Silica Nanoparticles and the Potential Role of Peritoneal Macrophages; L González-Fajardo. Session 3 Tumor Regression following Intravenous Administration of Lactoferrin- and Lactoferricin-bearing Dendriplexes; C Dufes.

Session 2 Tumor-targeted Delivery of Bevacizumab Using Heparin-Pluronic Nanogels ; J Bae. Session 3 Tumor-targeted Delivery of Paclitaxel using Low Density Lipoproteinmimetic Solid Lipid Nanoparticles; J Kim. Session 1 Variation of PEG Length and Its Effect on the Targeting Efficacy of APTEDB-Liposome in vitro and in vivo; P Saw. Session 3

610 613 614 615 617 618 619

621

622 623 625

Novel Developments in Formulation, Analytical Chemistry, and Processing in Animal Health and Preclinical Sciences 627 628

630 632 634 636

638 639 640 641

Continuous production of Solid Lipid Nanoparticles via Hot-Melt Extrusion; H Patil. Session 2 Detection of Cathepsin-K activity for osteoarthritic diagnosis using FRET with a gold nanorod-based fluorescent probe; C Lee. Session 3 Development and Validation of an Analytical Method for Ketoprofen Determination in Matrix Tablets by High Performance Liquid Chromatography; M Vueba. Session 2 Development of manufacturing process for a parenteral depot formulation by in situ precipitation; E Corona. Session 1 In situ forming composite gel (ISFcG) designed for local antibiotic delivery and bone regeneration; B Conti. Session 3 Rapid HPLC Method supporting rennin inhibitor enteric coated beads formulation development; S Kirsh. Session 2 Role of water sorption capacity of tableting excipients to protect protein drugs from structural changes during storage using infrared spectroscopy; M Klukkert. Session 1 Surface engineered Nanoannomaal: A nanoparticulate system for targeted antimalarial chemotherapy; K Singh. Session 2 Targeted Nanoparticle for Cancer Imaging; R Savla. Session 3 Validation of an LC-MS/MS method for the simultaneous quantification of eight permeability standard drugs; M Leclaire.

Session 1

Overcoming Barriers in the GI Tract 642 643

644 645 646

Amorphous Drugs in Porous Materials – Stability, Solubility & Tablet Performance; R Müller. Session 2 Cell penetrating peptides - is charge important for improved uptake of nanoparticles?; A McDowell. Session 3 Comparison of CapsMorph® and Nanocrystals of Poorly Soluble Drugs; R Müller. Session 1 pH-dependent FcRn-Mediated Transcytosis of Nanoparticles across the Intestinal Epithelium; M Yu. Session 2 Predicting the Impact of Ingested Lipids on Orally Delivered Drug Absorption: Mechanistic Studies and Modeling ; S Di Maio.

Session 3

Overcoming Biological Barriers 648 649 650

652

653 654 655 656 657 658 659 660

661

662 663 664 665

Development and Antimicrobial Evaluation of Cefuroxime Axetil Loaded Chitosan Films for the Treatment of Periodontitis; S Åženel.

Session 2 Development of a novel mucoadhesive precursor of based-chitosan liquid crystal system for buccal administration.; G Calixto. Session 3 Effect of low frequency sonophoresis in cetuximab skin penetration: a preliminary study; R Petrilli. Session 1 How terpene-based nanoparticles, harboring stimuli-responsive linker, overcome poor diffusion of β-lactam antibiotic to treat intracellular infection?; N Abed. Session 3 Human Serum Albumin Based Nanoparticles of Bridelia Retusa Extract as Vaginal Microbicide; K Singh. Session 1 In vivo Feasibility Study on Iontophoretic Transbuccal Peptide Drug Delivery in Rabbits; J Seo. Session 2 Nanoparticle Delivery to Intravaginal Mucosal Tissue and Target Lymphoid Organs Using Chitosan as a Mucosal Adjuvant; J Park.

Session 3 Polyethylene glycol-Rhodamine 123 Conjugates Remain P-gp Substrates ; L Crawford. Session 1 Rapid Screening of Anti-cancer Drugs and Delivery Vehicles Using Tumor-microenvironment-on-chip; A Ozcelikkale. Session 2 Release and corneal permeation of 2-oxothiazolidine-4-carboxylic acid from chitosan nanoparticles for cataract treatment ; A Al-kinani.

Session 3 Reverse engineering tumor invasiveness on nanoparticle surface to improve tumor penetration of nanoparticles; A Kirtane. Session 1 Rheological and bioadhesive behavior of hexagonal lyotropic basedchitosan liquid crystal systems intended to buccal drug delivery.; G Calixto. Session 2 Solubility and Cellular Internalization Enhancement of Formulations of Paclitaxel with β-Cyclodextrins: Physicochemical and In Vitro Assessments; M Shah. Session 3 Stiffness of Injection Site Increases Penetration Distance of Drug Released from In Situ Forming Polymer Implants ; C Hernandez.

Session 1 Targeted miRNA delivery for psoriasis treatment based on modified starch and ultrasound application; R Lifshiz. Session 2 Topical Nanomedicine – overcoming the barriers; T Prow. Session 3 Two-photon microscopy analysis of drug delivery through the bloodbrain barrier using focused ultrasound in a mouse model of Alzheimer’s disease. ; K Hynynen. Session 1

Proteins, Peptides, and Vaccines 666 667 668 669 670 671 672 673 674 678 681 682

683 684 686

A Designed Nanocage Displaying Ligand-specific Peptide Bunches for High Affinity and Biological Activity; I Kim. Session 2 Adjusting bevacizumab – lipid particles eletrostatic interactions by freeze-drying process: towards new carriers for monoclonal antibodies; C Kiill. Session 3 Basic analysis for screening a novel bone-regenerating peptide from the phage peptide library; N Takashi. Session 1 Biomimetically Engineered Demi-bacteria Potentiate Vaccination Against cancer; W Wei. Session 2 Cellular Uptake of FITC-Rath peptide; J Kuo. Session 3 Ceramic-based Nanosystem for Oral Delivery of Proteins and Peptides ; D Lowry. Session 1 Comparison of two different site-specific conjugates of hGH in biophysical and in vivo studies; G Pasut. Session 2 Comprehensive characterization of vesicle formation with a selfassembling amphiphilic peptide; M Rad-Malekshahi. Session 3 Conjugation free oral microparticulate meningitis vaccine formulation and evaluation; R Gala. Session 1 Delivering Recombinant Melittin for Treatment of High Grade Astrocytoma; J Buhrman. Session 2 Development and anti-tumor activity of a novel anti-human claudin-3/-4 dual-specific antibody; Y Kimura. Session 2 Efficacy of liposomal nanocarriers in targeted delivery of ETB receptor agonist, IRL-1620 for the treatment of Alzheimer’s Disease; B Oesterling. Session 3 Efficacy of PLGA particle vaccine against house dust mite allergen depends on size of PLGA particles and presence of CpG; V Joshi.

Session 1 Enhanced in vivo CTL activity by newly synthesized micelles loaded with Trp2 peptide; Q Zeng. Session 2 Formulation and Evaluation of therapeutic vaccine microparticles for Breast Cancer; N Mulla. Session 1

687 688

690 691

693

694 695

696

697 698

699

700

701

702

703 704 706 707

708 709

710 711 712

Formulation and Packaging Optimization for Microneedle Delivery of Abaloparatide, a Novel Peptide for Treatment of Osteoporosis; Y Zhang. Session 2 Generation of a bispecific antibody (EphA10/CD3) as a novel biodrug candidate against breast cancer; S Taki. Session 3 In vivo inhibition of hepatitis C virus infection by anti-human claudin 1 monoclonal antibodies; M Iida. Session 2 Intra-Articular injection of a Hyaluronic acid - Salmon Calcitonin Conjugate as Potential Treatment of Osteoarthritis; G Pasut.

Session 3 Lamellar to cubic phase transitions: Tackling the bioactive frontier; T Hartnett. Session 2 Lipid-based Nanoparticles Co-loaded with Tumor Cell Lysate and Immunostimulatory Agents for Cancer Immunotherapy; L Ochyl.

Session 3 Maximising the Half-Life of Bone Morphogenetic Protein (BMP) using Sustained Release Calcium Phosphate Microcrystals; J Vos. Session 1 Melittin-GST fusion protein and hyaluronic acid have augmented anti-inflammatory properties when combined; J Rayahin. Session 2 Microgels for the Controlled Release of Proteins; J Rios. Session 3 Microparticle-Mediated Delivery of Growth Factors Promotes Cardiac Repair in Infarcted Rats ; F Formiga. Session 1 Novel hollow microneedle technology for depth controlled microinjection-mediated dermal vaccination: a study with polio vaccine in rats; J Bouwstra. Session 2 Novel Vaccine Delivery System Induces Robust Humoral and Cellular Immnune Responses Based on Multiple Mechanisms; G Ma. Session 3 pH responsive liposomes for enhanced local protein delivery to cancer tissues; S Salmaso. Session 1 Physicochemical Characterization of an Endogenous Anti-ageing and Wound Healing Tripeptide GHK-Cu; T Badenhorst. Session 2 Phytantriol based novel crystalline self-assemblies for oral insulin delivery; S Jain. Session 3 Protein Crystallization for Delivery; K Shi. Session 1 Reversible and tunable PEGylation at Arginine residues; Y Gong.

Session 3 Self-Encapsulating PLGA Microspheres: A Novel Method for Delivery of Vaccine Antigens; B Bailey. Session 1 Short noncoding DNA fragments improve immune potency of electroporation mediated pCMV-EGFRvIII vaccination; J Peng.

Session 2 Spray-dried poly(anhydride) nanoparticles containing peanut allergens reduces pro-allergic immune trend after oral immunization; J Rebouças. Session 3 Subunit Vaccine Design of the Schistosomiasis Japonica Insulin Receptor; R Stephenson. Session 1 The preparation and in vivo vaccination effects of PLGA emulsion gels; Y Yang. Session 2 Thermally triggered release of a pro-osteogenic peptide from a functionalized collagen-based scaffold using thermosensitive liposomes; A Lopez-Noriega. Session 3

Transdermal Delivery 713

714

715

716

719

722 724

725 726

727

A miniaturized instrument for rapid in vitro release testing of semi-solid formulations in pharmaceuticals: application to ibuprofen gel ; A Chapman. Session 1 A Predictive Microscopic Mathematical Diffusion Model for Finite Dose Skin Penetration: Extension of the Model Considering Stratum Disjunctum Layers; M Heisig. Session 2 Adjustment of Needle-free Jet Injector Control to Account for Viscous Loss; R Williams. Session 3 An Investigation of Cutaneous Absorption of Caffeine through Elderly Female Epidermis; S Lee. Session 1 Comparative study of Different Skin Penetration Delivery Vehicles for Retinol, Resveratrol, Epigallocatechin gallate, and Vitamin C; M Lopez Garcia. Session 1 Effect of polymorphism on crystallization of donepezil in drug-inadhesive matrix; H Choi. Session 1 Enhanced local delivery of topical anaesthetics; A Raphael.

Session 3 Enhanced Transdermal Adsorption of L-DOPA with Glycerol Dendrons; T Ooya. Session 1 Epidermis-target by iontophoresis of ovalbumin-loaded liposomes for transcutaneous immunization; D Bernardi. Session 2 Establishing IVIVR for passive transdermal patches: a case study of Lidocaine; R P K. Session 3 continued

43

Transdermal Delivery continued

736

728

737

729

730

731 733 734 735

Evaluation of a Transdermal Murine Breast Cancer Vaccine administered via Micro-needles; N Mulla. Session 1 Evaluation of antifungal activity of some propiconazole nitrate gels; E Popa. Session 2 Formulation and Evaluation of Transdermal Microparticulate Vaccine for Ovarian Cancer; R Gala. Session 3 Formulation of Cationic Niosomes for Dermal Delivery of an Endogenous Anti-aging Tripeptide Using a Post-insertion Technique; T Badenhorst. Session 1 Improved Terbinafine Formulations, Based on Third Generation Deformable Vesicles, for Noninvasive Topical Application and Superficial Mycoses Therapy; M Elsayed. Session 3 In Vitro Drug Release and In Vivo Efficacious Study of Lyogels Containing Hydrocortisone for the Treatment of Eczema; S Ng. Session 1 Intradermal RNAi therapeutic system by novel class of RNAi agents and functional peptide for atopic dermatitis ; T Kanazawa. Session 2

738 740 741 742 743

Optimization of Dissolving Microneedle Formulations Using Dissolution Rate Studies; J Kennedy. Session 3 Penetration and Distribution Studies of Sensitive Nanoparticles to the pH of the Skin: Targeting the Follicular Pathway; I CalderonLojero. Session 1 Preparation of Redispersible Liposomal Dry Powder by an Ultrasonic Spray Freeze Drying Technique for Transdermal Delivery of EGF; X Zhang. Session 2 Thermoresponsive nanogels based on hyperbranched polyglycerol for dermal protein delivery; M Molina Soler. Session 1 Topical Delivery of Macromolecules to the Breast through NippleAreola Complex; K Dave. Session 2 Transdermal delivery of pravastatin sodium in transdermal patches using solid microneedles; I Calderón Lojero. Session 3 Transdermal Hyaluronate-Myostatin Peptide Conjugate for the Treatment of Muscular Dystrophy; W Kong. Session 1

From the Controlled Release Society and the American Association of Pharmaceutical Scientists

Animal Health Drug R&D: Formulation, Delivery & Development to Market Cosponsored by Peter Cremer North America November 1–2, 2014 • San Diego, California, U.S.A. Held immediately prior to the AAPS Annual Meeting Workshop Organizers David Brayden, University College Dublin, Ireland Peter Cheifetz, Merial Limited (A Sanofi Company), U.S.A. Michael Rathbone, ULTI Pharmaceuticals, New Zealand Shoban Sabnis, Zoetis, U.S.A. This is a can’t-miss event for anyone in animal health drug development. If your organization is working on novel formulations, medical devices, drug–device combinations, or trying to take novel veterinary therapeutic concepts commercial, this is your chance to hear from the experts, connect with major animal health companies, and meet with your colleagues worldwide.

Sessions Announced!

Register by August 22, 2014, and Save!

Want more on animal health? Check out Long Acting Animal Health Drug Products

Hosted by two premier scientific organizations in the area of drug delivery and pharmaceuticals, this workshop features an incredible international program, including speakers on: • • •

•

•

Human-veterinary technology crossovers Opportunities and challenges in emerging markets Novel analytical methods for drug release from veterinary formulations Bioanalytical tools to speed veterinary medicine product development And much more

This is the first meeting of its kind in nearly a decade—and this area of science is developing rapidly. Do not miss this opportunity!

For the full listings of sessions and the schedule, visit controlledreleasesociety.org/AnimalHealth Molecular background ©wawritto / Shutterstock.com; Scientists courtesy of Comstock; Syringe courtesy of istockphoto.com

44

Experience the CRS Exposition!

Come to the Exhibit Hall Salons C and D for discovery, solutions, and opportunities. This is the place for the business of delivery science and profitable collaboration. The CRS Registration Desk is in Exhibit Hall Salon C.

When is the Exposition open?

On Sunday evening (17:30–19:30), the Exposition kicks off with a welcome reception designed for networking among colleagues.

Booths are again open for visitors during dedicated exhibit hours on Monday and Tuesday.

Monday, July 14 09:30 – 17:30

09:30 – 10:30 16:30 – 17:30

Exposition/Poster Hall Open Dedicated Exposition Hours Meet with Exhibitors Happy Hour and Networking

Tuesday, July 15 09:30 – 16:00

09:30 – 10:30 15:00 – 16:00

Exposition/Poster Hall Open Dedicated Exposition Hours Networking and Refreshment Break Networking and Refreshment Break

What else is in the Exposition Hall?

This is the central hub for poster viewing, registration, program breaks, networking, refreshments (thank you Café Sponsors), and CRS Central.

Who will be at the Exposition?

Knowledgeable representatives from leading companies that provide products, services, and technologies for the delivery science market. Don’t forget to bring your business cards!

Exhibitors of the 41st CRS Annual Meeting & Exposition The following descriptions, supplied by the exhibiting companies as of May 14, 2014, provide product, service, and contact information. Please see the program addendum for additional exhibitor information.

S 400

S

– Sponsor

CS

– Café Sponsor

3M Drug Delivery Systems, U.S.A., Tel:

+1.651.736.0233, www.3M.com/DDS. 3M Drug Delivery Systems partners with pharmaceutical and biotech companies to develop and manufacture pharmaceutical products using 3M’s inhalation, transdermal, and microneedle drug delivery technology. 3M offers a full range of feasibility, development, and manufacturing capabilities to help bring products to market. For more information, please visit www.3M.com/dds or call 1.800.643.8086.

205

Adhesives Research, Inc./ARx, LLC, U.S.A., Tel:

704

Advanced Polymer Materials Inc., Canada, Tel:

S

+1.717.235.7979, www.adhesivesresearch.com.

Adhesives Research is a leading developer and manufacturer of specialty adhesives and films for transdermal, oral delivery, and body-worn devices.

ARx, LLC, is FDA registered and fully GMP compliant, specializing in the development and manufacture of drug-loaded transdermal/topical patches and oral/mucosal thin-film drug delivery systems. ISO 9001 & 13485 certified, DEA license.

+1.514.683.8488, www.apmpolymers.com. We are a Canada-based manufacturer with R&D capability, producing innovative, unique biodegradable and biocompatible polymers and block copolymers (mPEGs, functional PEGs, multi-arm PEGs, and functional PEG/PLA, PLGA, and PCL) to fill the need for scientific advancement in pharmacy, biomaterials, and functional nanoparticles. We do custom syntheses and contract research.

404

Agilent Technologies, U.S.A., Tel: +1.408.345.8886, www.agilent.com. Agilent manufactures and distributes a complete line of instrumentation serving the clinical, analytical, biotech, environmental, pharmaceutical, forensic science, food and flavor, academia, and all other laboratory markets that have needs for the best in quality, performance, and serviceability in the instruments they purchase.

707

Akina, Inc.: PolySciTech Division, U.S.A., Tel: +1.765.464.0501, www.polyscitech.com. Research products available include biodegradable block and specialty copolymers (polyvivo), fluorescent dyes (FlammaFluor), specialty chitosan variations (Kitopure), and release media (polyvitro). Custom synthesis to match your specification and contract analysis services are also available. Also available is scale-up, template-based microparticle manufacturing device (spinswiper) for quick generation of uniform microparticles.

214

Anton Paar USA, U.S.A., Tel: +1.804.550.1051, www.anton-paar.com. SAXSpace is a laboratory instrument for small-angle and wide-angle X-ray scattering (SAXS and WAXS/XRD). Combined in the SAXSpace system, these two techniques form a powerful analytical solution for investigating liquid crystals, dispersions, polymers, proteins, and much more. A compact instrument that provides ultimate clarity for your materials research and quality control.

45

413

CS

Avanti Polar Lipids, Inc., U.S.A., Tel: +1.205.663.2494, www.avantilipids.com. Avanti Polar Lipids, with an unparalleled reputation for purity, is clearly established as world leader in the production of phospholipids, sphingolipids, and sterols. Exciting new products for the research chemist and cGMP lipids for pharmaceutical production. Recent developments include adjuvants, glycosylated sphingolipids, new fluorescent and deuterated lipids; plus analytical services.

200

Bend Research, Inc., U.S.A., Tel: +1.541.382.4100,

220

BioPharm Solutions, Inc., U.S.A., Tel:

706

302/ 304

S

215

46

www.bendresearch.com. Bend Research is now part of Capsugel’s Dosage Form Solutions business unit headquartered in Morristown, N.J., providing access to additional technologies, R&D capabilities, and global manufacturing infrastructure for the advancement of client compounds from concept through clinical to commercial manufacture.

+1.848.448.8481, www.biopharmsolutions.com.

BioPharm Solutions, Inc. (BPS) is a dynamic biotech company dedicated to developing industrially feasible delivery systems for biologic medicines. By collaborating with university partners, BPS R&D team has achieved sustained-release delivery of native proteins, efficient and accurate transdermal delivery of insulin, as well as easy-operating and environmentally friendly manufacturing processes.

BUCHI Corporation, U.S.A., Tel: 877.MYBUCHI,

www.buchi.com. For 75 years, BUCHI has been known as the market leader of laboratory products based on evaporation and vacuum technologies. In addition, BUCHI Corporation is the North American provider of spray drying and encapsulation solutions, as well as, NIR spectroscopy, Kjeldahl and solvent extraction solutions, and melting point products.

410 Colorcon, U.S.A., Tel: +1.215.699.7733, www.

CS

203 CordenPharma, Switzerland, Tel: +41 61 906 5959,

S

417

CS

Celanese EVA Polymers, U.S.A., Tel:

1.800.661.3663, www.vitaldose.com. Celanese EVA Polymers combines the unique properties of VitalDose™ excipients with high-touch service, indepth technical expertise, and comprehensive regulatory knowledge to help customers meet their product objectives. VitalDose™ EVA polymers are used for controlled release drugs and medical devices through many routes of administration. Learn more at www.VitalDose.com.

www.cordenpharma.com. CordenPharma is your fullservice CMO partner in the contract development and manufacturing of APIs, drug products, and associated packaging services from R&D to commercialization. With multiple cGMP facilities across Europe and the United States, CordenPharma specializes in supplying custom synthesized materials such as lipids, peptides, lipo-peptide conjugates, and carbohydrates.

Croda Inc., U.S.A., Tel: +1.732.417.0800, www.croda.

com/healthcare. Croda offers a complete range of products including high-purity multicompendial solvents, solubilizers, and surfactants for parenteral, oral, ophthalmic, and topical formulations. Featured products include Super Refined™ ingredients: castor and other oils, oleic acid, oleyl alcohol, PEGs, polysorbates, propylene glycol, dimethyl isosorbide, medical-grade lanolins, poloxamers, and omega-3 fatty acid concentrates.

401

Delta Industrial Services Inc., U.S.A., Tel:

1012

Destination Edinburgh, United Kingdom, Tel: +44

605

Dissolution Technologies, U.S.A., Tel:

Catalent Pharma Solutions, U.S.A., Tel:

+1.732.537.6200, www.catalent.com. From drug development services to delivery technologies and supply solutions, we are the catalyst for your success.

Catalent has the deepest expertise and the most innovative drug delivery technologies to enhance your product performance, including OSDrC® OptiDose™ optimized dosing, Zydis® fast-dissolve formulations, and OptiMelt™ hot melt extrusion.

colorcon.com. Colorcon is a world leader in the development, supply, and technical support of formulated film coating systems, modified release technologies, and functional excipients for the pharmaceutical industry. Our best-in-class products and technologies are complimented by our valueadded services, which support all phases of solid oral dose design and development.

S

1.800.279.3358, www.deltamodtech.com.

(0)131 473 3876, www.marketingedinburgh.org/ conventions. Scotland’s capital is an award-winning city of breathtaking beauty where rich cultural heritage combines with stunning new developments.

Delegates can attend the purpose-built conference centre (EICC) while staying in the luxurious Sheraton Grand Hotel & Spa, all within walking distance from the city centre. Edinburgh, a world-class destination. +1.302.235.0621, www.dissolutiontech.com.

Dissolution Technologies is a peer-reviewed, indexed quarterly journal reporting current information and scientific articles on dissolution testing. Books related to dissolution topics are available for sale on the searchable website, www.dissolutiontech.com. The website contains all back and current issues, and these articles are available for free as a PDF download.

700

604

S

1006

S

310

Distek, Inc., U.S.A., Tel: +1.732.422.7585, www.distekinc.com. Distek, Inc., is a leading manufacturer of pharmaceutical laboratory instruments, specializing in dissolution testing products, and an experienced provider of validation and qualification services. Distek has grown to offer their innovation and support to companies worldwide.

For technological advancements that offer reliable and consistent performance, the pharmaceutical industry trusts Distek.

Drug Delivery Partnerships (IIR), U.S.A., Tel:

211

S

Erbo Spraytec AG, Switzerland, Tel: +41 62 958 88

210

Evonik Corporation, U.S.A., Tel: +1.732.981.5269,

320

DURECT Corp./LACTEL® Absorbable Polymers,

U.S.A., Tel: 1.877.705.8072, www.absorbables.com, www.durect.com. DURECT Corporation is a specialty pharmaceutical company developing therapeutics based on its proprietary delivery technologies, including injectable depot, oral sustained-release, transdermal, and biodegradable implant. In addition, DURECT produces the LACTEL Absorbable Polymers line of biodegradable polyesters for use in the pharmaceutical and medical device industries. www.absorbables.com/crs14, www.durect.com

CS

Controlled Release, an official journal of the Controlled Release Society and the Japanese Society of Drug Delivery System. Elsevier is the leading publisher dedicated to providing authors the latest articles, tools, and resources within pharmaceutical sciences.

88, www.erbo-spraytec.ch. ERBO Spraytec AG, Switzerland, is a specialist for microencapsulation, functional coatings, controlled release, and tailormade granules. We develop and produce highly defined powders for our customers serving the food, feed, and cosmetic industries worldwide. Various packaging and worldwide logistic services are offered as well. Welcome to the powder professionals. www.evonik.com/pharma. Evonik, a global leader in specialty chemicals, provides drug delivery technologies, API manufacturing, intermediates, and amino acids. Delivery technologies include development services, solubility enhancement, functional excipients, and GMP manufacturing for oral and parenteral formulations. Advanced delivery technologies provided for small molecules, peptides, proteins, antibodies, and nucleic acids used in extended-release parenterals.

Fluid Imaging Technologies, Inc., U.S.A., Tel:

+1.207.289.3200, www.fluidimaging.com. Fluid Imaging manufactures the FlowCAM®, a continuousimaging particle analysis instrument. FlowCAM combines the speed of data acquisition of typical particle analyzers with the detailed individual particle information typical of microscopy. Intuitive VisualSpreadsheet software facilitates rapid analysis of particle data and sophisticated pattern recognition operations for particle identification.

500

Formex LLC, U.S.A., Tel: +1.858.529.6600, www.

512

Freund-Vector Corporation, U.S.A., Tel:

1008 Elsevier, United Kingdom, +1.212.989.5800,

www.elsevier.com. Elsevier publishes the Journal of

S

emdmillipore.com. EMD Millipore is the life science division of Merck KGaA. We provide excipients, ODT technology, drug delivery compounds, and chemicals to support all stages of drug manufacturing from research to industrial-scale production and quality control. Our products meet the highest purity standards, with extensive documentation and services assuring regulatory compliance.

514

+1.646.895.7316, www.ddpevent.com. Drug Delivery Partnerships is hailed as the world’s most authoritative conference on collaboration to drive progress in drug delivery. Your roadmap to success starts at DDP15, the only event that delivers the perfect mix of technology, insights, and innovation with access to partneringONE, the state-of-the-art partnering tool.

Drug Development & Delivery, U.S.A., Tel: +1.973.299.1200, www.drug-dev.com. Drug Development & Delivery is a print and online content provider that presents the latest scientific methods in drug development for professionals working in research and development, particle design, APIs, preformulation, formulation development, and analytical methods. Editorial topics include: APIs, biological drug development, bioavailability and solubility enhancement, contracting/outsourcing services, controlled release devices (injectable, needleless, inhalation, nasal, and transdermal), drug delivery technologies (all delivery routes), excipients, formulation development and design, life-cycle management, particle design, and regulatory issues.

EMD Millipore, U.S.A., Tel: 1.800.225.3384, www.

formexllc.com. Formex, a leader in bioavailability enhancement techniques including HME and SDD, manufactures cGMP drug products for uses ranging from clinical trials to commercial distribution. Formex facilities are equipped with cytotoxic and high potent compound containment capabilities. Expert analytical support accompanies our formulation services to deliver comprehensive solutions for your organization.

+1.319.377.8263, www.freund-vector.com. FreundVector Corporation is a world leader in the design, manufacturing, and marketing of solid dosage processing equipment for the coating, granulating, and drying of powders, granules, beads, and tablets for the pharmaceutical and healthcare industries. Product lines include tablet pan coaters, roll compactors, fluid bed granulators/coaters/dryers, high-shear granulators, and automated process control systems.

47

906 Gattefossé, U.S.A., Tel: +1.201.265.4800,

www.gattefosse.com. A leading provider of excipients and formulation solutions to the health industries worldwide, Gattefossé offers bioavailability enhancers; sustained release matrices; solubilizers and permeation enhancers; emulsifiers for topical and vaginal formulations; and tableting aids. Provided with extensive safety, regulatory, and QbD support; formulation assistance; proof of concept services; educational seminars; and so on.

501

Gaylord Chemical Company, U.S.A., Tel:

807

+1.985.649.5464, www.GaylordChemical.com.

Gaylord produces Procipient® (dimethyl sulfoxide USP, PhEur) a high-purity DMSO manufactured according to cGMP (ICH Q7A) guidelines. It is supported by a Health Canada DMF, a Type II Drug Master File, and CEP granted by EDQM. Procipient is efficaciously utilized in numerous registered pharmaceutical dosages and medical devices worldwide.

Hanson Research, U.S.A., Tel: +1.818.882.7266,

www.hansonresearch.com. Hanson is a world leader in dissolution test technology for the pharmaceutical industry. We design, manufacture, install, and service equipment for pharmaceutical research and quality control and offer a complete line of tablet dissolution, topical, and transdermal test systems. We support customers throughout the United States and over 75 countries worldwide.

212 Hovione, Portugal, Tel: +351 21 982 9000, www.

hovione.com. Hovione offers branded pharmaceutical customers services for the development and compliant manufacture of innovative new drugs, niche generic API products, proprietary product development, and licensing opportunities for drug products. With particle engineering technologies, Hovione solves problems like poor bioavailability, patient acceptability, or enabling optimal delivery by non-oral routes of administration.

702

907

48

Intec Pharma Ltd., Israel, Tel: + 972 2 5864657,

www.intecpharma.com. Intec Pharma is a drug development company applying its innovative proprietary drug delivery gastric retention platform technology, the Accordion Pill™, to improve existing drugs. Accordion Pill™ is a proven solution for low bioavailability and non-linear pharmacokinetics of BCS class II and IV drugs and for poor efficacy of narrow absorption window drugs.

Izon Science Limited, U.S.A., Tel: +1.617.945.5936, www.izon.com. Izon Science designs and manufactures precision instrumentation for nano- and micro-scale particle analysis. The qNano, qMicro, and qViro-X utilize tunable resistive pulse sensing (TRPS) to accurately measure the size, concentration, and zeta-potential of individual particles in solution.

This provides a level of detail and assurance not available with light-based techniques.

202

KORSCH America, Inc., U.S.A., Tel: +1.508.238.908, www.korsch.com. KORSCH America is the North American Division of KORSCH AG, a premier global supplier of tablet compression equipment.

KORSCH offers cutting-edge technology for feasibility, development, scale-up, and high-speed production. The KORSCH product line includes specialty equipment for multi-layer, WIP, and highcontainment applications.

1007

Ligand Pharmaceuticals Incorporated, U.S.A., Tel: +1.877.575.5593, Web: www.captisol.com.

Ligand-owned CAPTISOL®, a systemically safe modified cyclodextrin, is used to address solubility, stability and delivery limitations in seven FDA-approved, CAPTISOL-enabled® medications marketed by Merck, Pfizer, Zoetis, BMS, Baxter and Onyx (Amgen). Information regarding our solvent-free, ultra-low endotoxin, GMP-manufactured CAPTISOL® is contained in our Type IV and V DMFs.

204

Lipoid LLC, U.S.A., Tel: +1.973.735.2692, www.lipoid. com. Lipoid is a manufacturer of pharmaceutical-grade phospholipids from three cGMP facilities based in Germany. In addition to synthetic phospholipids used in controlled release, Lipoid produces parenteral, topical, and oral grade egg, soy, and rapeseed lecithin.

Lipoid has over 40 Drug Master Files for excipients on file with the FDA.

111

Logan Instruments Corp., U.S.A., Tel: +1.732.302.

9888, www.loganinstruments.com. Known for premier transdermal testing instrumentation, Logan Instruments also manufactures dissolution testing devices. Logan plans to showcase their new Disso 3-7, which will allow users to run USP3 and USP7 tests on the same instrument.

216

217

Lubrizol Advanced Materials, Inc., U.S.A., Tel:

+1.216.447.5000, www.lubrizol.com/ lifesciencepolymers. Lubrizol LifeScience Polymers provides innovative solutions for controlled release pharmaceutical products. Our portfolio includes Carbopol® polymers and Pathway™ TPU excipients that enhance performance in OSD, implantable, and transdermal applications. A leader in the pharmaceutical industry, Lubrizol’s expert team will work with you to customize the right solution for your needs.

Malvern Instruments NanoSight, U.S.A., Tel: +1.508.768.6400, www.malvern.com. Malvern supports better characterization/control of proteins/ macromolecules. Charge, size, mass, molecular weight, and polydispersity are critical parameters, measured using the following: Zetasizer, dynamic/static light scattering for size, molecular weight, and protein charge; NanoSight nanoparticle tracking analysis, particle-by-particle characterization; Viscotek SEC, molecular weight/structure; Sysmex FPIA-3000, size/ shape analysis of aggregates/subvisible particles; and Viscosizer 200, particle size, concentration, and formulation viscosity.

503

221

902

904

504

505

Medimetrics Personalized Drug Delivery B.V.,

The Netherlands, Tel: +0031408516451, www. medimetrics.com. Medimetrics is the pioneer and global leader in electronic oral drug delivery. With the IntelliCap system, the world’s first and only intelligent oral system, the company provides services to explore controlled release approaches. This enables you to attain rapid and reliable in vivo absorption data throughout the gastrointestinal tract.

Nanocopoeia, Inc., U.S.A., Tel: +1.651.209.1184, www.nanocopoeia.com. Nanocopoeia is a therapeutic particle engineering company providing nano-enabled particle design, services, and equipment to the pharmaceutical industry. We offer particle engineering and rapid formulation prototyping to solve formulation and solubility problems. The patented ElectroNanospray™ ENS process is a highly robust system for creating complex nanoparticles in a single processing step.

NanoImaging Services, Inc., U.S.A., Tel: +1.888.675.8261, www.nanoimagingservices.com. NanoImaging Services provides transmission electron microscopy imaging and analysis services to a wide range of biotechnology and pharmaceutical companies.

We specialize in characterization of nanoparticles, including drug delivery vehicles and biologics for therapeutics/vaccines. We use both cryoTEM and negative stain preparation methods along with advanced image processing, analysis, and reconstruction.

Nisso America Inc., U.S.A./Japan, Tel:

301

S

801

www.dds-drug.com. NOF Corporation DDS Division produces and supplies worldwide, GMPgrade activated PEGs, phospholipids, ultra-pure polysorbates 20 and 80, and excipients for controlled release technology research and development. We continue to provide cutting-edge products for siRNA formulation, antibody-drug conjugation, hydrogel medical devices, and targeted delivery of oncology drugs.

Northern Lipids Incorporated, Inc., Canada, Tel:

+1.604.222.2548, www.northernlipids.com. A CRO modeled around the CMC needs of pharmaceutical and biotech firms engaged in the development of complex lipid-based delivery systems. Services are adapted to meet the client’s needs and include prototype identification, formulation development and scale-up, analytical method development and validation, and sterile product manufacturing under cGMP for clinical trial supplies only.

1159 55 33 55, www.biopharma.novozymes. Our customer-focused approach packages our awardwinning technologies like Veltis® in half-life extension with over 25 years of scientific and regulatory support to customers for the delivery of improved and better-performing products.

Recombinant albumin and hyaluronic acid are produced in large-scale manufacturing facilities worldwide operated to Q7 cGMP quality standards.

OctoPlus, a subsidiary of Dr. Reddy’s Laboratories Ltd., The Netherlands, Tel: +31

CS

715244044, www.octoplus.nl. Companies approach OctoPlus for our expertise in injectable drug delivery.

We are a CDMO for formulation development, scaleup, and GMP manufacturing of any type of injectable drug product, microspheres (proprietary technology for proteins and PLGA), liposomes, highconcentration proteins, peptides, nucleic acid derived compounds, and so on, both liquid and freeze dried.

605

ONdrugDelivery Magazine, United Kingdom, Tel:

S

+44 1273 78 24 24, www.ondrugdelivery.com. Now in its 10th year as a specialist B2B publication covering the global drug delivery industry, ONdrugDelivery is known throughout the pharma and biotech sector as the magazine that focuses right down on specific topics within drug delivery with each issue. Subscribe to the PDF and/or print version FREE online!

112

Optofluidics, Inc., U.S.A., Tel: +1.215.970.2683,

403

Patheon Pharmaceuticals Inc., U.S.A., Tel:

+1.212.490.0350, www.nissoexcipients.com. Nisso America Inc. is a wholly owned subsidiary of Nippon Soda Co., Ltd. (Tokyo, Japan), manufacturers of Nisso HPC (hydroxypropyl cellulose). Nisso HPC is available in a wide range of viscosities, including special low-viscosity grades. For wet/dry binding, sustained release matrix tablet, film coating, and dissolution enhancement applications.

NOF Corporation, Japan, Tel: +81 3 5424 6741,

Novozymes Biopharma, United Kingdom, Tel: +44

S

1003

S

www.opfluid.com. Optofluidics is a particle analysis instrumentation provider based out of Philadelphia, Pennsylvania. Optofluidics manufactures and sells scientific instruments that analyze single nanoparticles, measuring meaningful physical and chemical parameters including nanoparticle coating quality, affinity, composition, stability, and size, with applications to nanodrug delivery and biopharm quality control. +1.919.226.3168, www.patheon.com. Patheon is a leading provider of contract development and commercial manufacturing (CDMO) services to the global pharmaceutical industry for a full array of solid and sterile dosage forms. Patheon, a DPX business unit, encompasses the combined CMO capabilities, pharmaceutical product development services (PDS), biosolutions, and biologics businesses.

Pharmaceutical Technology, U.S.A., Tel: +1.732.346.3019, www.pharmtech.com.

Pharmaceutical Technology offers news, analysis, and peer-reviewed research in formulation development (including excipients) and drug manufacturing to more than 38,000 decision-makers in the top pharmaceutical, specialty pharmaceutical, and biotechnology companies via the Pharmaceutical Technology print magazine, PharmTech.com, and three newsletters: ePT, Sourcing and Management, and the Equipment and Processing Report.

49

420

PolyMicrospheres–Advanced Nanotechnologies,

318

Polymun Scientific Immunbiologische Forschung GmbH, Austria, Tel: +43 2243 25060 300, www.

U.S.A., Tel: +1.317.549.3764, www.polymicrospheres. com. PolyMicrospheres and Advanced Nanotech, Divisions of Vasmo, Inc., design, develop, and manufacture microsphere- and nanoparticle-based drug delivery systems and medical devices to provide controlled-release delivery of pharmaceutical/bioactive agents from days to several weeks. We work with water-soluble and water-insoluble drugs from small molecules to very large proteins.

polymun.com. Polymun Scientific GmbH is a private Austrian company offering contract development and production of liposomes and lipid nanoparticle formulations using its patented formulation technology, as well as development and manufacturing of biopharmaceuticals. Polymun is EMEA certified and provides customized formulation development, scale-up, and analytical services from R&D to commercialization.

213

908

803

50

805

Shin-Etsu Chemical Co., Ltd., U.S.A., Tel: +1.973.837.8001, www.shinetsupharmausa.com. ShinEtsu is the leading manufacturer of pharmaceutical excipients based on cellulose chemistry. Apart from different viscosity grades of HPMC and MC (Pharmacoat and Metolose), the company is the originator of HPMCAS and HPMCP for solid dispersion and enteric coating. Our L-HPC products have been recognized as problem solving binders and disintegrants.

909

Siegfried USA, LLC, U.S.A., Tel: 1.877.763.8630,

305

Simulations Plus Inc., U.S.A., Tel: +1.661.723.7723, www.simulations-plus.com. GastroPlus™ sets the standard for PBPK/PD modeling for different administration routes in humans and animals plus population simulations and DDI capabilities.

DDDPlus™ and MembranePlus™ offer simulations of in vitro dissolution and permeability experiments.

The ADMET Design Suite™ mines compound libraries, designs new molecules, and virtually screens structures for ADMET properties.

316

Sirius Analytical, Inc., U.S.A., Tel: +1.978.338.5790, www.sirius-analytical.com. Sirius Analytical offers instrumentation and CRO services for pKa, logP/ logD, solubility, dissolution, supersaturation, lipolysis, and particle size/shape measurement and new instrumentation for surface dissolution imaging for monitoring real-time drug release—revealing data at early stages of preformulation and development— allowing informed decisions to be made earlier in the drug development process.

Polysciences Inc., U.S.A., Tel: +1.215.488.7498,

www.polysciences.com. Polysciences, Inc., provides custom manufacturing and development of biodegradable materials for drug discovery and delivery, medical devices, biotechnology, electronics, and analytical chemistry industries, as well as high purity optical monomers, UV absorbing materials, and specialty polymer additives to the ocular lens industry.

To learn more, please visit www.polysciences.com/ biomaterials or call +1.215.343.6484.

ProMed Pharma LLC, U.S.A., Tel: +1.763.331.3800,

www.promedpharmallc.com. ProMed specializes in the molding of silicone and thermoplastic components and leverages this expertise to manufacture drug releasing implants and combination devices. From CTMs to commercial products, ProMed supports pharmaceutical and medical device companies for extended release formulations including subcutaneous, orthopedic, cardiovascular, and ophthalmic implants, intravaginal rings, and steroid collar.

510 SOTAX, U.S.A., Tel: +1.508.417.1112, www.sotax.

com. The SOTAX Group is an international leader in the development and manufacturing of equipment for dissolution testing, automated sample preparation, and physical testing of pharmaceutical dosage forms.

Providing high-quality testing solutions for pharmaceutical dosage forms has been our expertise and passion for more than 40 years.

Purac Biomaterials, U.S.A., Tel: +1.847.550.8006,

www.puracbiomaterials.com. Corbion Purac Biomaterials has more than 40 years of experience as a leading global supplier of lactide/glycolide resorbable homopolymers and copolymers. We offer a broad range of standard PURASORB® polymers and monomers as well as provide custom synthesis capabilities for specific formulation requirements.

www.siegfried.ch. Expect more with Siegfried as your preferred partner, as we enhance your product’s value chain by offering chemical synthesis and complex product formulation under one roof. Our clients benefit from a broad base of know-how and manufacturing expertise in complex oral drug delivery systems and sterile fill finish.

405

Southwest Research Institute, U.S.A., Tel:

+1.210.522.2913, www.swri.org. SwRI® provides extensive contract R&D capabilities, including the development of custom encapsulation and controlled release formulations for applications ranging from pharmaceuticals to consumer and diversified products.

Capsules and particles can be prepared in sizes from nanometers to several millimeters. Biomaterials, materials development, synthesis, and modeling capabilities are also available.

218 Springer, U.S.A., Tel: +1.212.460.1600, www.

S

705

219

springer.com. Come and browse current Springer titles. Get 20% off print books and eBooks—and learn about MyCopy editions. Springer, your partner in publishing. Meet our editors at the Springer booth to discuss your publishing proposal. Stop by to purchase your CRS Advances in Delivery Science and Technology books.

703

Thermo Scientific, U.S.A., Tel: +1.908.212.4651, www.thermoscientific.com/mc. Thermo Fisher Scientific is a world leader in extruder technology for hot-melt extrusion and continuous granulation.

Perform benchtop processing with the Thermo Scientific™ Pharma 11 twin-screw extruder, requiring only a small amount of active pharmaceutical ingredient, operating at throughput levels as low as 20 g/h—ideal for experimentation and scale-up applications.

1010

UKICRS Local Chapter, United Kingdom/Ireland,

321

Vision Processing Technologies, Inc., U.S.A., +1.507.444.3957, www.vision-processing.com. VPT is a U.S.-based particle processing company with unmatched flexibility and scalability to meet the needs of our customers (large and small). We utilize a proprietary-designed fluid bed microencapsulation technology that offers cost-effective and materialefficient coating solutions. Our solutions are customized and defined through collaboration and partnership with our customers.

Surface Measurement Systems, U.S.A., Tel:

+1.610.798.8299, www.thesorptionsolution.com.

SMS, innovator of dynamic vapor sorption (DVS), offers a family of water/organic vapor instruments with high-throughput, video, and Raman hyphenation options, plus a novel second-generation surface energy analyzer (SEA) compatible with a wide range of materials and morphologies (including powders/ fibers/films) and featuring a unique heterogeneity mapping capability.

Suven Life Sciences Limited, India, Tel: +91 40

23556038, www.suven.com. Suven is an innovationdriven drug discovery and development company with a decade of experience in progressing NCEs to clinic.

It offers services to advance promising drug candidates to pharmaceutical companies. These include preformulation, formulation, drug delivery, technology support, phase I drug product and cGMP manufacturing.

Sympatec Inc., U.S.A., Tel: +1.609.303.0066, www.sympatec.com.

S

419

303

Technology Catalysts International, U.S.A., Tel:

311

Texture Technologies Corp., U.S.A., Tel: +1.978.468.9969, www.texturetechnologies.com. The TA.XTPlus and TA.HDPlus texture analyzers measure the physical properties of pharmaceutical products and medical devices. They provide extremely repeatable results for quantifying firmness, adhesiveness, disintegration, cohesiveness, swelling, friction, and other physical properties of tablets, ODTs, gels, microspheres, mucoadhesives, patches, creams, lotions, gel caps, syringability, MDIs, powders, and so on.

CS

+1.703.531.0257, www.technology-catalysts.com.

TCI, a global technology and business consulting firm, serves the pharmaceutical, drug delivery, and OTC industries. TCI offers analysis-driven consulting in technology assessments, in- and out-licensing, business intelligence, market research, mergers and acquisitions, and strategic business needs. Reports on drug delivery, drug-device combinations, medical foods, ODTs, and OTFs are available.

402

www.ukicrs.org. The UKICRS, formed in 1998, is a dynamic national chapter of CRS. We have a geographically diverse committee membership, a successful symposium/workshop and an exciting and vibrant annual newsletter. We currently having more than 556 members and are highly active in promoting Drug Delivery across the UK and Ireland.

Wyatt Technology Corporation, U.S.A., Tel: +1.805.681.9009, www.wyatt.com. Wyatt Technology is the recognized leader in instrumentation for determining the absolute molar mass, size, charge, and interactions of macromolecules and nanoparticles in solution. These tools include in-line multiangle static light scattering, high-throughput dynamic light scattering, differential refractometry, electrophoretic mobility, differential viscosity, field flow fractionation, and automated composition gradient.

51

Sponsors of the 41st CRS Annual Meeting & Exposition Sponsors Make It Happen Thanks to our wonderful sponsors! We extend our sincere appreciation to our sponsors, without whom the CRS Annual Meeting would not be possible. Many of the events are possible only through the generosity of sponsors. Please join CRS in thanking our 2014 sponsors,* who support delivery science and add substantial value to the CRS Annual Meeting & Exposition. *Sponsors as of May 30, 2014. Please see the program addendum for additional sponsors.

With more than 50 years of global pharmaceutical development and manufacturing services experience, 3M Drug Delivery Systems is proud to provide customers with proven inhalation, transdermal, oral and topical manufacturing expertise, while ensuring the highest standards of manufactured product delivery from feasibility to market. Meet with our drug delivery specialists at CRS, booth #400. www.3m.com/dds

Advanced Polymer Materials Inc. is a Canada-based manufacturer with R&D capability, producing innovative, unique biodegradable and biocompatible polymers and block copolymers (mPEGs, functional PEGs, multi-arm PEGs, and functional PEG/PLA, PLGA, and PCL) to fill the need for scientific advancement in pharmacy, biomaterials, and functional nanoparticles. We do custom syntheses and contract research. www.apmpolymers.com Since the 1950s, Ashland has provided solutions for tablet binding, film coating and disintegration, controlledrelease formulation, and drug solubilization including Aqualon™ and Blanose™ sodium carboxymethylcellulose, Aqualon™ ethylcellulose, Aquarius™ coating systems, Benecel™ methylcellulose and hypromellose, Cavamax*, Cavitron™, and Cavasol* cyclodextrins, Klucel™ hydroxypropylcellulose, Natrosol™ hydroxyethylcellulose, Plasdone™ povidone and copovidone, and Polyplasdone™ crospovidone. *Registered trademark owned by Wacker Chemie AG. Ashland Inc. acts as a worldwide distributor for Wacker. www. ashland.com

Aspect Imaging’s “M-Series” compact high-performance MR imaging systems enable a broad range of in vivo imaging applications for preclinical phenotyping and drug development.

All systems are self-shielded, silent, require no cryogens, no special siting, and have no external fringe field—allowing them to be placed in a lab, imaging core, or even behind the barrier. www.aspectimaging.com 52

Catalent’s Applied Drug Delivery Institute was founded to serve as a link between industry and academia to advance education and training in drug delivery technology applications for better treatments and foster collaboration on major issues pertaining to drug development, formulation, and delivery. For more info, visit www.drugdeliveryinstitute.com.

Coating Place Inc. develops and manufactures modified release products. We are the leading provider of Wurster microencapsulation services, which include formulation development, technology transfer, scale-up, and commercial manufacturing. We process solvent and aqueous formulations and offer capsule filling, tableting, pan coating, extrusion spheronization, and nanomilling capabilities.

Controlled substances schedule II–V. www.coatingplace.com Corden Pharma is your full-service CMO partner in the contract development and manufacturing of APIs, drug products, and associated packaging services from R&D to commercialization. With multiple cGMP facilities across Europe and the United States, CordenPharma specializes in supplying custom synthesized materials such as lipids, peptides, lipo-peptide conjugates, and carbohydrates. www.cordenpharma.com Dissolution Technologies is a peer-reviewed, indexed quarterly journal reporting current information and scientific articles on dissolution testing. Books related to dissolution topics are available for sale on the searchable website, www.dissolutiontech.com. The website contains all back and current issues, and these articles are available for free as a PDF download. www.dissolutiontech.com

Sponsors Diurnal Limited applies advanced drug delivery solutions to approved drugs t o address unmet patient needs.

Diurnal’s lead product is Chronocort®—modified release hydrocortisone—a first-in-class circadian therapy to treat the orphan diseases congenital adrenal hyperplasia and adrenal insufficiency. Chronocort® has just completed phase 2 clinical trials at the NIH (US). www.diurnal.co.uk Dow Chemical Co. combines the power of science and technology to passionately innovate what is essential to human progress. Serving customers in approximately 180 countries, Dow’s integrated, market-driven, industry-leading portfolio of specialty chemical, advanced materials, agrosciences, and plastics businesses delivers a broad range of solutions to meet emerging challenges around the world. www.dow.com Drug Delivery Partnerships is hailed as the world’s most authoritative conference on collaboration to drive progress in drug delivery. Your roadmap to success starts at DDP15, the only event that delivers the perfect mix of technology, insights, and innovation with access to partneringONE, the state-of-the-art partnering tool. www.ddpevent.com JANUARY 28-30, 2015 BOCA RATON, FL

Drug Development & Delivery is a print and online content provider that presents the latest scientific methods in drug development for professionals working in research and development, particle design, APIs, preformulation, formulation development, and analytical methods. Editorial topics include controlled release, bioavailability and solubility enhancement, outsourcing services, devices (injectable, needleless, inhalation, nasal, and transdermal), drug delivery technologies (all delivery routes), excipients, formulation development and design, and life-cycle management. www.drug-dev.com EMD Millipore is the life science division of Merck KGaA. We provide excipients, ODT technology, drug delivery compounds, and chemicals to support all stages of drug manufacturing from research to industrial-scale production and quality control. Our products meet the highest purity standards with extensive documentation and services assuring regulatory compliance. www.emdmillipore.com

Merial LTD is a world-leading, innovation-driven animal health company, providing a comprehensive range of products to enhance the health, well-being, and performance of a wide range of animals. Merial employs approximately 6,200 people and operates in more than 150 countries worldwide with close to €2 billion of sales in 2013. Merial is a Sanofi company. For more information, please see www.merial.com.

Microtek Labs Inc. leads the way in microencapsulation technologies. As a privately held company founded in 1985, we specialize in custom microencapsulation and product development services.

From product conception, to process development, to full production, we strive to leverage our more than 100 years combined microencapsulation experience for the benefit of our clients. www.microteklabs.com The Nagai Foundation Tokyo was founded in 1986 in commemoration of Prof. Tsuneji Nagai receiving the 1986 Hoest-Madsen Medal from FIP as the first for the Japanese. Then the Foundation was officially approved as government-licensed in 1994 for the purpose of promoting international exchange in pharmacy and pharmaceutical sciences. www.nagai-found.or.jp Now in its tenth year as a specialist B2B publication covering the global drug delivery industry, ONdrugDelivery Magazine is known throughout the pharma and biotech sector as the magazine that focuses right down on specific topics within drug delivery with each issue. Subscribe to the PDF and/or print version FREE online! www. ondrugdelivery.com Patheon Pharmaceutical Services Inc. is a leading provider of contract development and commercial manufacturing (CDMO) services to the global pharmaceutical industry for a full array of solid and sterile dosage forms. Patheon, a DPX business unit, encompasses the combined CMO capabilities, pharmaceutical product development services (PDS), biosolutions, and biologics businesses. www.patheon.com

53

Sponsors At Pfizer, we strive to set the standard for quality, safety, and value in the discovery, development, and manufacturing of medicines for people. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time. www.pfizer.com Pharmaceutical Technology offers news, analysis, and peer-reviewed PharmTech.com research in formulation development (including excipients) and drug manufacturing to more than 38,000 decision-makers in the top pharmaceutical, specialty pharmaceutical, and biotechnology companies via the Pharmaceutical Technology print magazine, PharmTech.com, and three newsletters: ePT, Sourcing and Management, and the Equipment and Processing Report. www.pharmtech.com Advancing Development & Manufacturing

PharmaCircle is an intuitive, dynamic online information resource that integrates over 40 formulation, drug delivery, regulatory, and commercial datasets focused on the global pharmaceutical, biotechnology, medical device, and animal health industries. Stop by our display, visit www. pharmacircle.com, or contact us at +1.760.436.1199 or contact@pharmacircle.com; call to arrange an online demo.

Ronald T. Dodge Company has extensive capabilities and technology skills in the complex field of microencapsulation serving a worldwide customer base. Capsules have been processed from the nano level to 2.5 mm in multiple processing formats of complex coacervation, fluid bed processing, and vapor phase deposition. www.rtdodge.com

54

Springer is the proud publisher of Drug Delivery and Translational Research, an official journal of CRS, as well as the book series Advances in Delivery Science and Technology, published in partnership with CRS. Please stop by our booth to meet our Senior Editor, Christina Dzikowski. www.springer.com Upsher-Smith Laboratories, Inc., founded in 1919, is a growing pharmaceutical company dedicated to its mission: “Advancing Pharmacotherapy. Improving Life.â€? With capabilities ranging from early-stage research to delivering on-market products, Upsher-Smith is committed to developing quality products that enable people to live life to its greatest potential. www.upsher-smith.com Vision Processing Technologies Inc. is a U.S.-based particle processing company with unmatched flexibility and scalability to meet the needs of our customers (large and small). We utilize a proprietary designed fluid bed microencapsulation technology that offers cost-effective and material-efficient coating solutions. Our solutions are customized and defined through collaboration and partnership with our customers. www.vision-processing.com Zoetis (zĹ?-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses.

Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures, and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. www.zoetis.com

2014 CRS Awards & Recognition Join Us in Celebrating Our Esteemed Colleagues The Controlled Release Society is proud to honor this year’s awardees for their dedication and contributions to delivery science and the CRS. Join us in honoring all stages of what it means to be a delivery scientist, from recognizing tomorrow’s leaders with the Postdoctoral Achievement Award of the Foundation’s prestigious fellowship to celebrating the lifelong dedication of our newest inductees into the College of Fellows. Awards will be given at the opening session and the three plenary sessions. See individual award times on the following pages.

Congratulations, 2014 CRS awardees!

2014 Annual Meeting Program Committee Thank you to the 2014 Annual Meeting Program Committee for their time and talents in planning this scientifically outstanding meeting.

Special thanks and appreciation to the following members of the Board of Scientific Advisors who will be rotating off the committee for their service to CRS over the past three years.

Chair: Ick Chan Kwon, KIST, Korea Deputy Chair: Justin Hanes, Johns Hopkins University, U.S.A. Members: You Han Bae, University of Utah, U.S.A. Donald Barbieri, Patheon, U.S.A. Ben Boyd, Monash University, Australia Peter Cheifetz, Merial Limited, U.S.A. Samir Mitragotri, University of California, U.S.A. Ruth Schmid, SINTEF, Norway Hardik Shah, Alkermes Pharma Ireland Limited, Ireland Ronald Smith, Merck, U.S.A. Geert Verreck, Janssen Pharmaceutica, Belgium Fanwen Zeng, Dow Chemical Company, U.S.A. With immense appreciation and sincere gratitude, we honor the following members of the Board of Directors for their leadership and service to CRS over the past years:

Ben Boyd Chair Monash University, Australia

James Oxley Southwest Research Institute, U.S.A.

Mansoor Amiji Northeastern University, U.S.A.

Pavla Simerska University of Queensland, Australia

Distinguished Service Award The Distinguished Service Award is presented to a CRS member who has exhibited exceptional commitment and service to the society and is selected by the Board of Directors.

Kazunori Kataoka Immediate Past President University of Tokyo, Japan

Debra Bingham Secretary Valeo Partners, U.S.A.

Tamara Minko Director-at-Large Rutgers University, U.S.A.

Presentation: Opening Session, Monday, July 14 08:10 – 09:30 Diane Burgess is a Board of Trustees Distinguished Professor of Pharmaceutics at the University of Connecticut, U.S.A. She has over 170 publications, over 450 research presentations at major scientific meetings, over 260 invited lectures, and has presented 20 keynote addresses. Dr. Burgess was the 2010 president of CRS, the 2002 president of AAPS, and is an AAPS, CRS, AIBE, and APSTJ fellow. She is editor of the International Journal of Pharmaceutics.

55

College of Fellows The College of Fellows recognizes those members who have made outstanding contributions to the field of delivery science and technology over a minimum of 10 years. Contributions may have been technical, scientific, and/or managerial in one or more fields of research, commercial development, education, and/or leadership within the areas of interest to CRS. Fellowship is the most prestigious level of membership in CRS. Presentation: Opening Session, Monday, July 14 08:10 – 09:30 Mansoor Amiji is currently a distinguished professor and chairman of the Department of Pharmaceutical Sciences and codirector of the Northeastern University Nanomedicine Education and Research Consortium (NERC) at Northeastern University in Boston, Massachusetts, U.S.A. He received a B.S. degree in pharmacy from Northeastern University in 1988 and a Ph.D. in pharmaceutical sciences from Purdue University in 1992. Dr. Amiji’s research focuses on development of biocompatible materials from natural and synthetic polymers, target-specific drug and gene delivery systems, and nanotechnology applications for medical diagnosis, imaging, and therapy.

You Han Bae is a professor in pharmaceutics at the University of Utah, U.S.A. He has published over 250 peer-reviewed scientific articles (>18,000 citations), book chapters, and U.S. patents on stimuli-sensitive polymers and drug delivery. A fellow of AIMBE (2001) and AAPS (2006), he served CRS as a member of the Board of Scientific Advisors (2000–2003), as a member and chair of the Young Investigator Award Committee (1999–2007), and as a program cochair for the 34th CRS annual meeting (2007). He is an associate editor for the Americas and the concept papers editor for the Journal of Controlled Release.

Joseph Kost is the Abraham and Bessie Zacks Professor of Biomedical Engineering and the dean of the Faculty of Engineering Sciences at Ben-Gurion University in Israel.

He completed his undergraduate and graduate degrees in chemical engineering at Technion and earned a doctorate in biomedical engineering at the same institution. He is a pioneer in the field of responsive drug delivery systems, cofounder of Sontra Medical, and coinventor of the FDA-approved ultrasound-based transdermal delivery system. His research interests include biotechnology, biomaterials, nanotechnology, polymeric systems for genes and drug delivery, application of ultrasound for enhanced transport through membranes, and cellular and intracellular transport.

56

Jean-Christophe Leroux is a professor of drug formulation and delivery at ETH Zurich, Switzerland, and an associate editor of the Journal of Controlled Release. He received his Ph.D. in pharmaceutical sciences from the University of Geneva and completed postdoctoral training at the University of California, San Francisco.

Before joining ETH, he was a professor at the University of Montreal. He is the (co)author of more than 190 refereed articles, book chapters, and patents/patent applications. His distinctions include the CRS Young Investigator Award, the Debiopharm Life Sciences Award, and the APV Research Award for innovative research in pharmaceutical technology.

Tamara Minko is a distinguished professor and chair of the Department of Pharmaceutics, Rutgers University, U.S.A. Her current research interests include nanoscale-based targeted delivery of drugs, peptides, and nucleic acids. Prof. Minko is an author of more than 400 publications. Many of her papers are well cited (6,396 times; Hirsch factor is 42) and published in prestigious journals. She is a fellow of AAPS and AIMBE, Director-at-Large on the CRS Board of Directors, recipient of numerous awards, an editor of Pharmaceutical Research, and an executive editor of Advanced Drug Delivery Reviews. Her research is supported by NIH and other sources.

Looking for the Abstracts?

Three easy ways to access the abstracts: 1. USE YOUR MOBILE DEVICE Access the abstracts from your mobile device

using the 2014 CRS Meeting App. Search for “CRS Meeting” in the iTunes store or Google Play to download the app, or use the desktop app website: mobileapp.controlledrelease.org

2. USE THE ABSTRACT PRINTING STATION

Search and print abstracts for both podium and poster presentations at the Abstract Printing Station located within CRS Central in Exhibit Hall Salon D.

3. VISIT THE CRS WEBSITE The abstracts are also available on the CRS

website and can be accessed using your CRS username and password.

College of Fellows Panel Discussion: Innovation to Commercialization

Founders Award

Tuesday, July 15, 16:00 – 17:30 This special panel discussion on innovation to commercialization is presented by the CRS College of Fellows. The panel this year features College of Fellows members who have direct and successful experience in bringing pharma and non-pharma (consumer and diversified) products to market where controlled release is essential.

Panel Moderator:

The society grants this honor to a current CRS member who is internationally recognized for outstanding contributions in the science and technology of controlled release.

Presentation: Opening Session, Monday, July 14 08:10 – 09:30 Award Lecture: From Swelling Restriction to Module Assemblage in Oral Drug Release Control Paolo Colombo is a professor of pharmaceutical technology at the University of Parma, Italy. He became an AAPS fellow in 1996 and received the CRS Outstanding Paper Award (1999), Maurice-Marie Janot Award from APGI (2004), and CRS Reiner Hofmann Award (2007). He published more than 250 research papers and filed more than 35 patents on drug delivery. The best-known product is Geomatrix® technology, the partially coated hydrophilic matrix (Dilacor XR, Xatral). Dome Matrix is the most recent product in development, consisting of assembling module technology for combination drug controlled release.

Susan Cady Merial Ltd., U.S.A. Panelists:

Young Investigator Award Cosponsored by Catalent Pharma Solutions

Terry Allen University of Alberta, Canada

Art Tipton Southern Research Institute, U.S.A.

Gary Cleary Corium International Inc., U.S.A.

Ron Versic Ronald T. Dodge Company, U.S.A.

Joseph (Yosi) Kost Ben-Gurion University, Israel

This award recognizes a CRS member, age 40 years or younger on December 31 of the current year, who has made outstanding contributions in the science of controlled release.

Presentation: Opening Session, Monday, July 14 08:10 – 09:30 Award Lecture: Peptides and Polymers for Biomedical Applications Suzie H. Pun received her chemical engineering Ph.D. in 2000 from the California Institute of Technology under the guidance of Mark E. Davis. She worked as a senior scientist at Insert Therapeutics/ Calando Pharmaceuticals developing polymeric drug delivery systems before joining the Department of Bioengineering at the University of Washington (UW), U.S.A. She is the Robert J. Rushmer Associate Professor of Bioengineering, an adjunct associate professor of chemical engineering, and a member of the Molecular Engineering and Sciences Institute at UW. Her research focuses on drug and gene delivery systems, and she has published over 70 research articles. She was recognized with a Presidential Early Career Award for Scientists and Engineers in 2006.

57

CRS/T. Nagai Postdoctoral Research Achievement Award Cosponsored by The Nagai Foundation Tokyo This award recognizes an individual postdoc who has recently completed postdoctoral research in controlled release science and technology and the postdoc’s advisor, who played an integral role in the achievements.

Presentation: Opening Session, Monday, July 14 08:10 – 09:30 Award Lecture: Design of MMP2-Sensitive Multifunctional Nanocarriers for Drug Delivery Lin Zhu is an assistant professor in the College of Pharmacy at Texas A&M Health Science Center. After receiving his Ph.D. in pharmaceutics from the University of Tennessee Health Science Center, he did his postdoctoral training at Northeastern University (2010–2013). He has published 25 articles, held two patents, and won several awards, including the AAPS Graduate Student Symposium Award and an American Cancer Society Postdoctoral Fellowship. His research focuses on the development of nanocarriers/ nanomedicine for targeted and stimuli-sensitive drug delivery.

Vladimir Torchilin is a university distinguished professor and director of the Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, U.S.A. He has published 350+ original papers and 150+ reviews and book chapters, written and edited 10 books, and holds 40+ patents. He is editor-in-chief of Current Drug Discovery Technologies and Drug Delivery. He is a member of European Academy of Sciences, fellow of AIMBE, AAPS, and CRS, and received many important awards, including the 2013 Blaise Pascal Medal in Biomedicine. In 2005 he was president of CRS. Times Higher Education ranked him second among top world scientists in pharmacology for 2001–2010.

CRS Foundation CRS Foundation postdoctoral fellowships support advanced research for an outstanding CRS member. Selected from a pool of outstanding candidates, the CRS Foundation fellows reflect the highest level of scientific excellence and leadership potential in delivery science. The fellowships are named in honor of Controlled Release Society leaders who have made exceptional lifetime contributions to delivery science.

Alexander “Sandy” Florence Postdoctoral Fellowship 2014 Presentation: Plenary Session, Monday, July 14 13:30 – 14:45 Christopher Nelson completed his undergraduate studies at the University of Arkansas, U.S.A., in 2009 and began doctoral studies in biomedical engineering at Vanderbilt University. Under the direction of Prof. Craig Duvall, his work focused on controlled delivery strategies for nucleic acids, proteins, and small-molecule drugs.

Most notably, his thesis work involved creating a platform for 58

the controlled delivery of small interfering RNA to improve tissue regeneration. After obtaining his Ph.D., Christopher joined the laboratory of Prof. Charles Gersbach at Duke University to develop technologies for genome engineering.

FOUNDATION

The CRS Foundation thanks individual and corporate donors for making the postdoctoral fellowship program possible.

Jorge Heller Journal of Controlled Release Outstanding Paper Award Cosponsored by Elsevier This award recognizes an outstanding regular paper related to the science of controlled release (not an invited, review, or special meeting paper) that was published during 2013 in the Journal of Controlled Release.

Presentation: Plenary Session, Tuesday, July 15 08:00 – 09:30 Frits Thorsen is a professor, platform leader of the Molecular Imaging Center, and one of the principal investigators in the KG Jebsen Brain Tumor Research Center at the Department of Biomedicine, University of Bergen, Norway.

Thorsen’s research increases understanding of metastatic cancer spread to the brain. His group developed novel animal systems in which human metastatic cell lines are injected systemically into immunodeficient animals to study metastatic spread to the brain as well as treatment efficacy using advanced imaging and genetic profiling. Thorsen is a member of several national and international grant review panels, imaging consortia, and cancer research societies.

Multimodal Imaging Enables Early Detection and Characterization of Changes in Tumor Permeability of Brain Metastases Journal of Controlled Release 172: 812-822 (2013) Frits Thorsen, Brett Fite, Lisa M. Mahakian, Jai W. Seo, Shengping Qin, Victoria Harrison, Sarah Johnson, Elizabeth Ingham, Charles Caskey, Terje Sundstrøm, Thomas J. Meade, Patrick N. Harter, Kai Ove Skaftnesmo, and Katherine W. Ferrara

Drug Delivery and Translational Research Outstanding Paper Award Cosponsored by Springer This award recognizes outstanding research in the field of drug delivery and translational research that was published during 2013 in Drug Delivery and Translational Research.

Presentation: Plenary Session, Tuesday, July 15 08:00 – 09:30 Prabodh Sadana received his bachelor’s degree in pharmacy and master’s degree in pharmacology from the University of Delhi, India. He received his Ph.D. in pharmacology from the University of Tennessee in 2007. Dr. Sadana is currently an assistant professor of pharmaceutical science at Northeast Ohio Medical University, U.S.A. His research interests focus on the pharmacological targeting of hyperlipidemia and ischemic brain stroke. In addition, molecular determinants of hyperlipidemia and stroke are also areas of active investigation in his laboratory. Dr. Sadana has published in peer-reviewed journals and has served as an ad hoc reviewer for many journals.

Engineering Triiodothyronine (T3) Nanoparticle for Use in Ischemic Brain Stroke Drug Delivery and Translational Research 3: 309-317 (2013) Prabodh Sadana, Alexander Mdzinarishvili, Vijaykumar Sutariya, Phani K. Talasila, and Werner J. Geldenhuys

Outstanding Chapter of the Year Award The CRS Chapter of the Year Awards recognize both a local chapter and a student chapter that have provided exceptional service to their members and to the Controlled Release Society. The award will be presented during the Tuesday morning plenary session to the chapters that have best met these criteria.

Presentation: Plenary Session, Tuesday, July 15 08:00 – 09:30 2014 CRS Outstanding Local Chapter of the Year: New Zealand Local Chapter 2014 CRS Outstanding Student Chapter of the Year: NJ-NY-PA Student Chapter Congratulations to these two outstanding chapters!

Outstanding Annual Meeting Abstract Paper Awards Presentation: Plenary Session, Wednesday, July 16 09:45 – 11:00

Outstanding Oral Drug Delivery Paper Award Cosponsored by Patheon Pharmaceutical Services This award recognizes a CRS member whose winning abstract relates specifically to oral drug delivery.

Microfluidic Templated Multistage Porous Silicon Based Platform for Enhanced Enteric Cancer Drug Delivery Presenting author: Hongbo Zhang, University of Helsinki, Finland Coauthors: D. Liu, M. Shahbazi, E. Mäkilä, J. Salonen, J. Hirvonen, and H. A. Santos Author present: Poster Session 1, #161 Hongbo Zhang is a visiting scholar at the School of Engineering and Applied Sciences, Harvard University, U.S.A., and a postdoctoral researcher in the Faculty of Pharmacy, University of Helsinki, Finland.

Dr. Zhang received his bachelor’s degree from Fudan University, China, and then finished his Ph.D. in pharmacy at the University of Helsinki, Finland, in 2012. His research focus is microfluidic templated porous silicon-based platforms for biomedical application. He combines the advantage of porous silicon nanoparticles and the microfluidic technique to design multistage multifunctional drug delivery platforms for oral and intravascular drug delivery.

Outstanding Pharmaceutical Paper Award Cosponsored by PharmaCircle This award recognizes a CRS member whose wining abstract relates specifically to pharmaceutical research.

Cholesterol Esterification-Blocking Nanoparticles for Targeted Aggressive Cancer Therapy Presenting author: Seung-Young (Steve) Lee, Purdue University, U.S.A. Coauthors: Junjie Li, Jien Nee, Kinam Park, and Ji-Xin Cheng Author present: Poster Session 2, #540 Seung-Young (Steve) Lee received his B.S. degree from the Department of Chemical Engineering at Hongik University, South Korea, in 2004. He received his M.S. degree from the Department of Materials Science and Engineering at Gwangju Institute of Science and Technology, South Korea. After working as a research associate at Korea Institute of Science and Technology, he joined the Ph.D. program at the Department of Biomedical Engineering at Purdue University. His current research focuses on the development of nanomedicine for nontoxic chemotherapy. To date, he has published 23 peer-reviewed papers, one book chapter, and five technical patents.

59

Outstanding Transdermal Drug Delivery Paper Award

Outstanding Preclinical Sciences & Animal Health Paper Award

Cosponsored by 3M Drug Delivery Systems

Cosponsored by Zoetis

This award recognizes a CRS member whose winning abstract relates specifically to transdermal drug delivery research.

This award recognizes a CRS member whose winning abstract relates specifically to preclinical sciences and animal health research.

Inactivated Polio Vaccination Using a Microneedle Patch Presenting author: Jessica Joyce, Georgia Institute of Technology, U.S.A. Coauthors: C. Edens, H. Eichenbaum, N. Dybdahl-Sissoko, J. Norman, W. Weldon, S. Oberste, and M. Prausnitz

Versatile Platform for Sustained Gene Silencing Improves Excisional Wound Healing in Diabetic Rats Presenting author: Christopher Nelson, Vanderbilt University, U.S.A. Coauthors: John R. Martin, Mukesh K. Gupta, Elizabeth J. Adolph, Fang Yu, Jeffrey M. Davidson, Scott A. Guelcher, and Craig L. Duvall

Author present: Podium Session Tuesday, July 15, #84 Jessica Joyce received her bachelor’s degree in bioengineering from Rice University in 2012. She is currently a Ph.D. student in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University, U.S.A. Working in the lab of Dr. Mark Prausnitz, her research involves the development of microneedle patch technology for vaccine delivery. Specifically, she is studying the effects of controlled release of antigens on immune response.

Author present: Podium Session Monday, July 14, #27 Christopher Nelson completed his undergraduate studies at the University of Arkansas, U.S.A., in 2009 and began doctoral studies in biomedical engineering at Vanderbilt University. Under the direction of Prof. Craig Duvall, his work focused on controlled delivery strategies for nucleic acids, proteins, and small-molecule drugs.

Most notably, his thesis work involved creating a platform for the controlled delivery of small interfering RNA to improve tissue regeneration. After obtaining his Ph.D., Christopher joined the laboratory of Prof. Charles Gersbach at Duke University to develop technologies for genome engineering.

Honoring CRS Leaders Past, Present, and Future You’re Invited Join us July 14 in Chicago when the CRS Foundation presents the 2014 Alexander “Sandy” Florence Postdoctoral Fellowship Award to Christopher Nelson.

The 2014 Alexander “Sandy” Florence Postdoctoral Fellowship Award honors Prof. Florence’s service to CRS and his many contributions to delivery science, both in academia and industry.

Alexander “Sandy” Florence

Christopher Nelson

Give It Forward You can help support excellence in delivery science through your support of the CRS Foundation. Donations can be made online or at the annual meeting registration desk.

FOUNDATION

In 2007 CRS established the CRS Foundation, a 501(c)(3) educational endowment, to honor individuals who have made notable contributions to the society and its technologies and to support the scientific training of its future leadership.

60

Acknowledgements Volunteers Make It Happen From annual meeting program planning to specialized committees providing leadership and oversight on everything from awards to satellite meetings, CRS volunteers are the engines that drive our society forward. In return, they gain valuable experiences, professional connections, and the knowledge that they have made a real difference in their careers and in their profession.

Thank you to the many volunteers listed here who have served CRS during the past year.

CRS Board of Directors

Board of Scientific Advisors

President: Ian G. Tucker University of Otago, New Zealand

Director-at-Large: Christine J. Allen University of Toronto, Canada

President Elect: Arthur J. Tipton Southern Research Institute, U.S.A.

Director-at-Large: Maria Jose Alonso Universidade de Santiago de Compostela, Spain

Immediate Past President: Kazunori Kataoka University of Tokyo, Japan

Director-at-Large: Andrew L. Lewis Ipsen, France

Secretary: Debra J. Bingham Valeo Partners, U.S.A.

Director-at-Large: Tamara Minko Rutgers University, U.S.A.

Treasurer: Marcus E. Brewster Johnson & Johnson, Belgium

Director-at-Large: Yvonne Perrie Aston University, United Kingdom

Chair: Ben J. Boyd Deputy Chair: Edith Mathiowitz Members: Theresa M. Allen, Mansoor M. Amiji, Jake E. Barralet, Justin S. Hanes, Leaf Huang, Akihiko Kikuchi, Richard W. Korsmeyer, Glen S. Kwon, Claus-Michael Lehr, Barbara Lueckel, James D. Oxley, Thomas Rades, Pavla Simerska, Gert Storm, Ernst Wagner Board Liaison: Christine J. Allen

Treasurer-Elect: Ruth B. Schmid SINTEF, Norway 2014 Annual Meeting Program Committee Chair: Ick Chan Kwon.

Deputy Chair: Justin S. Hanes. Members: You Han Bae, Donald Barbieri, Ben J. Boyd, Peter Cheifetz, Samir Mitragotri, Ruth B. Schmid, Hardik Shah, Ronald L. Smith, Geert Verreck, Fanwen Zeng.

Annual Meeting Program Committee Chair: Christian Seiler.

Deputy Chair: David J. Brayden. Members: Marcus E. Brewster, Steven A. Giannos, Sandra Klein, Richard W. Korsmeyer, Ron Ortiz, Nicole PapenBotterhuis, Mark R. Prausnitz, Ali Rajabi-Siahboomi, Arthur J. Tipton.

Audit Committee Chair: Marcus E. Brewster.

Deputy Chair: Ruth B. Schmid. Members: Christopher W. McDaniel, Tom E. Redelmeier, Julius F. Remenar, Martha Sloboda, Patrick A. Walters.

College of Fellows Selection Committee Chair: Susan M. Cady.

Deputy Chair: Ronald J. Versic. Members: Theresa M. Allen, Lisa Brannon-Peppas, Diane J. Burgess, Ronald A. Siegel. Board Liaison: Kazunori Kataoka.

CRS Foundation Chair: Randall J. Mrsny.

Members: Susan M. Cady, Martyn C. Davies, Alexander T. Florence, Richard H. Guy, Tsuneji Nagai, Kinam Park.

Ex-officio: Rudy Emmelot.

Board Liaison: Tamara Minko.

CRS Outstanding Oral Drug Delivery Best Paper Award Chair: Sonke Svenson.

Deputy Chair: Woei Ping Cheng. Members: Carla M. Caramella, Xiu Xiu Cheng, Anil Kane, Peter Timmins, Christopher A. Zordan.

Consumer and Diversified Products Division Committee Chair: Nicole PapenBotterhuis. Deputy Chair: Christopher W. McDaniel.

Secretary: Jei C. McKinney.

Members: Igor Bodnar, John C. Brahms, Craig R. Bunt, Kenneth H. Carson, Douglas A. Dale, Jiten O. Dihora, Charles R. Frey, Irwin C. Jacobs, Jean-Antoine Meiners, Claudio Ortiz, James D. Oxley, Ronald J. Versic, Teresa Virgallito, Fanwen Zeng. Board Liaison: Ruth B. Schmid.

CRS Founders Award Chair: Yechezkel Barenholz.

Deputy Chair: Richard H. Guy. Members: ClausMichael Lehr, Tamara Minko, Francis C. Szoka, Jr.

CRS Outstanding Pharmaceutical Paper Award Chair: You Han Bae. Members: Laura Marie Ensign, Hamid Ghandehari, Seulki Lee.

CRS Journal of Controlled Release Best Paper Award Chair: Thomas Rades.

Deputy Chair: Veronique Preat. Members: Abdul W. Basit, Elias Fattal, JeanChristophe Leroux, Ravi Kumar N. V. Majeti, Anette Mullertz, Yvonne Perrie, Steven P. Schwendeman.

CRS Outstanding Preclinical Sciences & Animal Health Best Paper Award Chair: Sevda Senel.

Deputy Chair: Susan M. Cady. Members: Terry L. Bowersock, Mark G. Papich, Thierry Vandamme.

continued 61

CRS Outstanding Transdermal Drug Delivery Paper Award Chair: Vinod D. Labhasetwar.

Members: Kentaro Kogure, Narasimha S. Murthy, Tim Peterson.

CRS T. Nagai Postdoctoral Research Achievement Award Chair: Stefaan De Smedt.

Members: Mansoor M. Amiji, Hideyoshi Harashima, Leaf Huang, Ernst Wagner.

CRS Young Investigator Award Chair: Steven P. Schwendeman. Members: Joke A. Bouwstra, Alexander V. Kabanov, Claus-Michael Lehr, Jean-Christophe Leroux, Samir Mitragotri, Kinam Park, Mark R. Prausnitz, W. Mark Saltzman, Molly M. Stevens.

Drug Delivery and Translational Research Outstanding Research Paper Selection Committee Chair: V. Prasad R. Shastri.

Deputy Chair: Elka Touitou.

Members: Franco Alhaique, Sing Yian Chew, Padma V. Devarajan, David R. Friend, Vinod D. Labhasetwar, Natalie Medlicott.

Drug Delivery and Translational Research Editorial Board Editor-in-Chief: Vinod D. Labhasetwar. Associate Editors: Martyn C. Davies, Kensuke Egashira, Justin S. Hanes. Editors: Rinti Banerjee, Raymond T. Bartus, Jayesh Bellare, Ben J. Boyd, Diane J. Burgess, Perry Calias, Sing Yian Chew, Mark Davis, Kenneth A. Dawson, Farid A. Dorkoosh, Elazer R. Edelman, Pierandrea Esposito, David R. Friend, Rogerio S. Gaspar, Kenneth A. Howard, Jeffrey A. Hubbell, Lisbeth Illum, Mansoor A. Khan, Robert

62

Levy, Weiyue Lu, David M. Lynn, Natalie Medlicott, Tamara Minko, Samir Mitragotri, Kinam Park, Mark R. Prausnitz, Suzie Pun, Michael J. Rathbone, V. Prasad R. Shastri, Lonnie D. Shea, Patrick J. Sinko, Thomas R. Tice, Elka Touitou, Ijeoma Uchegbu, Xiao Yu Wu, Qiang Zhang.

Finance Committee Chair: Marcus E. Brewster.

Deputy Chair: Ruth B. Schmid. Members: Christopher W. McDaniel, Tom E. Redelmeier, Julius F. Remenar, Martha Sloboda, Patrick A. Walters.

International Committee Chair: Claudio Ortiz.

Deputy Chair: Ronit Satchi-Fainaro. Members: Christophe J. Barbe, Michael Doschak, Roderick B. Walker.

Board Liaison: Yvonne Perrie.

Marketing Committee Chair: Robert Bloder.

Members: Joseph A. Fix, Izabela Galeska, Jei C. McKinney, Erin O’Brien, Teresa Virgallito. Board Liaison: Andrew L. Lewis.

Newsletter Committee Chair: Yvonne Perrie.

Deputy Chair: Roderick B. Walker. Members: Charles R. Frey, Steven A. Giannos, Arlene McDowell, Bozena B. Michniak-Kohn.

Nominating Committee Chair: Kazunori Kataoka.

Members: Diane J. Burgess, Michael Doschak, Marilyn N. Martinez, Ronald A. Siegel, Arthur J. Tipton, Istvan Toth.

Ocular Drug Delivery Focus Group Committee Chair: Ilva D. Rupenthal.

Deputy Chair: Andrew Urquhart. Members: Samirkumar R. Patel, Ruud Verrijk.

Oral Drug Delivery Focus Group Committee Chair: Ali Rajabi-Siahboomi.

Preclinical Sciences & Animal Health Division Committee Chair: Marilyn N. Martinez.

Deputy Chair: Peter Cheifetz. Past Chair: Michael J. Rathbone. Members: Terry L. Bowersock, David J. Brayden, Praveen S. Hiremath, Michail Kastellorizios, Tim McCaffery, Sevda Senel, Thierry Vandamme. Board Liaison: Tamara Minko.

Satellite Meeting Committee Chair: James D. Oxley.

Deputy Chair: Khaled Greish. Members: Christopher W. McDaniel, Chi-Hwa Wang, James West.

Board Liaison: Ruth B. Schmid.

Volunteer Recruitment Committee Chair: Arlene McDowell.

Deputy Chair: Louise Rosenmayr-Templeton.

Members: David Chen, Prajakta Dandekar-Jain, Biana Godin Vilentchouk, Hideyoshi Harashima. Board Liaison: Maria Jose Alonso.

Website Committee Chair: Hardik Shah. Deputy Chair: Xiaoming Xu. Members: Sebastien Boridy, Fransisca Leonard. Board Liaison: Andrew L. Lewis.

Young Scientist Committee Chair: Joshua J. Reineke.

Deputy Chair: Patrick Lim Soo. Past Chair: Ron Ortiz.

Members: Mohammad Shahriarul Absar, Adam Bohr, David Chen, Kaushalkumar Dave, Emmanuel Ho, Ratnesh Jain, Joke Meeus, Yewande I. Oni, Hardik Shah, Pirthi Pal Singh, Jorrit Water, Jinzi Zheng. Board Liaison: Christine J. Allen.

CRS Local Chapters Australian Local Chapter President: Ben J. Boyd Canadian Local Chapter President: Todd R. Hoare Germany Local Chapter President: Regina Scherliess Greece Local Chapter President: Panos Macheras India Local Chapter President: Amarjit Singh Israeli Local Chapter President: Ronit SatchiFainaro Italy Local Chapter President: Bice A. Conti Malaysia Local Chapter President: Mohd Cairul Iqbal Mohd Amin New Zealand Local Chapter President: Arlene McDowell Nordic Local Chapter Chair: Ingunn Tho Taiwan Local Chapter President: Ming-Thau Sheu Turkey Local Chapter President: Yildiz OzsoyErginer United Kingdom-Ireland Local Chapter President: Gavin Andrews CRS Student Chapters Student Chapter Connecticut President: Michail Kastellorizios Student Chapter Illinois Vice President: Ryan Pearson Student Chapter NJ/NY/PA President: Tannaz Ramezanli Student Chapter The Hebrew University of Jerusalem Chair: Joseph Fanous

2014 CRS Presenting Author Index Abstract authors named as the presenting author for a particular abstract can be found in the index below. To search all authors of an abstract, please use the CRS Annual Meeting App, CRS website, or abstract printing station.

Abed, N................................ 652 Abedin Dorkoosh, F............. 162 Abo-zeid, Y M..................... 389 Adeleke, O A........................ 254 Aguilar, I N........................... 220 Ahmed, K K......................... 102 Ahmed, S.............................. 158 Ahn, J................................... 545 Ahnfelt, E............................. 283 Aizik, G................................ 369 Alameh, M G....................... 175 Aliyar, H A........................... 723 Al-Jamal, K T................ 379, 589 Al-Kassas, R......................... 118 Al-Kinani, A A...... 129, 280, 658 Al-Lami, H S....................... 305 Almomen, A......................... 255 Almutairi, A........................... 80 Alonso, M J............................ 85 Alqahtani, M........................ 470 Amar-Lewis, E..................... 199 Ambrose, J J.......................... 167 Anzai, R................................ 391 Asadian-Birjand, M.............. 718 Asthana, A............................ 475 Aviv, O.................................. 240 Badenhorst, T................ 702, 731 Bae, J W................................ 622 Bailey, B A............................ 707 Ball, C................................... 335 Bar-Shalom, D..................... 438 Basra, A S............................. 414 Baumhof, P............................. 88 Beg, S................................... 482 Bernardi, D S........................ 726 Bettinger, C J.......................... 93 Betzer, O................................ 99 Beyer, S..................................... 3 Birchall, J C............................ 62 Bodmeier, R................... 441, 483 Bohr, A................................. 174 Bolkestein, M....................... 549 Borkar, N.............................. 461 Bouwstra, J....................... 40, 699 Boyd, B J.......................... 59, 472 Brewster, M........... 259, 260, 451 Brito, L A............................... 26 Brock, R.................................. 12 Brown, L................................. 29 Buaron, N............................. 178 Buckley, S T............................ 44 Bugno, J................................ 523 Buhrman, J S........................ 678 Burgess, A............................. 665 Burnett, D J........... 267, 268, 269 Byeon, Y............................... 594 Byun, Y..................................... 6 Cadete Pires, A..................... 565 Cady, S M............................. 108 Cai, S.................................... 548 Calderón Lojero, I O..... 737, 742 Calixto, G...................... 649, 660

Campbell, S.......................... 124 Cano-Sarabia, M.................. 350 Carson, D S............................ 81 Castro-Vidal, D A................ 420 Cavalli, R.............................. 553 Chapman, A......................... 713 Chaturvedi, A....................... 555 Chen, F................................. 403 Chen, G................................ 340 Chen, J................... 104, 396, 397 Chen, S................................. 172 Chen, X................................ 115 Chen, Y................. 303, 607, 608 Chen, Y................................ 303 Chen, Y C..................... 514, 605 Chereddy, K K........................ 83 Cho, C S............................ 7, 507 Cho, D Y.............................. 398 Cho, H........................... 368, 500 Choi, H K............................. 722 Choi, Y S.............................. 399 Conti, B......................... 465, 634 Cooper, D L.................. 357, 429 Cornejo-Bravo, J M.............. 383 Corona, E............................. 632 Crawford, L A...................... 656 Cuppok-Rosiaux, Y.............. 445 Cury, B F............... 317, 321, 353 Dall, O M............................. 372 Dametto, P........................... 485 Dave, K................................. 741 Davé, R N................................. 4 David, A............................... 590 Davoodi, P............................ 539 De Souza, R............................ 64 del Río-Sancho, S................. 635 Di Maio, S............................ 646 Discher, D.............................. 16 D’mello, S.............. 205, 342, 348 Doi, Y................................... 538 Dorkoosh, F... 106, 203, 309, 336, 501, 596, 609 Dormer, N....................... 68, 376 DuBose, D B........................ 143 Dufes, C............................... 621 Duffy, G P............................ 422 El-Ashmawy, A A................ 360 Eloy, J O............................... 382 Elsayed, M M....................... 733 ElShaer, A................................ 8 Ensign, L................................ 57 Erginer, Y............................. 266 Esim, O................................ 263 Fattal, E.................................. 73 Feast, G C............................ 416 Fischer, K E.......................... 312 Fleming, A B........................ 290 Fonseca, M........................... 341 Formiga, F R........................ 698 Freyman, T........................... 152 Fukasawa, M......................... 297 Gala, R P............... 408, 674, 730

Gao, Z.................................. 212 Gaowa, A.............................. 558 Garg, S M............................. 582 Gaudin, A............................. 517 Gehris, A S........................... 244 Gella, S R.............. 265, 282, 458 Giulbudagian, M.................. 166 Gleeson, J P.......................... 241 Gong, Y................................ 706 González-Fajardo, L A......... 619 Goss, M................................ 272 Govindarajan, R..................... 90 Grother, L P.................. 434, 435 Gu, B.................................... 339 Gu, J..................................... 170 Gujrati, M............................ 542 Gujrati, V............................. 534 Günday Türeli, N.................... 74 Gungor, S............................. 125 Guo, X.................................. 298 Gupta, j................................. 535 Haas, H.................................. 28 Hadipour Moghaddam, S P. 574 Hage, N A.............................. 58 Hagner Nielsen, L................ 460 Hahn, S K............................... 42 Hamano, N........................... 511 Hartnett, T........................... 693 Hasegawa, U......................... 345 Hashimoto, Y....................... 355 Heisig, M.............................. 714 Heo, R.................................. 366 Hernandez, C....................... 662 Hewlett, K O........................ 257 Hillaireau, H......................... 346 Hiruta, Y.............................. 231 Hoare, T.......................... 50, 510 Hollis, C P............................ 275 Hoppel, M............................ 107 Hossain, M A....................... 327 Howard, K..................... 354, 421 Hsu, H j................................ 325 Hu, Z.................................... 394 Huh, Y M............................. 114 Humphries, P......................... 47 Hunter, R P............................ 23 Hwang, K M........................ 450 Hwang, S J..................... 164, 261 Iida, M.................................. 690 Ikeda, Y.................................. 19 Ioannidis, N.......................... 225 Islam, M S............................ 498 Ivanova, V............................. 144 Jacob, D................................ 223 Jafary Omid, N.............. 431, 487 Jain, S................................... 703 Jean, M.................. 177, 187, 188 Jeon, O.................................. 160 Jeong, E J.............................. 198 Jeong, H J............................. 533 Jhan, H J............................... 286 Jin, T.................................. 14, 94

Jones, S................................. 208 Joshi, M D............................ 351 Joshi, V.......................... 322, 683 Joyce, J.................................... 84 K, R P.............................. 66, 727 Kafa, H................................. 506 Kakadia, P............................ 424 Kalscheuer, S........................ 588 Kanazawa, T......................... 735 Kapadia, C J.......................... 448 Kapoor, M.............................. 95 Kastellorizios, M..................... 63 Kastner, E............................. 256 Katayama, Y............................ 24 Kawano, T............................ 364 Kawashima, Y....................... 323 Kendall, M.............................. 39 Kennedy, J............................. 736 Keskin, D.............................. 744 Khaja, F................................ 176 Khoury, L R.......................... 310 Ki, M..................................... 251 Kiill, C P........................ 509, 667 Kilambi, P............................. 432 Kim, A.................................. 497 Kim, A J.................................. 35 Kim, D H............................. 245 Kim, H.................. 239, 296, 393 Kim, H J............................... 207 Kim, H K................................ 71 Kim, I S................................ 666 Kim, J H........................ 561, 623 Kim, M G............................. 559 Kim, M J.......................... 25, 494 Kim, N W............................... 89 Kim, S................................... 529 Kim, W J.............................. 395 Kim, Y.................................... 78 Kim, Y C.............................. 130 Kimura, Y............................. 681 Kirsh, S................................. 636 Kirtane, A R.................. 525, 659 Klukkert, M.......................... 638 Ko, H.................................... 598 Kolhatkar, V......................... 202 Kondappan, A...................... 449 Kong, W H........................... 743 Koning, G A......................... 613 Kuai, R.................................. 610 Kuo, J h S.............................. 670 Kyung, H.............................. 419 LaBella, G..................... 294, 308 Labhasetwar, V....................... 91 Lalatsa, A............................. 474 Lambert, A S........................ 262 Lammers, T.......................... 113 Lavin, D M...................... 97, 385 Leclaire, M E....................... 641 Lee, B H............................... 551 Lee, C Y............................... 628 Lee, D.................... 347, 455, 584 Lee, D Y................................. 15

63

Lee, H.................................. 365 Lee, J............................. 430, 522 Lee, J E................................. 181 Lee, K C................................. 46 Lee, K Y............................... 591 Lee, M K.............................. 234 Lee, S....................... 43, 371, 716 Lee, S Y................................ 540 Lee, W H............................. 141 Lee, Y............................ 185, 319 Lesniak, M S.......................... 98 Levchenko, T........................ 334 Li, C..................................... 568 Li, D..................................... 246 Liaw, J................................... 307 Lifshiz, R.............................. 663 Lima, E M............................ 126 Lin, C W.............................. 320 Liu, J..................................... 216 Liu, S...................................... 92 Liu, Y.................................... 242 Lokerse, W........................... 583 Loo, C Y............................... 146 Lopez Garcia, M.................. 719 Lopez-Noriega, A................ 712 Loreti, G........................ 446, 480 Lowry, D....................... 140, 671 Lu, J........................................ 54 Ma, G................................... 700 MacKay, J A............................ 48 Magaña-Badilla, H A........... 478 Mahdi, M H......................... 454 Maisel, K................................ 10 Maithania, H V.................... 363 Manthe, R L........................... 38 Markovsky, E.......................... 56 Mason, L M......................... 456 Mastorakos, P....................... 173 Matsuyama, T....................... 417 Maudens, P........................... 410 McDowell, A........................ 643 McLaughlin, R T................... 45 Meeus, J........................... 31, 285 Mencia Castaño, I................ 194 Meneguin, A B..................... 375 Mirza, S................................ 222 Mohs, A M........................... 564 Moir, L A............................. 546 Mole, J........................... 258, 273 Molina Soler, M A............... 740 Moriyama, M....................... 324 Movassaghian, S................... 195 Mu, H................................... 491 Mujoo, H.............................. 745 Mukai, H.............................. 100 Mulla, N................ 359, 686, 728 Müller, R H... 407, 471, 642, 644 Mullertz, A........................... 463 Mura, S................................... 53 Muro, S.............................. 13, 17 Mussi, S V............................ 579 Mutaf, O F........................... 426 Myung, J H........................... 236 Na, K.................................... 189 Nagasaki, Y........................... 338 Naim, M............................... 603 Nakase, I............................... 495 Nam, J................................... 343

64

Nascimento, T L................... 180 Nassajian Moghadam, M..... 332 Navarro, F, 196 Navarro, G..................... 191, 201 Navon, N.............................. 489 Nayanabhirama, U................ 224 Nelson, C E............................ 27 Ng, S F................................. 734 Nieto, K................................ 133 Nishimura, T........................ 316 Obara, S................................ 277 Ochyl, L J............................. 694 Oesterling, B M.................... 682 Ofokansi, k C....................... 439 Ooya, T................................. 725 Osswald, C R........................ 121 Ozcelikkale, A...................... 657 Pan, W.................................. 119 Papen-Botterhuis, N E......... 230 Papich, M G........................... 22 Papisov, M I............................ 20 Park, I K............................... 496 Park, J................................... 655 Park, J B......................... 473, 488 Park, S.................................. 138 Pasut, G................. 204, 672, 691 Patel, R R............................. 476 Paterson, M.......................... 300 Patil, H.......................... 484, 627 Patil, S S............................... 443 Pearson, R M........................ 612 Peng, J................................... 708 Pensado, A............................ 210 Perera, P A H....................... 560 Petrilli, R.............................. 650 Pham, Q................................... 9 Pitt, W G.............................. 120 Popa, E A............................. 729 Portilla-Arias, J..................... 576 Prasadarao K, E V................ 580 Prow, T W............................ 664 Qiu, y Y................................ 518 Quadir, A.............................. 253 Rabanel, J M......................... 299 Rad-Malekshahi, M............. 673 Rafiee-Tehrani, M................ 464 Rahimian, S..................... 87, 544 Rajabi-Siahboomi, A R........ 287 Ramazani, F.......................... 136 Ramezanli, T.......................... 41 Rangaramanujam, K............... 34 Raphael, A P......................... 724 Rayahin, J E.......................... 696 Rebouças, J........................... 709 Rezhdo, O............................ 427 Ribeiro, A J........................... 374 Rich, M H............................ 226 Rios, J L................................ 697 Roberts, J.............................. 384 Rockett, S............................. 467 Rosenberger, I....................... 571 Rosiaux, Y...................... 486, 490 Rossi, A................................ 453 Rubinstein, A......................... 82 Rupenthal, I D....................... 51 Ruyra, A............................... 109 Sadhukha, T......................... 554 Sahoo, D K.................... 165, 436

Saita, M................................ 437 Salem, H F........................... 128 Salmaso, S.............. 502, 587, 701 Salzano, G..................... 516, 592 Sanchez-Bustos, E................ 606 Sarisozen, C.......................... 520 Sathigari, S............................... 1 Savla, R................................. 640 Saw, P E............................... 625 Sawicki, W.................... 228, 477 Schmid, R B......................... 392 Schmid-Baumberger, R.......... 32 Şenel, S................................. 648 Seo, J E................................. 654 Seol, J H............................... 532 Seth, A.................................... 61 Shah, M................................ 661 Shah, N................................. 103 Shen, M H........................... 402 Shen, Y................................... 52 Shi, K.................................... 704 Shimizu, J............................. 433 Shimoda, A........................... 400 Shin, C S.............................. 276 Shirakura, T.......................... 344 Silva, C M............................ 378 Singh, K................................ 566 Singh, K K..... 123, 288, 639, 653 Skilling, K J.......................... 233 Sladek, S............................... 412 Somani, S............................. 519 Son, J Y................................. 362 Song, D................................ 573 Sousa-Herves, A................... 387 Souza, A L R........................ 380 Sriraman, S K................ 556, 602 Stapleton, S.......................... 569 Staufenbiel, S......... 377, 406, 515 Stayton, P............................... 11 Steffensen, S L...................... 413 Stephenson, R....................... 710 Suárez del Pino, J A.............. 537 Suen, W l L..... 49, 116, 122, 127 Sugisawa, K................... 151, 156 Sun, B................................... 578 Sun, J.................................... 614 Sun, M.................................. 524 Sun, X................................... 179 Sutton, S C............................. 21 Svirskis, D M.......................... 96 Tabata, Y............................... 237 Tahara, Y.............................. 401 Takami, T............................. 147 Takashi, N............................ 668 Takeda, S.............................. 493 Taki, S................................... 688 Tan, M.................................. 227 Tang, M................................ 575 Taratula, O........................... 526 Tavakoli Naeini, A................ 159 Tchuenbou-Magaia, F L........... 5 Tewari, D.............................. 293 Tian, H................................... 72 Tice, T.................................... 67 Tomoda, K............................ 597 Tres, F..................................... 30 Tripathy, N........................... 604 Udupa, N.............................. 388

Ugaonkar, S.......................... 252 van der Vlies, A J.................. 337 van Elk, M............................ 425 van Sleeuwen, R M............... 249 Vandamme, T....................... 112 Veilleux, D............................ 190 Veršič, R J............................... 69 Vos, J..................................... 695 Vueba, M L.......................... 630 Walker, R B........... 270, 271, 508 Walsh, C L............................... 2 Walsh, P L.............................. 65 Wang, C........................ 221, 505 Wang, C H........................... 352 Wang, J................................. 328 Wang, L................................ 492 Wang, Q................................. 79 Water, J J............................... 367 Wei, W................................. 669 Wei, X................................... 311 Wen, J................................... 373 Williams, R M...................... 715 Williford, J M....................... 182 Windhab, E J.......................... 75 Wong, J................................. 145 Wongrakpanich, A. 215, 217, 499 Wu, C................................... 148 Wu, F.................................... 229 Wu, J.............................. 318, 404 Xia, D..................................... 60 Xie, y..................................... 214 Xin, C................................... 248 Xu, H.................................... 615 Xuan, S................................. 531 Yadav, R................................ 278 Yamada, H............................ 171 Yamazaki, T.......................... 405 Yamazaki, Y.......................... 137 Yang, J..................................... 76 Yang, M M........................... 600 Yang, S.................................. 186 Yang, Y.................... 86, 274, 711 Yen, H C............................... 547 Yliperttula, M....................... 211 Yoo, H.................................. 329 Yoshida, C............................ 313 You, D G.............................. 617 Young, P M............................ 70 Yu, M.................................... 645 Yuan, W................................ 504 Yuksel, N.............................. 481 Zeng, F................................... 33 Zeng, Q................................ 684 Zeng, S................................. 618 Zhang, B............................... 295 Zhang, C A.......................... 543 Zhang, H.............................. 161 Zhang, P.................. 18, 466, 586 Zhang, Q.............................. 390 Zhang, W............................. 117 Zhang, X........................ 585, 738 Zhang, Y........ 183, 370, 557, 687 Zheng, J................................ 238 Zhong, Q................................ 77 Zhong, X.............................. 503 Zhou, H................................ 289 Zhu, X.................................. 193 Zordan, C A......................... 111

42nd Annual Meeting & Exposition of the Controlled Release Society July 26-29, 2015 Edinburgh International Conference Centre Edinburgh, Scotland Creating Value Through Customised Delivery

Exhibit and Sponsorship Selection Available Now

ŠHeartland Arts / Shutterstock.com

Call For Papers Opens November 2014

Introducing A new low solubility solution

The Customizable, Fixed-Price Solution to Rapidly Improve Solubility Never before has it been so fast and simple to overcome solubility challenges. With SoluPath Flex™, you’ll have access to the choices and scientific expertise you need to meet your unique needs.

• Full array of solubility technologies and services.

• Hand-pick the services for your molecule and business.

• Know all costs, timelines and API requirements in advance.

• Consult with a solubility expert at the earliest stages.

• Plan, quote and launch project in days.

• Rapid results from dedicated equipment and teams.

Only with SoluPath Flex™ can you accelerate development with a solubility enhancement solution custom tailored to meet the specific requirements of your molecule, timeline and budget. Plus, you can finalize your plan with a solubility expert in just one meeting.

Get exactly what you need, and get it faster with SoluPath Flex™ +1 866.PATHEON • www.patheon.com • doingbusiness@patheon.com

©Patheon Inc. All rights reserved. Published 4/14 PATH0364R1

Visit us at booth #403